

WEST

Generate Collection

Search Results - Record(s) 1 through 3 of 3 returned.☐ 1. Document ID: US 5997865 A

L5: Entry 1 of 3

File: USPT

Dec 7, 1999

US-PAT-NO: 5997865

DOCUMENT-IDENTIFIER: US 5997865 A

TITLE: Agonist antibodies against the flk2/flt3 receptor and uses thereof

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; Brian D.	South San Francisco	CA	94080	N/A
Broz; Susan D.	South San Francisco	CA	94080	N/A
Matthews; William	South San Francisco	CA	94080	N/A
Zeigler; Francis C.	South San Francisco	CA	94080	N/A

US-CL-CURRENT: 424/130.1; 424/143.1, 530/387.3, 530/388.22, 530/389.1

ABSTRACT:

Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.

20 Claims, 12 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RWAC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 5877396 A

L5: Entry 2 of 3

File: USPT

Mar 2, 1999

*ACK2 antibody
stem cell signal*

US-PAT-NO: 5877396

DOCUMENT-IDENTIFIER: US 5877396 A

TITLE: Mice mutant for functional Fc receptors and method of treating autoimmune diseases

DATE-ISSUED: March 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ravetch; Jeffrey V.	New York	NY	N/A	N/A
Takai; Toshiyuki	Okayama	N/A	N/A	JPX
Sylvestre; Diana	New York	NY	N/A	N/A
Clynes; Raphael	New York	NY	N/A	N/A

US-CL-CURRENT: 800/3; 424/9.1, 424/9.2, 800/11, 800/18, 800/9

ABSTRACT:

Disclosed herein is a non-naturally occurring non-human vertebrate animal incapable of expressing a functional Fc receptor which may optionally be capable of expressing a protein which comprises a domain of a human Fc receptor, as well as DNA encoding such Fc receptor-based proteins. Also disclosed are in vivo methods for identifying proinflammatory agents that depend on a functional Fc receptor, in vivo methods for identifying proinflammatory agents that do not depend on a functional Fc receptor, and both in vivo and in vitro methods of identifying anti-inflammatory agents. Pharmaceutical compositions containing, and methods of treating inflammation with anti-inflammatory agents are also described.

18 Claims, 112 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 3. Document ID: US 5635388 A

L5: Entry 3 of 3

File: USPT

Jun 3, 1997

US-PAT-NO: 5635388

DOCUMENT-IDENTIFIER: US 5635388 A

TITLE: Agonist antibodies against the flk2/flt3 receptor and uses thereof

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; Brian D.	Pacifica	CA	N/A	N/A
Broz; Susan D.	San Bruno	CA	N/A	N/A
Matthews; William	Woodside	CA	N/A	N/A
Zeigler; Francis C.	San Mateo	CA	N/A	N/A

US-CL-CURRENT: 435/334; 424/85.1, 424/85.2, 424/85.5, 435/320.1, 435/328, 435/70.21, 530/351, 530/387.3, 530/388.22, 530/389.1, 536/23.53

ABSTRACT:

Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.

15 Claims, 12 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

[Generate Collection](#)

Term	Documents
(4 OR 3).USPT.	3

[Display](#)

20

Documents, starting with Document:

3

Display Format:[rev](#)[Change Format](#)

=> d his

(FILE 'HOME' ENTERED AT 08:45:09 ON 28 JUN 2000)
 SET COST OFF
 SET AUHELP OFF

FILE 'HCAPLUS' ENTERED AT 08:45:19 ON 28 JUN 2000

L1	3528 S STEM(10A)CELL(10A)FACTOR
L2	3036 S STEM(5A)CELL(5A)FACTOR
L3	492 S L1 NOT L2
L4	21434 S SCF
L5	1255 S L4 AND STEM(L)CELL(L)FACTOR
L6	3049 S L2,L5
L7	7 S L6 AND DERMATITIS
L8	101 S L6 AND SKIN
L9	25 S L6 AND SKIN(L) (DISEASE OR DISORDER)
L10	28 S L8 AND ?PIGMENT?
L11	30 S L6 AND MASTOCYT?
L12	4 S L6 AND URTICAR?
L13	452 S L6 AND MAST (L) CELL
L14	56 S L8 AND L13
L15	19 S L8 AND ?INFLAM?
L16	6 S L6 AND (ECZEM? OR ACNE? OR PSORIA? OR ANTIECZEM? OR ANTIACNE?
L17	167 S L6 AND (MELAN? OR KERATIN?)
L18	47 S L8 AND L17
L19	322 S L6 AND (TYROSINE(L)KINASE)
L20	20 S L8 AND L19
L21	17 S L6 AND ?ASTHM?
L22	1 S L21 AND (METHOD# AND ANTIBOD?)/TI
L23	182 S L6 AND (?ALLERG? OR HYPERSENS? OR HYPOSENS? OR SENSITIV?)
L24	7 S L23 AND L8
L25	24 S L23 AND (LUNG OR PULMON? OR BROCH? OR AIRWAY OR RESPIR? OR BR
L26	2 S L25 AND (SKIN OR HYPERREAC?)/TI
L27	27 S L23 AND ?HISTAMIN?
L28	16 S L27 NOT L24-L26
L29	3 S L28 AND (NASAL OR NOSE)
L30	1 S L23 AND (?RHIN? OR ?NASAL? OR NOSE) NOT L24-L29
L31	9 S L6 AND ?ANAPHYL?
L32	5 S L31 AND (RECOMBINANT OR EFFECT#)/TI
L33	2 S L32 AND (MELANOCYT? OR SURVIVAL)/TI
L34	7 S L6 AND SHOCK
L35	0 S L34 AND L23
L36	0 S L34 AND L31
L37	785 S L6 AND (C(A)KIT OR CKIT)
L38	175 S L37 AND ?SIGNAL?
L39	112 S L37 AND STROMA?
L40	8 S L39 AND (?GASTRO? OR ?GASTRI? OR ?INTESTIN? OR DIGEST?)
L41	3 S L40 AND GAIN/TI
L42	59 S L37 AND GERM (L) CELL
L43	13 S L42 AND (?TUMOR? OR ?NEOPLAS? OR ?CANCER? OR ?CARCIN? OR ?MET
L44	8 S L43 NOT (ANEMIA OR STEEL FACTOR OR BUFFALO OR THYMOCYTES)/TI
L45	41 S L42 AND GERM CELL NOT L43
L46	1 S L45 AND CLINICAL
L47	8 S L37 AND ACK2
L48	33 S L37 AND ?DIMER?
L49	11 S L6 AND ?BRONCH?
L50	1 S L49 AND RECOMBIN?/TI
L51	124 S L6 AND (CONTRACEP? OR PREGNAN? OR FERTIL? OR INFERTIL? OR SPE
L52	25 S L22,L30,L33,L41,L44,L46,L47,L50
L53	359 S L7,L9-L12,L14-L16,L18,L20,L24-L29,L31-L34,L40-L51
L54	23 S L52 AND L53
L55	25 S L52,L54
L56	336 S L53 NOT L55
L57	17 S L56 AND (1 OR 63)/SC
L58	20 S L56 AND (1 OR 63)/SX

L59 34 S L57,L58
 L60 145 S L56 AND 15/SC,SX
 L61 12 S L60 AND L59
 L62 11 S L61 NOT 3/SC,SX
 L63 1 S L62 AND RHINITIS
 L64 22 S L59 NOT L61
 L65 4 S L64 AND CYCLOSPORIN
 L66 1 S L65 AND FK 506
 L67 30 S L55,L63,L65,L66

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 09:49:49 ON 28 JUN 2000
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 28 Jun 2000 VOL 133 ISS 1
 FILE LAST UPDATED: 27 Jun 2000 (20000627/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.

=> d all tot 167

L67 ANSWER 1 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 2000:277810 HCAPLUS
 DN 132:326056
 TI Systems for oral delivery
 IN Russell-Jones, Gregory John
 PA Biotech Australia Pty. Ltd., Australia
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 ICI A61
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000022909	A2	20000427	WO 1999-IB1872	19991018
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1998-PV104827 19981019

AB A pharmaceutical and a biol. active substance, for oral administration, can be "coated" or "encapsulated" with a carboxylic acid, such that the substance is protected from proteolysis in the stomach and is taken up from the intestine. It is thought that the carboxylic acids coat and protect the active agent from the proteolytic environment of the stomach, allowing the agent to pass safely through the stomach and to be absorbed in the small intestines. The carboxylic acid agent complex can be adopted for oral, **nasal**, buccal, and transdermal delivery of moderately sol. and even insol. bioactive agents.

ST carboxylate enteric coating encapsulation

IT Eotaxin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Platelet-derived growth factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AA; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Platelet-derived growth factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AB; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Platelet-derived growth factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BB; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Chemokines

(C-X-C, SDF-1/PBSF; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Chemokines

(C-X-C, SDF-1.alpha./PBSF; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Chemokines

(C-X-C, SDF-1.beta./PBSF; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Chemokines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ENA 78; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Hemopoietins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Flt-3 ligand; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Immunostimulants

(adjuvants; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Drug delivery systems

(aerosols; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Diagnosis

(agents; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Lipids, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(blood, regulators; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Neurotrophic factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain-derived; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Drug delivery systems

(capsules; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Adrenoceptor agonists

Allergy inhibitors

Analgesics
Anthelmintics
Anti-inflammatory agents
Antiarrhythmics
Antibiotics
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antitussives
Antiviral agents
Anxiolytics
Appetite depressants
Blood products
Cholinergic agonists
Diuretics
Dopamine agonists
Expectorants
Fungicides
Hemostatics
Hypnotics and Sedatives
Imaging agents
Immunosuppressants
Inotropics
Muscarinic antagonists
Muscle relaxants
Radiopharmaceuticals
Thyroid gland
Tranquilizers
Vasodilators
Wound healing promoters
 (carboxylic acids for encapsulating or enteric coating biol. active
 agents for delivery to intestine)

IT Angiogenic factors
CTLA-4 (antigen)
Carboxylic acids, biological studies
Chemotactic factors
Ciliary neurotrophic factor
Corticosteroids, biological studies
Eotaxin
Erythropoietin receptors
Hepatocyte growth factor
Insulin-like growth factor receptors
Interferons
Interleukin 10
Interleukin 11
Interleukin 12
Interleukin 13
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 18
Interleukin 1.alpha.
Interleukin 1.beta.
Interleukin 2
Interleukin 3
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 7
Interleukin 8

Interleukin 9
 Lactoferrins
 Lymphotoxin
 Macrophage inflammatory protein 1.alpha.
 Macrophage inflammatory protein 1.beta.
 Macrophage inflammatory protein 2
 Macrophage migration inhibitory factor
 Midkines
 Monocyte chemoattractant protein-1
 Neuropeptides
 Platelet-derived growth factors
 Pleiotrophins
 Prostaglandins
 RANTES (chemokine)
 Sex hormones
Stem cell factor
 Steroids, biological studies
 Tumor necrosis factors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Glycosides
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cardiac; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Neurotrophic factor receptors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ciliary; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Imaging agents
 (contrast, radiog.; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Imaging agents
 (contrast; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Neurotrophic factors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (glial derived; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Proteins, specific or class
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (granulocyte chemotactic, carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Proteins, specific or class
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (latency-assocd.; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Drug delivery systems
 (lotions; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Drug delivery systems
 (lozenges; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Cytokines
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrophage inflammatory protein 3.beta.; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Chemokines
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrophage-derived; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Proteins, specific or class
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrophage-stimulating; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; carboxylic acids for encapsulating or enteric coating
biol. active agents for delivery to intestine)

IT Chemokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monocyte chemoattractant protein 3; carboxylic acids for encapsulating
or enteric coating biol. active agents for delivery to intestine)

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monocyte chemoattractant protein 4; carboxylic acids for encapsulating
or enteric coating biol. active agents for delivery to intestine)

IT Drug delivery systems
(ointments, creams; carboxylic acids for encapsulating or enteric
coating biol. active agents for delivery to intestine)

IT Drug delivery systems
(ointments; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(placenta; carboxylic acids for encapsulating or enteric
coating biol. active agents for delivery to intestine)

IT Drug delivery systems
(powders; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Drug delivery systems
(suppositories; carboxylic acids for encapsulating or enteric coating
biol. active agents for delivery to intestine)

IT Drug delivery systems
(syrups; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Drug delivery systems
(tablets; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Drug delivery systems
(tinctures; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Heregulins
Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Adrenoceptor antagonists
(.beta.-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.1-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.2-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.3-; carboxylic acids for encapsulating or enteric coating biol.
active agents for delivery to intestine)

IT Microglobulins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.2-; carboxylic acids for encapsulating or enteric coating biol.
 active agents for delivery to intestine)

IT Transforming growth factors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.5; carboxylic acids for encapsulating or enteric coating biol.
 active agents for delivery to intestine)

IT Interferons

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.gamma.; carboxylic acids for encapsulating or enteric coating biol.
 active agents for delivery to intestine)

IT 50-02-2 50-33-9, Phenylbutazone, biological studies 50-56-6, Oxytocin,
 biological studies 53-86-1, Indomethacin 57-10-3, Hexadecanoic acid,
 biological studies 57-11-4, Octadecanoic acid, biological studies
 60-33-3, Linoleic acid, biological studies 76-93-7, Benzilic acid,
 biological studies 83-49-8, Hyodeoxycholic acid 85-01-8, Phenanthrene,
 biological studies 91-20-3, Naphthalene, biological studies 92-13-7,
 Pilocarpine 92-92-2, 4-Biphenylcarboxylic acid 98-73-7,
 4-tert-Butylbenzoic acid 106-14-9, 12-Hydroxystearic acid 112-37-8,
 Undecanoic acid 112-38-9, Undecylenic acid 112-79-8, Elaidic acid
 112-80-1, Oleic acid, biological studies 123-76-2, Levulinic acid
 126-07-8, Griseofulvin 127-27-5, Pimaric acid 128-13-2,
 Ursodeoxycholic acid 129-20-4, Oxyphenbutazone 130-15-4,
 1,4-Naphthalenedione 141-22-0, Ricinoleic acid 143-07-7, Dodecanoic
 acid, biological studies 302-79-4, Retinoic acid 303-98-0,
 Ubidecarenone 334-48-5, Decanoic acid 373-49-9, Palmitoleic acid
 459-67-6, Hydnocarpic acid 463-40-1, Linolenic acid 474-25-9,
 Chenodeoxycholic acid 503-07-1, Vernolic acid 506-25-2, Isanic acid
 506-26-3, .gamma.-Linolenic acid 506-30-9, Eicosanoic acid 506-32-1,
 Arachidonic acid 514-10-3, Abietic acid 524-42-5, 1,2-Naphthalenedione
 525-66-6, Propranolol 530-78-9, Flufenamic acid 544-63-8,
 Tetradecanoic acid, biological studies 544-64-9, Myristoleic acid
 611-95-0, 4-Benzoylbenzoic acid 621-82-9, Cinnamic acid, biological
 studies 641-81-6, Apocholic acid 646-30-0, Nonadecanoic acid
 693-72-1, Vaccenic acid 1142-39-8, 4-Hexyloxybenzoic acid 1406-18-4,
 Vitamin E 2168-75-4, Ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
 2270-20-4, 5-Phenylvaleric acid 2430-94-6, cis-5-Dodecenoic acid
 2493-84-7 2608-24-4, Pipsulfan 2777-65-3, 10-Undecynoic acid
 2984-55-6, 2-Hydroxydodecanoic acid 3115-49-9, (p-Nonylphenoxy)acetic
 acid 3575-31-3, 4-Octylbenzoic acid 4419-39-0, Beclomethasone
 4521-28-2, 4-(4-Methoxyphenyl)-butyric acid 5104-49-4, Flurbiprofen
 5451-55-8, 4-tert-Butylcyclohexanecarboxylic acid 5728-52-9,
 4-Biphenylacetic acid 5731-13-5 6402-36-4, Traumatic acid 6950-82-9,
 7-Hydroxycoumarin-4-acetic acid 6990-06-3, Fusidic acid 7689-03-4,
 Camptothecin 8001-27-2, Hirudin 9001-12-1, MMP-1 9001-27-8, Factor
 VIII 9001-28-9, Factor IX 9002-64-6, Parathyroid hormone 9003-99-0,
 Myeloperoxidase 9004-10-8, Insulin, biological studies 9005-49-6,
 Heparin, biological studies 9007-12-9, Calcitonin 9014-00-0,
 Luciferase 9014-42-0, Thrombopoietin 9034-40-6D, LHRH, analogs
 9041-92-3 9054-89-1, Superoxide dismutase 9061-61-4, Nerve growth
 factor 11000-17-2, Vasopressin 11096-26-7, Erythropoietin
 13539-59-8, Azapropazone 13598-36-2D, Phosphonic acid, alkylidenebis-
 derivs. 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 15872-42-1,
 4-Heptyloxybenzoic acid 15872-43-2, 4-Nonyloxybenzoic acid 15872-44-3,
 4-Undecyloxybenzoic acid 17230-88-5, Danazol 20651-71-2,
 4-Butylbenzoic acid 21643-38-9, 4-Hexylbenzoic acid 22071-15-4,
 Ketoprofen 22204-53-1, Naproxen 23812-34-2 25167-62-8,
 Docosahexaenoic acid 25354-97-6, 2-Hexyldecanoic acid 25378-27-2,
 Eicosapentaenoic acid 26171-23-3, Tolmetin 26764-41-0, Eicosenoic acid
 27070-56-0, Eicosatrienoic acid 29679-58-1, Fenoprofen 29973-91-9,
 4-Benzyloxy-3-methoxyphenylacetic acid 30748-29-9, Feprazone
 34645-84-6, Fenclofenac 36322-90-4, Piroxicam 38194-50-2, Sulindac
 38289-29-1, trans-4-Pentylcyclohexanecarboxylic acid 38350-87-7,
 4-Heptylbenzoic acid 51110-01-1, Somatostatin 53483-12-8 55837-18-8,
 Butibufen 58574-03-1, 4'-Hydroxy-4-biphenylcarboxylic acid 58957-92-9,
 Idarubicin 59865-13-3, Cyclosporin 62229-50-9, Epidermal

growth factor 67763-96-6, Insulin-like growth factor I 67763-97-7, Insulin-like growth factor II 74397-12-9, Limaprost 79955-99-0, MMP-3 81627-83-0, Macrophage colony stimulating factor 83869-56-1, Granulocyte macrophage colony stimulating factor 85637-73-6, Atriopeptin 105844-41-5, Plasminogen activator inhibitor 106096-92-8, Endothelial cell growth factors 106096-93-9, Fibroblast growth factor basic 106956-32-5, Oncostatin M 107000-34-0 113427-24-0 117147-70-3, Amphiregulin 120373-36-6, Unoprostone 121181-53-1, Filgrastim 122312-54-3, Epoetin beta 122320-05-2, Secretory leukocyte protease inhibitor 123584-45-2, Fibroblast growth factor 4 123626-67-5, Endothelin-1 123774-72-1, Sargramostim 127464-60-2, Vascular endothelial growth factor 129653-64-1, Fibroblast growth factor 5 130939-41-2, Fibroblast growth factor 6 130939-66-1, Neurotrophin 3 139639-23-9, Tissue plasminogen activator 141256-52-2, MMP 7 143011-72-7, Granulocyte colony stimulating factor 143090-92-0, Anakinra 143375-33-1, Neurotrophin 4 146480-35-5, MMP 2 146480-36-6, MMP 9 148348-15-6, Fibroblast growth factor 7 151185-16-9, Fibroblast growth factor 9 155646-83-6, Heregulin-.beta.1 163150-12-7, Betacellulin 169494-85-3, Leptin 169592-56-7, Apopain 214210-48-7, **Placenta** growth factor 2 265112-35-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT 9004-06-2, Elastase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

IT 164003-41-2, Fibroblast growth factor 8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(isoforms b and c; carboxylic acids for encapsulating or enteric coating biol. active agents for delivery to intestine)

L67 ANSWER 2 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 2000:162430 HCAPLUS

TI **Stem cell factor** is not essential for
cell survival and proliferation of soft tissue sarcoma of
neuroectodermal origin

AU Ricotti, Emanuela; Bertorello, Nicoletta; Vai, Sergio; Pagani, Alberto; Di
Montezemolo, Luca Cordero; Madon, Enrico; Basso, Giuseppe

CS Department of Pediatrics, University of Turin, Turin, 10131, Italy

SO Haematologica (1999), 84(10), 879-886

CODEN: HAEMAX; ISSN: 0390-6078

PB Ferrata Storti Foundation

DT Journal

LA English

CC 15 (Immunochemistry)

AB Background and Objectives. **Stem cell factor** (**SCF**), and its receptor (**c-kit**) play key roles in the expansion and differentiation of hematopoietic progenitor **cells**, melanoblasts and primordial **germ cells**, making it possible that **SCF** and **c-kit** are involved in **neoplastic** processes deriving from these **cells**. **C-kit** has been described to be expressed at different levels in neuroblastoma and in soft tissue sarcoma of neuroectodermal origin, and seems to be required for survival processes. In this study we investigate how **c-kit** expression is regulated and whether a **SCF** autocrine loop is essential for survival of sarcoma **cell** lines. Design and Methods. **C-kit** modulation and internalization was evaluated incubating **cells** with rhSCF. **Cell** differentiation and proliferation expts. were performed to test whether **c-kit** expression is related to **cell** cycle progression or to differentiation processes. **Cell** cultures were treated with neutralizing antibody and antisense oligonucleotides in order to assess the possible significance of the **SCF** autocrine loop. Results. In vitro **SCF** stimulation induces **c-**

c-kit down-regulation; this phenomenon could be connected with receptor internalization, and new protein synthesis is necessary for its re-expression. The **cell** proliferation arrest in G0/G1 does not modify **c-kit** expression while down-regulation of **c-kit** was demonstrated after **cells** had been treated with differentiating agents. **SCF** neutralization does not influence either the S phase or apoptosis in sarcoma **cell** lines. Interpretation and Conclusions. In sarcoma **cell** lines, **c-kit** is regulated by differentiation processes; moreover our results suggest that **c-kit** activity, but probably not the **SCF** autocrine loop, is essential for survival of these **cell** lines.

RE.CNT 23

RE

- (1) Alai, M; J Biol Chem 1992, V267, P18021 HCAPLUS
- (2) Beck, D; Blood 1995, V86, P3132 HCAPLUS
- (3) Broudy, V; Blood 1997, V90, P1345 HCAPLUS
- (4) Campana, D; J Immunol 1987, V138, P648 HCAPLUS
- (5) Carroll, M; J Biol Chem 1990, V265, P19812 HCAPLUS
- (6) Carroll, M; J Biol Chem 1991, V266, P14964 HCAPLUS
- (7) Cavazzana, A; Am J Pathol 1987, V127, P507 MEDLINE
- (8) Cohen, P; Blood 1994, V84, P3465 HCAPLUS
- (9) Hirota, S; Brain Res Mol Brain Res 1992, V15, P47 HCAPLUS
- (10) Horie, M; J Biol Chem 1993, V268, P968 HCAPLUS
- (11) Matsumi, Y; Nature 1990, V347, P667
- (12) Miyazawa, K; Blood 1994, V83, P137 HCAPLUS
- (13) Miyazawa, K; Exp Hematol 1991, V19, P1110 HCAPLUS
- (14) Pagani, A; Int J Cancer 1995, V63, P738 MEDLINE
- (15) Ricotti, E; Blood 1998, V91, P2397 HCAPLUS
- (16) Schimdt, D; Cancer 1991, V68, P2251
- (17) Shimizu, Y; J Immunol 1997, V156, P3443
- (18) Thiele, C; Cancer Metastasis Rev 1991, V10, P311 MEDLINE
- (19) Timeus, F; Exp Hematol 1997, V25, P1253 HCAPLUS
- (20) Torti, M; J Biol Chem 1992, V267, P8293 HCAPLUS
- (21) Triche, T; Hum Pathol 1983, V14, P569 MEDLINE
- (22) Weiler, S; Blood 1996, V87, P3688 HCAPLUS
- (23) Yee, N; J Biol Chem 1994, V269, P31991 HCAPLUS

L67 ANSWER 3 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 2000:15227 HCAPLUS

DN 132:77836

TI Improved process for preparing Schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon

IN Hay, Bruce Allan; Clark, Michael Thomas

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K001-107

ICS C07K014-61; A61K047-48

CC 17-6 (Food and Feed Chemistry)

Section cross-reference(s): 18, 24, 27, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000507	A1	20000106	WO 1999-IB993	19990602
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9938424	A1	20000117	AU 1999-38424	19990602

PRAI US 1998-PV90714 19980626
 US 1998-90714 19980626
 WO 1999-IB993 19990602

OS MARPAT 132:77836

AB An improved process is described for prepg. Schiff base condensation adduct final products whose components comprise a protein having beneficial activity in animals, and an arom. o-hydroxy aldehyde, which comprises bringing together the above-mentioned components in an aq. environment at a pH of 7.0 or higher to form a reaction mixt., under conditions effective to drive said condensation reaction substantially to completion by removing from about 97.0 % to about 99.9 % by wt., preferably from about 98.0 % to about 99.0 % by wt. of the water already present or produced during said condensation reaction, consistent with maintaining the integrity of the condensation reactants and adduct final product, and to assure a rate of conversion to said condensation adduct final product, i.e. , with resulting yield of said condensation adduct final product of equal to or greater than about 98.5 % by wt., preferably equal to or greater than about 99.5 % by wt. based on the wt. of the reactants. Preferred arom. o-hydroxy aldehydes comprise o-vanillin; salicylaldehyde; 2,3-dihydroxybenzaldehyde; 2,6-dihydroxybenzaldehyde; 2-hydroxy-3-ethoxybenzaldehyde; or pyridoxal. A very wide range of proteins may be employed. The improved process provides yields over 90 % and substantially quant. conversion of the aldehyde and protein to the condensation adduct.

ST Schiff base protein amine arom hydroxyaldehyde; hormone arom hydroxyaldehyde Schiff base; drug peptide arom hydroxyaldehyde Schiff base; growth promoter arom hydroxyaldehyde Schiff base; feed additive protein amine arom hydroxyaldehyde Schiff base

IT Proteins, specific or class

RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ECP (eosinophil cationic protein); improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Immunoglobulins

RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(G; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Pituitary hormones

RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anterior; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Antiarteriosclerotics

(antiatherosclerotics; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Aldehydes, reactions

RL: RCT (Reactant)

(arom., o-hydroxy-; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Skin

(artificial; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Temperature effects, biological

(cold; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Anti-inflammatory agents

Antiasthmatics

Antidiabetic agents

Antihypertensives
 Antitumor agents
 Atomizing (spraying)
 Feed additives
 Immunostimulants
 Immunosuppressants
 Macrophage
 Temperature effects, biological
 (improved process for prepg. Schiff base adducts of peptide and protein
 amine groups with o-hydroxy aldehydes and compns. based thereon for
 food and drug use)

IT Cytokines
 Enkephalins
 Growth promoters, animal
 Hemoglobins
 Hemopoietins
 Immunoglobulins
 Interferons
 Interleukin 1
 Interleukin 10
 Interleukin 11
 Interleukin 12
 Interleukin 2
 Interleukin 3
 Interleukin 4
 Interleukin 5
 Interleukin 6
 Interleukin 7
 Interleukin 8
 Interleukin 9
 Interleukins
 Lymphotoxin
 Myoglobins
 Proteins, general, biological studies
Stem cell factor
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (improved process for prepg. Schiff base adducts of peptide and protein
 amine groups with o-hydroxy aldehydes and compns. based thereon for
 food and drug use)

IT Schiff bases
 RL: FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (improved process for prepg. Schiff base adducts of peptide and protein
 amine groups with o-hydroxy aldehydes and compns. based thereon for
 food and drug use)

IT Antibodies
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (monoclonal; improved process for prepg. Schiff base adducts of peptide
 and protein amine groups with o-hydroxy aldehydes and compns. based
 thereon for food and drug use)

IT Analgesics
 (opioid; improved process for prepg. Schiff base adducts of peptide and
 protein amine groups with o-hydroxy aldehydes and compns. based thereon
 for food and drug use)

IT Drying
 (spray; improved process for prepg. Schiff base adducts of peptide and
 protein amine groups with o-hydroxy aldehydes and compns. based thereon
 for food and drug use)

IT Interferons
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha.-2a; improved process for prepg. Schiff base adducts of peptide
 and protein amine groups with o-hydroxy aldehydes and compns. based
 thereon for food and drug use)

IT Interferons
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.alpha.-2b; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Interferons
 Tumor necrosis factors
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.alpha.; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Lactoglobulins
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.-; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Interferons
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.1a; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Interferons
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.gamma.1b; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT Interferons
 RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.gamma.; improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT 50-57-7, Lypressin 53-73-6, Angiotensin amide 56-59-7, Felypressin 58-82-2, Bradykinin 113-79-1, AVP 342-10-9, Kallidin 4117-65-1, Aspartocin 5534-95-2, Pentagastrin 8068-28-8, Colistimethate 9001-28-9, Blood-coagulation factor IX 9001-63-2, Lysozyme 9002-01-1, Streptokinase 9002-60-2, ACTH, biological studies 9002-61-3, Chorionic gonadotropin 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, FSH 9002-71-5, TSH 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-10-8D, Insulin, dalanated 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9014-42-0, Thrombopoietin 9034-39-3, Somatoliberin 9034-40-6, LHRH 9034-42-8, .beta.-MSH 9035-54-5, **Placental lactogen** 9039-53-6, Urokinase 9087-70-1, Aprotinin 11000-17-2, Vasopressin 11096-26-7, Erythropoietin 15958-92-6, 1-8-Bradykinin 16679-58-6, Desmopressin 16870-37-4, Amogastrin 16960-16-0, Cosyntropin 17650-98-5, Ceruletide 24305-27-9, Thyrotropin-releasing hormone 26305-03-3 33515-09-2, Gonadorelin 33605-67-3, Cargutocin 34765-96-3, Alsactide 35115-60-7, Teprotide 37025-55-1, Carbetocin 37213-49-3, .alpha.-MSH 37228-64-1, .beta.-Glucocerebrosidase 37332-99-3, Avoparcin 37377-93-8, .beta.-LPH 39422-22-5, .gamma.-LPH 51110-01-1, Somatostatin 53714-56-0, Leuprolide 54017-73-1, Murodermin 57773-63-4, Triptorelin 57773-65-6, Deslorelin 58569-55-4, [Met5]enkephalin 58822-25-6, 1-5-.beta.-Neoendorphin (human) 59865-13-3, **Cyclosporin** 60118-07-2, Endorphin 60173-73-1, Arfalsin 60267-61-0, Ubiquitin 60731-46-6, Elcatonin 61489-71-2, Human menopausal gonadotropin 62304-98-7, Thymalfasin 62683-29-8, Colony stimulating factor 63631-40-3, DADL 64695-06-3, Des-Arg9-[Leu8]-bradykinin 64854-64-4, FK-33824 65154-06-5, PAF 65647-03-2 65807-02-5, Goserelin 67269-08-3 67422-14-4, Proinsulin

human 67763-96-6, IGF-1 67763-97-7, IGF-2 69558-55-0, Thymopentin 69671-17-6, .alpha.-Neoendorphin 71800-36-7, 1-9-Kallidin 73168-24-8 74135-04-9, Morphiceptin 74913-18-1D, Dynorphin, derivs. 75644-90-5 76712-82-8, Histrelin 76932-56-4, Nafarelin 77752-00-2, .beta.-Neoendorphin 78123-71-4, DAMGO 79804-71-0, Corticorelin 81627-83-0, M-CSF 82030-87-3, Somatrem 83150-76-9, Octreotide 83397-56-2, PL-017 83784-18-3, Lutrelin acetate 85006-82-2, Dynorphin B 88161-22-2, Dynorphin A 88373-73-3 89383-13-1, Somidobove 90779-69-4, Atosiban 96353-48-9, Somagrebove 97048-13-0, Urofollitropin 97825-00-8, [D-Phe7]-bradykinin 99283-10-0, Molgramostim 102583-46-0, Detirelix acetate 102733-72-2, Sometripor 102744-97-8, Sometribove 103060-53-3, Daptomycin 103222-11-3, Vapreotide 103429-31-8, CTOP 105857-23-6, Alteplase 105953-59-1, Dumorelin 106282-98-8, Somalapor 110551-45-6 110881-59-9 110942-02-4, Aldesleukin 111212-85-2, Ersofermin 113189-02-9, Antihemophilic factor 113427-24-0, Epoetin alfa 114455-29-7 119693-74-2, Somenopor 120993-53-5, Desirudin 121181-53-1, Filgrastim 122302-71-0, Atriopeptin-21 122384-88-7, Amlintide 122752-15-2, Deltorphan C 122752-16-3, Deltorphan B 123774-72-1, Sargramostim 126752-39-4, Somavubove 127785-64-2, Basifungin 127984-74-1, Lanreotide acetate 128270-60-0, Bivalirudin 129566-95-6, Somfasepor 135968-09-1, Lenograstim 136105-89-0 137463-76-4, PIXY321 137487-62-8, Alvircept sudotox 138614-30-9, HOE 140 139639-23-9, Tissue plasminogen activator 142298-00-8, Emoctakin 143003-46-7, Alglucerase 143090-92-0, Anakinra 148637-05-2, Cilmotim 151126-32-8, Pramlintide 152923-56-3, Daclizumab 154248-96-1, Iroplact 154248-97-2, Imiglucerase 157238-32-9, Cetermin 165101-51-9, Becaplermin 166089-33-4, Nagrestipen 171870-23-8, Lanoteplase

RL: FFD (Food or feed use); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

IT 66-72-8, Pyridoxal 90-02-8, Salicylaldehyde, reactions 121-33-5, Vanillin 387-46-2, 2,6-Dihydroxybenzaldehyde 492-88-6, 2-Hydroxy-3-ethoxybenzaldehyde 24677-78-9, 2,3-Dihydroxybenzaldehyde

RL: RCT (Reactant)

(improved process for prepg. Schiff base adducts of peptide and protein amine groups with o-hydroxy aldehydes and compns. based thereon for food and drug use)

RE.CNT 12

RE

- (1) Anon; US 4886659 A
- (2) Anon; US 5633351 A
- (3) Brandon, D; Journal of Immunological Methods 1985, V78(1), P87 HCAPLUS
- (4) Clark; US 5198422 A 1993 HCAPLUS
- (5) Dalgety UK Limited; EP 0284186 A 1988
- (6) Dhont, J; Aroma Res Proc Int Symp 1975, P193 HCAPLUS
- (7) Dzhagarov, B; Zh Prikl Spektrosk 1994, V61(1-2), P95 HCAPLUS
- (8) Neorx Corporation; WO 9003401 A 1990
- (9) Tomlinson, A; Food Chemistry 1993, V48(4), P373 HCAPLUS
- (10) Williams, J; Biochim Biophys Acta 1968, V154(2), P323 HCAPLUS
- (11) Zaugg, R; Journal of Biological Chemistry 1977, V252(23), P8542 HCAPLUS
- (12) Zhu, T; Bioconjugate Chemistry 1994, V5(4), P312 HCAPLUS

L67 ANSWER 4 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:780242 HCAPLUS

DN 132:217164

TI **Stem cell factor/c-kit system in spermatogenesis**

AU Mauduit, Claire; Hamamah, Samir; Benahmed, Mohamed

CS INSERM U407, INSERM U407, Faculte de Medecine Lyon-Sud, Oullins, F-69921, Fr.

SO Hum. Reprod. Update (1999), 5(5), 535-545

CODEN: HRUPF8; ISSN: 1355-4786

PB Oxford University Press

DT Journal; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 Section cross-reference(s): 14
 AB A-review, with 92 refs., reporting a large no. of data, obtained essentially in animal models, that suggest an important role for the **SCF/c-kit** system in **spermatogenesis** and, as a corollary, its potential involvement in **spermatogenic** defects. One of the major unresolved questions with male **infertility** is the identification of the mol. origin of a great majority of the **spermatogenetic** arrests currently diagnosed as idiopathic male **infertility**. During the past years, several families of regulating **factors** have been implicated in **spermatogenesis** defects obsd. essentially in animal models. Among these **factors** are signalling mols., and particularly the **stem cell factor (SCF)/c-kit** system. The **SCF** and its receptor **c-kit** are an appropriate example to illustrate the role of signalling mols. in the physiol. and pathol. of **spermatogenesis**. The **SCF/c-kit** regulates primordial **germ cell** migration, proliferation and apoptosis during fetal gonadal development. The **SCF/c-kit** also regulates **spermatogonia** proliferation in the adult animal. In mutant mice, abnormalities of the **SCF/c-kit** gene expression, such as gene deletion, point mutation, alternative splicing defect, lead to different types of **spermatogenesis** alterations (e.g., decrease in primordial **germ cell** migration, decrease in **spermatogonia** proliferation). More recently, defects in **SCF/c-kit** gene expression have also been shown in human testicular dysfunctions. Indeed, a redn. in **SCF/c-kit** expression has been evidenced in oligozoospermia/azoospermia assocd. with an increase in the **germ cell** apoptosis process. In addn., **c-kit** seems to be a good marker of **seminoma** testicular tumors.

ST review **stem cell factor c kit** protein **spermatogenesis**; male **infertility**
stem cell factor c kit protein review; **seminoma stem cell factor c kit** protein review

IT Embryo, animal
 (fetus, development; **stem cell factor/c-kit** system in **spermatogenesis** in relation to)

IT **Fertility**
 (male, disorder; **stem cell factor/c-kit** system in **spermatogenesis** in relation to)

IT Testis, neoplasm
 (**seminoma**; **stem cell factor/c-kit** system in **spermatogenesis** in relation to)

IT **Spermatogenesis**
 Testis
 (**stem cell factor/c-kit** system in **spermatogenesis**)

IT **Stem cell factor**
c-Kit (protein)
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (**stem cell factor/c-kit** system in **spermatogenesis**)

IT Apoptosis
 Cell migration
 Cell proliferation
 Signal transduction, biological

Testis, disease

(stem cell factor/c-kit

system in spermatogenesis in relation to)

RE.CNT 93

RE

- (1) Albanesi, C; Development 1996, V122, P1291 HCAPLUS
- (2) Allard, E; Biol Reprod 1996, V55, P185 HCAPLUS
- (3) Anderson, D; Cell 1990, V63, P235 HCAPLUS
- (4) Ashby, J; Environ Health Perspect 1997, V105, P164 HCAPLUS
- (5) Bedell, M; Genes Dev 1995, V9, P455 HCAPLUS
- (6) Bellve, A; J Cell Biol 1977, V74, P68 MEDLINE
- (7) Benahmed, M; Male Infertility: Clinical Investigation, Cause, Evaluation and Treatment 1996, P55
- (8) Blanchard, K; Endocrinology 1998, V139, P236 HCAPLUS
- (9) Blume, J; EMBO J 1991, V10, P4121
- (10) Bokemeyer, C; J Cancer Res Clin Oncol 1996, V122, P301 HCAPLUS
- (11) Boussouar, F; Endocrinology 1999, V140, P3054 HCAPLUS
- (12) Brannan, C; Genes Dev 1992, V6, P1832 HCAPLUS
- (13) Brannan, C; Proc Natl Acad Sci 1991, V88, P4671 HCAPLUS
- (14) Breyer, P; Endocrinology 1996, V137, P2159 HCAPLUS
- (15) Carson, W; Proc Natl Acad Sci 1994, V91, P7553 HCAPLUS
- (16) Chabot, B; Nature 1988, V335, P88 HCAPLUS
- (17) Cheek, A; J Androl 1998, V19, P5 HCAPLUS
- (18) Cooper, R; J Endocrinol 1997, V152, P159 HCAPLUS
- (19) Copeland, N; Cell 1990, V63, P175 HCAPLUS
- (20) DeRooj, D; Curr Opin Cell Biol 1998, V10, P694
- (21) Dolci, S; Nature 1991, V352, P809 HCAPLUS
- (22) Dym, M; Biol Reprod 1995, V52, P8 HCAPLUS
- (23) Eddy, E; Gamete Res 1981, V4, P333
- (24) Feng, H; Biol Reprod 1997, V57, P194 HCAPLUS
- (25) Feng, H; Fertil Steril 1999, V71, P85 MEDLINE
- (26) Flanagan, J; Cell 1991, V64, P1025 HCAPLUS
- (27) Fritz, I; The Sertoli Cell 1993, P217
- (28) Fusigawa, M; Urology 1998, V3, P460
- (29) Geissler, E; Cell 1988, V55, P185 HCAPLUS
- (30) Geissler, E; Genetics 1981, V97, P337 MEDLINE
- (31) Giebel, L; Oncogene 1992, V7, P2207 HCAPLUS
- (32) Giebel, L; Proc Natl Acad Sci 1991, V88, P8696 HCAPLUS
- (33) Gilbert, S; Developmental Biology 1994, P788
- (34) Gnessi, L; Endocr Rev 1997, V18, P541 HCAPLUS
- (35) Godin, I; Nature 1991, V352, P807 HCAPLUS
- (36) Hakovirta, H; Endocrinology 1999, V140, P1492 HCAPLUS
- (37) Huang, E; Mol Biol Cell 1992, V3, P349 HCAPLUS
- (38) Izquierdo, M; J Pathol 1995, V177, P253 MEDLINE
- (39) Jiang, C; Gene 1997, V185, P285 HCAPLUS
- (40) Kierszenbaum, A; Endocr Rev 1994, V15, P116 MEDLINE
- (41) Lamb, D; J Androl 1999, V20, P23 MEDLINE
- (42) Lev, S; J Biol Chem 1992, V267, P15970 HCAPLUS
- (43) Longley, B; Proc Natl Acad Sci 1997, V94, P9017 HCAPLUS
- (44) Loveland, K; J Endocrinol 1997, V153, P337 HCAPLUS
- (45) Lyon, M; Genet Res 1984, V44, P161 MEDLINE
- (46) Majumdar, M; J Biol Chem 1994, V269, P1237 HCAPLUS
- (47) Manova, K; Dev Biol 1991, V146, P312 HCAPLUS
- (48) Manova, K; Dev Biol 1993, V157, P85 HCAPLUS
- (49) Manova, K; Development 1990, V110, P1057 HCAPLUS
- (50) Martin, F; Cell 1990, V63, P203 HCAPLUS
- (51) Marziali, G; Dev Biol 1993, V157, P182 HCAPLUS
- (52) Matsui, Y; Nature 1990, V347, P667 HCAPLUS
- (53) Matsui, Y; Nature 1991, V353, P750 MEDLINE
- (54) Mauduit, C; J Biol Chem 1999, V274, P770 HCAPLUS
- (55) Mauduit, C; Male Sterility for Motility Disorders: Etiological Factors and Treatment 1999, P173
- (56) McCoshen, J; Experientia 1975, V31, P589 MEDLINE
- (57) Meyts, E; J Pathol 1996, V178, P166 MEDLINE
- (58) Mintz, B; J Exp Zool 1957, V134, P207
- (59) Monk, M; J Embryol Exp Morphol 1981, V63, P75 MEDLINE

- (60) Morrison, G; Bio Essays 1993, V15, P77
- (61) Morrison, S; Cell 1997, V88, P287 HCAPLUS
- (62) Motro, B; Development 1991, V102, P1207
- (63) Nehar, D; Endocrinology 1997, V138, P1964 HCAPLUS
- (64) Nocka, K; EMBO J 1990, V9, P1805 HCAPLUS
- (65) Ogawa, M; J Exp Med 1991, V174, P63 HCAPLUS
- (66) Okabe, M; Am J Hum Genet 1998, V62, P1274 HCAPLUS
- (67) Orth, J; Mol Reprod Dev 1996, V45, P123 HCAPLUS
- (68) Pandiella, A; J Biol Chem 1992, V267, P24028 HCAPLUS
- (69) Rajpert-De Meyts, M; Int J Androl 1994, V17, P85
- (70) Reith, A; EMBO J 1991, V10, P2451 HCAPLUS
- (71) Reith, A; Genes Dev 1990, V4, P390 HCAPLUS
- (72) Robertson, D; Molecular Biology of the Male Reproductive System 1993, P411 HCAPLUS
- (73) Roosen-Runge, E; Ann NY Acad Sci 1952, V55, P574
- (74) Rossi, P; Biochem Biophys Res Commun 1991, V176, P910 HCAPLUS
- (75) Rossi, P; Dev Biol 1993, V155, P68 HCAPLUS
- (76) Sandlow, J; J Androl 1996, V17, P403 HCAPLUS
- (77) Sarvella, P; J Hered 1956, V47, P123
- (78) Schlegel, P; J Androl 1999, V20, P18 MEDLINE
- (79) Strohmeyer, T; J Urol 1995, V153, P511 MEDLINE
- (80) Tajima, Y; Development 1991, V113, P1031 HCAPLUS
- (81) Tam, P; J Embryol Exp Morphol 1981, V64, P133 MEDLINE
- (82) Tan, J; Science 1990, V247, P209 HCAPLUS
- (83) Tesarik, J; Mol Hum Reprod 1998, V4, P757 MEDLINE
- (84) Toksoz, D; Proc Natl Acad Sci 1992, V89, P7350 HCAPLUS
- (85) Vandenbark, G; Oncogene 1992, V7, P1259 HCAPLUS
- (86) Verhoeven, G; J Androl 1991, V12, P9 HCAPLUS
- (87) Vincent, S; Development 1998, V125, P4585 HCAPLUS
- (88) Wang, R; Biol Reprod 1998, V58, P1250 HCAPLUS
- (89) Wassarman, P; Reproductive Endocrinology, Surgery and Technology 1996, P341
- (90) Yan, W; Endocrinology 1999, V140, P1499 HCAPLUS
- (91) Yarden, Y; EMBO J 1987, V6, P3341 HCAPLUS
- (92) Yee, N; J Exp Med 1994, V179, P1777 HCAPLUS
- (93) Yoshinaga, K; Development 1991, V113, P689 MEDLINE

L67 ANSWER 5 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:776188 HCAPLUS

DN 132:135190

TI Role of the **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**

AU Bartmanska, Jolanta

CS Instytut Zoologiczny, Uniwersytet Wroclawski, Pol.

SO Postepy Biol. Komorki (1999), 26(3), 461-475

CODEN: PBKODV; ISSN: 0324-833X

PB Fundacja Biologii Komorki i Biologii Molekularnej

DT Journal; General Review

LA Polish

CC 13-0 (Mammalian Biochemistry)

AB A review with 72 refs. The **c-Kit** a receptor with tyrosine kinase activity is encoded by protooncogene **c-kit** situated in the mouse W (White Spotting) locus. It is expressed on the surface of gametogenic cells of various developmental stage. The only **c-Kit** independent cells are As **spermatogonia**. **SCF** (Stem Cell Factor), which is a ligand for **c-Kit** receptor is encoded in the Sl (Steel) locus and expressed in Sertoli cells. In male gonads there are two forms of **SCF**: mbSCF (membrane bound **SCF**) and sSCF (sol. **SCF**). Both forms are able to induce receptor phosphorylation. The **c-Kit/SCF** system plays a crucial function in regulation of multiplication and migration of PGCs (Primordial Germ Cells) and gonocytes, and also in multiplication and surviving of **spermatogonia**. It acts to prevent **spermatocytes** and **spermatids** apoptosis. The system

serves also as a **factor** facilitating motility, capacitation and acrosomal reaction of **spermatozoa**. Mutations at the mouse W and S1 locus lead to pleiotropic effects including reduced **fertility** or sterility and severe disturbances in hematopoiesis and melanogenesis. The **c-Kit/SCF** may be involved the initiation or progression of some testis **tumors**.

ST review **cKit SCF spermatogenesis**

IT Testis

(Sertoli cell; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT **Spermatogenesis**

(**c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT **Stem cell factor**

c-Kit (protein)

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(**c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT **Fertility**

(male; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT Gamete and **Germ cell**

(primordial; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT Cell migration

(**sperm** motility; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT **Sperm**

(**spermatocyte**; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

IT **Sperm**

(**spermatogonium**; **c-Kit/SCF** system in regulation of mammalian **spermatogenesis**)

L67 ANSWER 6 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:393951 HCAPLUS

DN 131:31048

TI **Method for treating asthma using stem cell factor (SCF) antibody**

IN Brownell, Elise; Lukacs, Nicholas; Kunkel, Steven L.; Strieter, Robert M.

PA Bayer Corporation, USA; Univ. of Michigan

SO U.S., 21 pp., Cont. of U.S. Ser. No. 431,314, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K039-395

NCL 424145100

CC 15-3 (Immunochimistry)

Section cross-reference(s): 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5911988	A	19990615	US 1997-912541	19970818
PRAI	US 1995-431314		19950428		

AB This invention provides pharmaceutical compns. comprising anti-**SCF** antibodies for the redn. of eosinophilia in the lungs of mammals. This invention also provides for methods of treating **asthma** and generating a murine model for **asthma**. **Asthma** model is prepd. in mice with immunization of *Schistosoma mansoni* egg antigen. In the invention, eosinophilia or eosinophil infiltration is also reduced by treating with anti-interleukin 4 antibodies.

ST **stem cell factor antibody asthma**

eosinophilia; interleukin 4 monoclonal antibody eosinophil infiltration; airway inflammation **SCF** IL4 antibody; mouse model **asthma** *Schistosoma* egg antigen

IT **Asthma**

Disease models
 Eosinophilia
 (anti-**stem cell factor** antibody and
 anti-interleukin 4 antibody for treating **asthma** or
 eosinophilic airway inflammation)

IT Antibodies
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (anti-**stem cell factor** antibody and
 anti-interleukin 4 antibody for treating **asthma** or
 eosinophilic airway inflammation)

IT Interleukin 4
Stem cell factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anti-**stem cell factor** antibody and
 anti-interleukin 4 antibody for treating **asthma** or
 eosinophilic airway inflammation)

IT Mouse
 (**asthma** model; mice immunized with *Schistosoma mansoni* egg
 antigen for use as **asthma** model)

IT Drug delivery systems
 (carriers; mice immunized with *Schistosoma mansoni* egg antigen for use
 as **asthma** model)

IT Eosinophil
 (infiltration; anti-**stem cell factor**
 antibody and anti-interleukin 4 antibody for treating **asthma**
 or eosinophilic airway inflammation)

IT Respiratory tract
 (inflammation, eosinophilic; anti-**stem cell**
factor antibody and anti-interleukin 4 antibody for treating
asthma or eosinophilic airway inflammation)

IT Drug delivery systems
 (intra-tracheal; mice immunized with *Schistosoma mansoni* egg antigen
 for use as **asthma** model)

IT Lung
 Mammal (Mammalia)
Schistosoma mansoni
 (mice immunized with *Schistosoma mansoni* egg antigen for use as
asthma model)

IT c-Kit (protein)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mice immunized with *Schistosoma mansoni* egg antigen for use as
asthma model)

IT Antigens
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (mice immunized with *Schistosoma mansoni* egg antigen for use as
asthma model)

IT Antibodies
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (monoclonal; anti-**stem cell factor**
 antibody and anti-interleukin 4 antibody for treating **asthma**
 or eosinophilic airway inflammation)

IT Egg
 (parasite; mice immunized with *Schistosoma mansoni* egg antigen for use
 as **asthma** model)

IT 9001-92-7, Protease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (**stem cell factor**-targeted; mice
 immunized with *Schistosoma mansoni* egg antigen for use as
asthma model)

RE.CNT 35

RE

- (1) Ackerman, V; Chest 1994, V105, P687 MEDLINE
- (2) Ando, A; J Clin Invest 1993, V92, P1639 HCAPLUS

- (3) Anon; WO 9217505 1992 HCAPLUS
- (4) Anon; Genzyme Catalog 1993, P196
- (5) Bischoff; J Exp Med 1992, V175, P237 HCAPLUS
- (6) Broxmeyer, H; Cancer Cells 1991, V3(12), P480 HCAPLUS
- (7) Chester; Tibtech 1995, V13, P294 HCAPLUS
- (8) Dastyh, J; J of Immunology 1994, V152, P213 HCAPLUS
- (9) Djukanovic, R; AAS 40 Update on Childhood Asthma 1993, P169 MEDLINE
- (10) Durum; Fundamental Immunology 1993
- (11) Dvorak, A; Int Arch Allergy Immunology 1993, V101, P247 MEDLINE
- (12) Dvorak, A; J Leukocyte Biology 1993, V54, P465 MEDLINE
- (13) Galli, S; Am Jour Pathobio 1993, V142(4), P965 HCAPLUS
- (14) Galli, S; J Clin Invest 1993, V91, P148 MEDLINE
- (15) Godfrey, S; AAS 40 Update on Childhood Asthma 1993, P109 MEDLINE
- (16) Iemura, A; Am J Pathobiology 1994, V144(2), P321 HCAPLUS
- (17) Kaushansky, K; Proteins:Structure, Function, and Genetics 1992, V12, P1 HCAPLUS
- (18) Kinashi, T; Blood 1994, V83(4), P1033 HCAPLUS
- (19) Li, M; Nouv Rev Fr Hematologie 1993, V35, P81 MEDLINE
- (20) Lukacs; European Journal of Immunology 1995, V25, P245 HCAPLUS
- (21) Lukacs; Journal of Leukocyte Biology 1996, V59, P13 HCAPLUS
- (22) Lukacs; The Journal of Immunology 1995, V154, P5411 HCAPLUS
- (23) Lukacs; The Journal of Immunology 1996, V156, P3945 HCAPLUS
- (24) Lukacs; The Journal of Immunology 1997, V158, P4398 HCAPLUS
- (25) Lukacs, N; Am J Respir Mol Biol 1994, V10, P526 HCAPLUS
- (26) Morley, J; Trends in Phar Sci 1993, V14, P208 MEDLINE
- (27) Page, C; Am Rev Respir Dis 1993, V147, PS29 MEDLINE
- (28) Rottem, M; J Immunology 1993, V151, P4950 HCAPLUS
- (29) Ryan, J; J Neurosci Research 1994, V37, P415 HCAPLUS
- (30) Saito, H; Int Arch Allergy Immunology 1994, V103, P143 HCAPLUS
- (31) Tsuura, Y; Virchows Archiv 1994, V424, P135 MEDLINE
- (32) Valent, P; Immunology Today 1994
- (33) Wegner; US 5324510 1994
- (34) Windt, M; Asthma:Evolving Therapeutic Regimens 1991, P23
- (35) Ziegler, I; J Biol Chem 1993, V268(17), P12544 HCAPLUS

L67 ANSWER 7 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:327752 HCAPLUS

DN 131:128007

TI Removal of **stem cell factor** or addition of monoclonal anti-**c-KIT** antibody induces apoptosis in murine melanocyte precursors

AU Ito, Masaru; Kawa, Yoko; Ono, Hirotake; Okura, Mitsuhiro; Baba, Takako; Kubota, Yasuo; Nishikawa, Sin-Ichi; Mizoguchi, Masako

CS Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan

SO J. Invest. Dermatol. (1999), 112(5), 796-801

CODEN: JIDEAE; ISSN: 0022-202X

PB Blackwell Science, Inc.

DT Journal

LA English

CC 13-3 (Mammalian Biochemistry)

AB Previous findings indicate that the protein **c-KIT** and its ligand, **stem cell factor (SCF)** play a crucial role in the development of melanocytes from their precursors in the embryonic neural crest cells. Using a monoclonal anti-**c-KIT** antibody, **ACK2**, which is an antagonistic blocker of **c-KIT** function, we and others demonstrated that mouse melanocytes disappeared with the injection of **ACK2** during certain periods of embryonic and postnatal life. The precise mechanisms of this disappearance, however, remain unclear. Because melanocytes disappeared without any inflammation in these in vivo studies, we suspect that apoptosis was a main cause of their disappearance. In this study, to clarify the underlying mechanism, we studied whether **ACK2** induces apoptosis in **c-KIT**-pos. melanoblasts, which appear in mouse neural crest cells cultured with **SCF** from 9.5 d old mouse embryos.

With an in situ apoptosis detection kit, a significant increase in apoptosis was detected after the removal of **SCF**, which further increased with the addn. of **ACK2** during **SCF**-dependent periods. The occurrence of apoptosis in the cultured cells was also demonstrated by a DNA anal. and electron microscopy. Immunohistochem. double staining confirmed that the apoptotic cells were **c-KIT** pos., and the electron microscopy showed that these apoptotic cells were melanocyte precursors. It was therefore demonstrated that apoptosis was induced in the **SCF**-dependent **c-KIT**-pos. melanocytes in vitro when the **SCF/c-KIT** interaction was obstructed. These findings elucidate the mechanism of the regulation of melanocyte development, and the survival and proliferation of these precursor cells, by **SCF/c-KIT** interaction.

ST **cKit stem cell factor** apoptosis
development melanocyte
IT Apoptosis
Development, mammalian postnatal
Embryo, animal
(removal of **stem cell factor** or addn. of
monoclonal anti-**c-KIT** antibody induces apoptosis in
murine melanocyte precursors)
IT **Stem cell factor**
c-Kit (protein)
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BIOL (Biological study); PROC (Process)
(removal of **stem cell factor** or addn. of
monoclonal anti-**c-KIT** antibody induces apoptosis in
murine melanocyte precursors)

RE.CNT 24

RE

- (1) Brown, D; J Biol Chem 1993, V268, P3037 HCAPLUS
- (2) Chabot, B; Nature 1988, V335, P88 HCAPLUS
- (3) Cohen; Immunol Today 1993, V14, P126 HCAPLUS
- (4) Gavrieli, Y; J Cell Biol 1992, V119, P493 HCAPLUS
- (5) Grabbe, J; Arch Dennatol Res 1994, V287, P78 HCAPLUS
- (6) Huang, E; Cell 1990, V63, P225 HCAPLUS
- (7) Huang, S; Oncogene 1996, V13, P2339 HCAPLUS
- (8) Iemura, A; Am J Pathol 1994, V144, P321 HCAPLUS
- (9) Ito, K; J Embryol Exp Morph 1984, V84, P49 MEDLINE
- (10) Kerr, J; Br J Cancer 1972, V26, P239 MEDLINE
- (11) Mayer, T; Dev Biol 1973, V34, P39 MEDLINE
- (12) Murphy, M; Dev Biol 1992, V153, P396 MEDLINE
- (13) Nishikawa, S; EMBO J 1991, V10, P2111 HCAPLUS
- (14) Ogawa, M; J Exp Med 1991, V174, P63 HCAPLUS
- (15) Okura, M; J Invest Dermatol 1995, V105, P322 HCAPLUS
- (16) Raff, M; Nature 1992, V356, P397 MEDLINE
- (17) Raskin, C; J Am Acad Dermatol 1997, V36, P885 MEDLINE
- (18) Rawles, M; Phys Zool 1947, V20, P248
- (19) Schmitz, G; Anal Biochem 1991, V192, P222 HCAPLUS
- (20) Steel, K; Development 1992, V115, P1111 MEDLINE
- (21) Williams, D; Cell 1990, V63, P167 HCAPLUS
- (22) Williams, G; Cell 1991, V65, P1097 HCAPLUS
- (23) Wyllie, A; Int Rev Cytol 1980, V68, P251 MEDLINE
- (24) Zsebo, K; Cell 1990, V63, P195 HCAPLUS

L67 ANSWER 8 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1999:305471 HCAPLUS

DN 131:67841

TI Effect of anti-allergic drugs on histamine release
from mast cells- Analysis with cord blood-derived human cultured mast
cells

AU Kanbe, Naotomo; Kurosawa, Motohiro; Igarashi, Yasushi; Amano, Hiroo;
Matsushima, Youichiro; Miyachi, Yoshiki

CS Department of Dermatology, Gunma University School of Medicine, Japan

- SO Ensho (1999), 19(2), 93-98
CODEN: ENSHEE; ISSN: 0389-4290
- PB Nippon Ensho Gakkai Jimukyoku
DT Journal
LA Japanese
CC 1-7 (Pharmacology)
- AB Mast cells have been regarded as one of the most important effector cells in IgE-dependent **allergic** response. Recently the heterogeneity of mast cells in localization and species have been recognized. However, whether anti-**allergic** drugs possess inhibitory effects on **histamine** release from human mast cells still remains uncertain. Therefore, in the present study, effects of anti-**allergic** drugs on **histamine** release from human mast cells, which were derived by the culture of cord blood cells with 80 ng/mL recombinant human **stem cell factor** and 50 ng/mL interleukin 6. The human cultured mast cells presented functional IgE receptors on their cell surfaces and were effectively stimulated to release **histamine** in dose-dependent and time-dependent manners of anti-IgE antibody. Anti-**allergic** drugs, such as azelastine, ketotifen, and emedastine, were able to inhibit **histamine** release from the human mast cells in dose-dependent manners. The immunosuppressive agent, **cyclosporin A**, and a flavonoid, quercetin, also showed inhibitory effects on the **histamine** release from the human cultured mast cells.
- ST **antiallergic histamine** mast cell IgE receptor
IT Immunoglobulins
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(E; effect of anti-**allergic** drugs on **histamine** release from mast cells- anal. with cord blood-derived human cultured mast cells)
- IT Immunoglobulin receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(IgE; effect of anti-**allergic** drugs on **histamine** release from mast cells- anal. with cord blood-derived human cultured mast cells)
- IT **Allergy** inhibitors
Mast cell
(effect of anti-**allergic** drugs on **histamine** release from mast cells- anal. with cord blood-derived human cultured mast cells)
- IT 117-39-5, Quercetin 34580-13-7, Ketotifen 58581-89-8, Azelastine 59865-13-3, **Cyclosporin A** 87233-61-2, Emedastine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of anti-**allergic** drugs on **histamine** release from mast cells- anal. with cord blood-derived human cultured mast cells)
- IT 51-45-6, **Histamine**, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(effect of anti-**allergic** drugs on **histamine** release from mast cells- anal. with cord blood-derived human cultured mast cells)
- L67 ANSWER 9 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1999:11267 HCAPLUS
DN 130:151533
TI Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: a Kit-KL interaction critical for meiosis
AU Vincent, Stephane; Segretain, Dominique; Nishikawa, Satomi; Nishikawa, Shin-Ichi; Sage, Julien; Cuzin, Francois; Rassoulzadegan, Minoo
CS Unite 470 de l'INSERM, Faculte des Sciences, Universite de Nice, Fr.
SO Development (Cambridge, U. K.) (1998), 125(22), 4585-4593
CODEN: DEVPED; ISSN: 0950-1991
PB Company of Biologists Ltd.
DT Journal

- LA English
- CC 13-6 (Mammalian Biochemistry)
- AB The Kit receptor and its ligand KL, which together constitute an essential effector at various stages of embryonic development, are both present during adult gametogenesis. In the testis, KL is expressed in Sertoli cells, and Kit in germ cells, starting at the premeiotic stages. A series of observations indicated previously a role in spermatogonia survival, without excluding a possible function at later stages. We identified a complex pattern of expression of the two components in the adult murine testis, suggestive of a role in the meiotic progression of spermatocytes. At stages VII-VIII of the cycle of the seminiferous epithelium, the time when spermatocytes enter meiosis, the membrane-assocd. form of KL extends on the Sertoli cell from the peripheral to the adluminal compartment of the tubule. We also found that the receptor is present on the surface of germ cells up to the pachytene stage. The availability of differentiated Sertoli cell lines, which express the KL protein and support part of the maturation of germ cells in coculture, allowed us to ask whether, in the in vitro reconstructed system, transit of spermatocytes through meiosis requires the Kit-KL interaction. Addn. of a blocking monoclonal antibody against the Kit receptor (ACK2) inhibited extensively the appearance of haploid cells and the expression of a haploid-phase-specific gene (Prml). Recognition of the supporting Sertoli cell by germ cells was not affected, indicating a requirement for the activity of the receptor for either entering or completing meiosis. Involvement of the membrane-assocd. form of the ligand was suggested by the observation that addn. of the sol. form of KL was equally inhibitory.
- ST Kit receptor **stem cell factor**
spermatogenesis meiosis cycle
- IT Cell cycle
Meiosis
Seminiferous tubule epithelium
Sertoli cell
Spermatocyte
Spermatogenesis
(stage-specific expression and interaction of Kit receptor and its ligand during male gametogenesis in mouse)
- IT **Stem cell factor**
c-Kit (protein)
RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(stage-specific expression and interaction of Kit receptor and its ligand during male gametogenesis in mouse)
- RE.CNT 29
- RE
- (1) Bellve, A; Methods in Enzymology 1993, V225, P84 HCAPLUS
 - (2) Besmer, P; Development 1993 Supplement 1993, P125 HCAPLUS
 - (3) Brannan, C; Genes Dev 1992, V6, P1832 HCAPLUS
 - (4) Chomczynski, P; Anal Biochem 1987, V162, P156 HCAPLUS
 - (5) Dirami, G; Signal Transduction in Testicular Cells 1996, P142
 - (6) Grandjean, V; Dev Biol 1997, V184, P165 HCAPLUS
 - (7) Harlow, E; J Virol 1981, V39, P861 HCAPLUS
 - (8) Huang, E; Mol Biol Cell 1992, V3, P349 HCAPLUS
 - (9) Jasin, M; Proc Natl Acad Sci USA 1992, V89, P10681 HCAPLUS
 - (10) Kunisada, T; Develop Growth Differ 1996, V38, P87
 - (11) Leblond, C; Ann N Y Acad Sci 1952, V55, P548
 - (12) Manova, K; Dev Biol 1993, V157, P85 HCAPLUS
 - (13) Manova, K; Development 1990, V110, P1057 HCAPLUS
 - (14) Meuwissen, R; EMBO J 1992, V11, P5091 HCAPLUS
 - (15) Motro, B; Development 1991, V113, P1207 MEDLINE
 - (16) Nishimune, Y; J Cell Physiol 1980, V105, P137 MEDLINE
 - (17) Ogawa, M; J Exp Med 1991, V174, P63 HCAPLUS
 - (18) Packer, A; Mol Reprod Dev 1995, V42, P303 HCAPLUS
 - (19) Qiu, F; EMBO J 1988, V7, P1003 HCAPLUS

- (20) Rassoulzadegan, M; Cell 1993, V75, P997 HCAPLUS
- (21) Rossi, P; Biochem Biophys Res Comm 1991, V176, P910 HCAPLUS
- (22) Russell, L; Histological and Histopathological Evaluation of the Testis 1990
- (23) Sage, J; Genomics 1997, V44, P118 HCAPLUS
- (24) Sawada, K; J Reprod Fertil 1991, V93, P287 MEDLINE
- (25) Sibony, M; Biol Reprod 1994, V50, P1015 HCAPLUS
- (26) Sorrentino, V; Oncogene 1991, V6, P149 HCAPLUS
- (27) Tajima, Y; Development 1991, V113, P1031 HCAPLUS
- (28) Tajima, Y; J Reprod Fertil 1991, V91, P441 MEDLINE
- (29) Yoshinaga, K; Development 1991, V113, P689 MEDLINE

L67 ANSWER 10 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1998:803214 HCAPLUS

DN 130:195670

TI **Stem cell factor** mRNA expression and production in human **nasal epithelial cells**: contribution to the accumulation of mast **cells** in the **nasal epithelium of allergy**

AU Otsuka, Hirokuni; Kusumi, Taeko; Kanai, Shozo; Koyama, Mamoru; Kuno, Yoko; Takizawa, Ryuta

CS Allergy and Immunology Laboratory. Department of Otorhinolaryngology. Nippon Medical School, Dai 2 Hospital, Kanagawa, 211, Japan

SO J. Allergy Clin. Immunol. (1998), 102(5), 757-764
CODEN: JACIBY; ISSN: 0091-6749

PB Mosby, Inc.

DT Journal

LA English

CC 15-9 (Immunochemistry)

Section cross-reference(s): 1

AB In **allergic rhinitis**, mast **cells** are increased in no. in the epithelium of the **nasal mucosa** and play an important role in the immediate response. However, the mechanism of the accumulation is not known. The purpose of this study was to det. whether the **nasal epithelial cells** produce **stem cell factor (SCF)**, the mast cell growth and chemoattractant **factor**, and contribute mast cell hyperplasia in the epithelium of **allergic rhinitis**. We have characterized the cellular localization of **SCF** using immunohistochem., reverse transcribed-PCR, and ELISA; compared **SCF** prodn. of cultured epithelial **cells** between patients with **allergic rhinitis** and **nonallergic** subjects; and compared the **SCF** prodn. with the no. of mast **cells** and the **histamine** content in the **nasal epithelial scrapings**. Immunohistochem., **SCF** was identified in the **nasal epithelium** of the biopsy specimens and in cultured **nasal epithelial cells**. **SCF** mRNA was expressed by cultured **nasal epithelial cells** not only in patients with **allergy** but also in subjects with no **allergy**. However, the **SCF/.beta.-actin** mRNA ratio and **SCF** prodn. in day 7 cultured epithelial **cells** was significantly higher in **allergic** than in **nonallergic** subjects. **SCF** prodn. from **nasal scrapings** in culture was strongly correlated with the no. of mast **cells** and the **histamine** content. These findings demonstrate that **nasal epithelial cells** produce **SCF** and may be important in the attraction, proliferation, and activation of mast **cells** in **allergic inflammation** in the nose.

ST **stem cell factor nasal epithelium**
mast cell allergic rhinitis

IT **Allergic rhinitis**
Hyperplasia
Mast cell
Nasal epithelium

(**stem cell factor** mRNA expression and prodn. in human **nasal epithelial cells** in relation

to accumulation of mast cells in allergic rhinitis)

IT **Stem cell factor**

RL: ADV (Adverse effect, including toxicity); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(stem cell factor mRNA expression and prodn. in human nasal epithelial cells in relation to accumulation of mast cells in allergic rhinitis)

IT 50-24-8, Prednisolone 59865-13-3, Cyclosporin a

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stem cell factor mRNA expression and prodn. in human nasal epithelial cells in relation to accumulation of mast cells in allergic rhinitis)

IT 51-45-6, Histamine, biological studies

RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)

(stem cell factor mRNA expression and prodn. in human nasal epithelial cells in relation to accumulation of mast cells in allergic rhinitis)

RE.CNT 48

RE

- (1) Anderson, D; Cell 1990, V63, P235 HCAPLUS
- (2) Beutler, E; J Lab Clin Med 1976, V88, P328 HCAPLUS
- (3) Bischoff, S; J Exp Med 1992, V175, P237 HCAPLUS
- (4) Bischoff, S; J Immunol 1997, V156, P5560
- (5) Calderon, M; J Allergy Clin Immunol 1997, V99, P65 MEDLINE
- (6) Chomczynski, P; Anal Biochem 1987, V162, P156 HCAPLUS
- (7) Columbo, M; J Immunol 1992, V149, P599 HCAPLUS
- (8) Copeland, N; Cell 1990, V63, P175 HCAPLUS
- (9) Costa, J; J Exp Med 1996, V183, P2681 HCAPLUS
- (10) Gibson, P; Ann Rev Resp Dis 1993, V148, P80 MEDLINE
- (11) Hamann, K; Br J Dermatol 1995, V133, P203 HCAPLUS
- (12) Huang, E; Cell 1990, V63, P225 HCAPLUS
- (13) Irani, A; Blood 1992, V80, P3009 HCAPLUS
- (14) Irani, A; Immunology 1995, V84, P72 HCAPLUS
- (15) Irani, A; Proc Natl Acad Sci USA 1986, V83, P4464 HCAPLUS
- (16) Ishizaka, T; Progr Allergy 1984, V34, P188 HCAPLUS
- (17) Kageyama, Y; Eur J Immunol 1994, V24, P1122 HCAPLUS
- (18) Kawabori, S; Jpn J Allergol 1993, V42, P894 MEDLINE
- (19) Kenney, J; J Allergy Clin Immunol 1994, V93, P1060 HCAPLUS
- (20) Kim, Y; J Allergy Clin Immunol 1997, V100, P389 HCAPLUS
- (21) Lee, L; J Clin Invest 1995, V95, P900 HCAPLUS
- (22) Longley, B; N Engl J Med 1993, V328, P1302
- (23) Marini, M; J Allergy Clin Immunol 1992, V89, P1001 MEDLINE
- (24) Mitsui, H; Proc Natl Acad Sci USA 1993, V90, P735 HCAPLUS
- (25) Nilsson, G; J Immunol 1994, V153, P3717 HCAPLUS
- (26) Ohtoshi, T; Am J Respir Cell Mol Biol 1991, V4, P255 HCAPLUS
- (27) Okuda, M; Ann Allergy 1983, V50, P116 MEDLINE
- (28) Okuda, M; Ann Allergy 1985, V54, P69 MEDLINE
- (29) Otsuka, H; Clin Allergy 1986, V16, P589 MEDLINE
- (30) Otsuka, H; J Allergy Clin Immunol 1985, V76, P695 MEDLINE
- (31) Otsuka, H; J Allergy Clin Immunol 1995, V96, P528 HCAPLUS
- (32) Otsuka, H; J Jpn Immunol Allergo Otolaryngol 1995, V13, P33
- (33) Pesci, A; Am Rev Respir Dis 1993, V147, P684 MEDLINE
- (34) Ruitenber, E; Int Archs Allergy Appl Immunol 1982, V67, P233 MEDLINE
- (35) Saito, H; J Immunol 1996, V157, P343 HCAPLUS
- (36) Schleimer, R; J Allergy Clin Immunol 1985, V76, P369 MEDLINE
- (37) Schwartz, L; J Immunol 1987, V138, P2611 HCAPLUS
- (38) Sperr, W; Int Arch Allergy Immunol 1993, V102, P170 HCAPLUS
- (39) Stellato, C; J Immunol 1995, V155, P410 HCAPLUS
- (40) Strobel, S; J Clin Pathol 1981, V34, P851 MEDLINE
- (41) Tsai, M; J Exp Med 1991, V74, P125

- (42) Undem, B; Am J Respir Cell Mol Biol 1994, V11, P646 HCAPLUS
 (43) Valent, P; Blood 1992, V80, P2237 HCAPLUS
 (44) Wen, L; Biochim Biophys Acta 1996, V1314, P183 HCAPLUS
 (45) Yamatodani, A; J Chromatogr 1985, V344, P115 HCAPLUS
 (46) Yankaskas, J; Am Rev Respir Dis 1985, V132, P1281 MEDLINE
 (47) Zsebo, K; Cell 1990, V63, P195 HCAPLUS
 (48) Zsebo, K; Cell 1990, V63, P213 HCAPLUS
- L67 ANSWER 11 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1998:730346 HCAPLUS
 DN 130:137443
 TI A novel **gain-of-function** mutation of **c-Kit** gene in **gastrointestinal stromal** tumors
 AU Nakahara, Masanori; Isozaki, Koji; Hirota, Seiichi; Miyagawa, Jun-Ichiro; Hase-Sawada, Naoko; Taniguchi, Masahiko; Nishida, Toshirou; Kanayama, Suji; Kitamura, Yukihiro; Shinomura, Yasuhisa; Matsuzawa, Yuji
 CS Second Department of Internal Medicine, Osaka University Medical School, Osaka, Japan
 SO Gastroenterology (1998), 115(5), 1090-1095
 CODEN: GASTAB; ISSN: 0016-5085
 PB W. B. Saunders Co.
 DT Journal
 LA English
 CC 14-1 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 3
 AB The **c-Kit** gene encodes a receptor tyrosine kinase (KIT). Recently, the authors found gain-of-function mutations of the **c-Kit** gene in **gastrointestinal stromal** tumors (GISTs). All mutations were confined within the 11 amino acids (Lys-550 to Val-560) in the juxtamembrane domain, but one GIST showed a novel deletion-type mutation at codon 579 (Asp) in the juxtamembrane domain. The aim of this study was to clarify whether the mutation is activating. Mutant **c-kit** cDNA was transfected into an interleukin 3 (IL-3)-dependent Ba/F3 murine lymphoid **cell** line, and the magnitude of autophosphorylation of the mutant KIT was examd. with or without **stem cell factor (SCF)**, a ligand of KIT. An in vitro kinase assay was also performed. The biol. behavior of the transfectant was estd. by both an in vitro proliferation assay and in vivo transplantation to nude mice. The mutant KIT exhibited constitutive phosphorylation and strong kinase activity without **SCF**. The transfectant grew autonomously without IL-3 and **SCF**, and it formed tumors in nude mice. Deletion at codon 579 (Asp) in the juxtamembrane domain of the **c-kit** gene is a novel gain-of-function mutation other than the region between Lys-550 and Val-560.
 ST **cKit** gene mutation **gastrointestinal stromal** tumor
 IT Autophosphorylation
 Deletion (mutation)
 Receptor phosphorylation
 (gain-of-function mutation of **c-Kit** with constitutive phosphorylation and kinase activity in absence of **stem cell factor** in human **gastrointestinal stromal** tumors)
 IT **c-Kit** (protein)
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutation of **c-Kit** with constitutive phosphorylation and kinase activity in absence of **stem cell factor** in human **gastrointestinal stromal** tumors)
 IT **c-kit** gene (animal)
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutation of **c-Kit** with

- constitutive phosphorylation and kinase activity in absence of
stem cell factor in human
gastrointestinal stromal tumors)
- IT **Stem cell factor**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gain-of-function mutation of **c-Kit** with
 constitutive phosphorylation and kinase activity in absence of
stem cell factor in human
gastrointestinal stromal tumors)
- IT **Cell proliferation**
 (gain-of-function mutation of **c-Kit** with
 constitutive phosphorylation and kinase activity in absence of
stem cell factor in human
gastrointestinal stromal tumors in relation to)
- IT **Digestive system tumors**
 (**gastrointestinal stromal tumor**; gain-of-function
 mutation of **c-Kit** with constitutive phosphorylation
 and kinase activity in absence of **stem cell**
factor in human **gastrointestinal stromal**
tumors)
- IT **Protein motifs**
 (juxtamembrane, mutation in; gain-of-function mutation of **c-**
Kit with constitutive phosphorylation and kinase activity in
 absence of **stem cell factor** in human
gastrointestinal stromal tumors)
- IT **Gastric tumors**
 (mesenchymal stomach tumor; gain-of-function mutation of **c-**
Kit with constitutive phosphorylation and kinase activity in
 absence of **stem cell factor** in human
gastrointestinal stromal tumors)
- IT **Tumors (animal)**
 (mesenchymal, mesenchymal stomach tumor; gain-of-function mutation of
c-Kit with constitutive phosphorylation and kinase
 activity in absence of **stem cell factor**
 in human **gastrointestinal stromal tumors**)
- IT **Mesenchyme**
 (tumors, mesenchymal stomach tumor; gain-of-function mutation of
c-Kit with constitutive phosphorylation and kinase
 activity in absence of **stem cell factor**
 in human **gastrointestinal stromal tumors**)
- IT 138359-29-2
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BOC (Biological occurrence); PRP (Properties);
 BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutation of **c-Kit** with
 constitutive phosphorylation and kinase activity in absence of
stem cell factor in human
gastrointestinal stromal tumors)

RE.CNT 25

RE

- (1) Besmer, P; Nature 1986, V320, P415 HCAPLUS
- (2) Chabot, B; Nature 1988, V335, P88 HCAPLUS
- (3) Chirgwin, J; Biochemistry 1979, V18, P5294 HCAPLUS
- (4) Fishman, A; Ackerman's surgical pathology. 8th ed 1996, P645
- (5) Furitsu, T; J Clin Invest 1993, V92, P1736 HCAPLUS
- (6) Geissler, E; Cell 1988, V55, P185 HCAPLUS
- (7) Hirota, S; Arch Pathol Lab Med 1993, V117, P996 HCAPLUS
- (8) Hirota, S; Lab Invest 1995, V72, P64 HCAPLUS
- (9) Hirota, S; Science 1998, V279, P577 HCAPLUS
- (10) Hofstra, R; Nature 1994, V367, P375 HCAPLUS
- (11) Huizinga, J; Nature 1995, V373, P347 HCAPLUS
- (12) Isozaki, K; Gastroenterology 1995, V109, P456 HCAPLUS
- (13) Kitamura, Y; Blood 1979, V53, P492 MEDLINE
- (14) Longley, B; Nat Genet 1996, V12, P312 HCAPLUS
- (15) Miettinen, M; Am J Surg Pathol 1995, V19, P207 MEDLINE
- (16) Mulligan, L; Nature 1993, V363, P458 HCAPLUS

- (17) Qiu, F; EMBO J 1988, V7, P1003 HCAPLUS
- (18) Russell, E; Adv Genet 1979, V20, P357 HCAPLUS
- (19) Stein, A; Nucleic Acids Res 1992, V20, P5237 HCAPLUS
- (20) Tsujimura, T; Blood 1994, V83, P2619 HCAPLUS
- (21) Tsujimura, T; Blood 1996, V87, P273 HCAPLUS
- (22) Tsujimura, T; Int Arch Allergy Immunol 1995, V106, P377 HCAPLUS
- (23) van de Rijn, M; Hum Pathol 1994, V25, P766 MEDLINE
- (24) Williams, D; Cell 1990, V63, P167 HCAPLUS
- (25) Yarden, Y; EMBO J 1987, V6, P3341 HCAPLUS

L67 ANSWER 12 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1998:414206 HCAPLUS
 DN 129:188006

TI The regulation of mast cell development, survival and function
 in vivo by **stem cell factor**, the ligand for
 the **c-kit** receptor: **clinical** implications
 AU Galli, S. J.; Costa, J. J.
 CS Department of Pathology, Harvard Medical School, Beth Israel Hospital,
 Boston, MA, 02215, USA
 SO New Trends Allergy IV Environ. Allergy Allergotoxicol. III, [Jt. Int.
 Symp.] (1997), Meeting Date 1995, 151-158. Editor(s): Ring, Johannes;
 Behrendt, Heidrun; Vieluf, Dieter. Publisher: Springer, Berlin, Germany.
 CODEN: 66ILAL

DT Conference; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review with 41 refs. **Stem cell factor**

SCF, the ligand for the receptor (SCFR) that is encoded by the
c-kit protooncogene, has many important effects in mast
 cell development, survival, and function, in both humans and
 exptl. animals. Recombinant **SCF** (r-**SCF**) can promote
 mast cell survival by suppressing apoptosis and can induce mast
 cell hyperplasia in murine rodents, cynomolgus monkeys, baboons,
 and humans. R-**SCF** also can directly induce SCFR-dependent mast
 cell mediator release and can significantly modulate the extent of
 mast cell activation by Fc.epsilon.RI-dependent and certain
 other mechanisms. However, **SCF** can importantly influence the
 biol. of many cell types other than the mast cell,
 including hematopoietic progenitor cells, melanocytes and
 germ cells. Indeed, findings, in phase 1 studies of
 r-human **SCF** (r-hSCF) indicate that r-hSCF can promote the
 hyperplasia and functional activation of both mast cells and
 melanocytes. These observations have implications for the clin.
 use of r-hSCF to promote hematopoiesis, as well as for our understanding
 of the role of endogenous **SCF** in disorders assocd. with mast
 cell hyperplasia and/or epidermal hypermelanosis; they also point
 to potentially significant new therapeutic opportunities.

ST review **stem cell factor** mast cell

IT Hyperplasia

(mast cell; regulation of mast cell development,
 survival and function by **stem cell factor**
 and its clin. implications)

IT Apoptosis

Hematopoiesis

Mast cell

Mast cell activation

Melanocyte

(regulation of mast cell development, survival and function
 by **stem cell factor** and its clin
 . implications)

IT **Stem cell factor**

RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (regulation of mast cell development, survival and function
 by **stem cell factor** and its clin
 . implications)

L67 ANSWER 13 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1998:390378 HCAPLUS
DN 129:135121
TI Morphological alterations in rat peritoneal mast cells by
stem cell factor
AU Kim, H. M.; Shin, H. Y.; Lee, E. H.
CS Department Oriental Pharmacy, College Pharmacy, Wonkwang University,
Chonbuk, S. Korea
SO Immunology (1998), 94(2), 242-246
CODEN: IMMUAM; ISSN: 0019-2805
PB Blackwell Science Ltd.
DT Journal
LA English
CC 15-9 (Immunochemistry)
Section cross-reference(s): 2
AB **Stem cell factor (SCF)** stimulates
mast cell adhesion and, because **SCF** is produced
normally in tissues, it may be a major **factor** responsible for
the adhesion of mast cells to connective tissue matrix. The
authors found that the morphol. of rat peritoneal mast cells
(RPMC) altered after the addn. of recombinant murine **SCF** (rmSCF)
in vitro. The ability of rmSCF to enhance morphol. alteration was dose
dependent and completely abolished by anti-**c-kit**
ACK2 monoclonal antibody. Exposure of RPMC to transforming growth
factor-.beta.1, wortmannin, genistein, herbimycin A,
staurosporine, indomethacin and cytochalasin D before the addn. of rmSCF
antagonized rmSCF-induced morphol. alteration. However,
nordihydroguaiaretic acid had no effect. Many RPMC appeared to respond
also to nerve growth **factor** (NGF) but the total no. of
cells with altered morphol. was much greater when the culture was
stimulated by rmSCF than by NGF. The authors suggest that morphol.
alterations of mast cells by rmSCF is an important step for the
participation in adhesion to tissue under resident physiol. conditions.
ST morphol mast cell **stem cell factor**
IT Cytoskeleton
(in **stem cell factor** alteration of rat
mast cell morphol.)
IT Transforming growth **factor** .beta.1
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(**stem cell factor** alteration of rat mast
cell morphol. is inhibited by)
IT Cell morphology
Mast cell
Rat
(**stem cell factor** alters rat mast
cell morphol.)
IT **Stem cell factor**
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(**stem cell factor** alters rat mast
cell morphol.)
IT 80449-02-1, Tyrosine kinase 115926-52-8, Phosphatidylinositol 3-kinase
141436-78-4, Protein kinase C
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(in **stem cell factor** alteration of rat
mast cell morphol.)
IT 506-32-1, Arachidonic acid
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(metabolites; in **stem cell factor**
alteration of rat mast cell morphol.)
IT 9061-61-4, Nerve growth factor
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(rat mast cell morphol. is altered by)

L67 ANSWER 14 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1998:84804 HCAPLUS
 DN 128:226598
 TI The **c-kit** receptor and its possible signaling transduction pathway in mouse **spermatozoa**
 AU Feng, Huailiang; Sandlow, Jay I.; Sandra, Alexander
 CS Department of Urology, The University of Iowa, Iowa City, IA, 52242-1089, USA
 SO Mol. Reprod. Dev. (1998), 49(3), 317-326
 CODEN: MREDEE; ISSN: 1040-452X
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 AB The presence and role of the **c-kit** protein was investigated in the mature **sperm** of the mouse. The **c-kit** monoclonal antibody (mAb) **ACK2** reacted specifically with the acrosomal region and the principal piece of fixed noncapacitated **sperm** but did not react with the acrosome region in acrosome-reacted **sperm**. **ACK2** significantly inhibited the acrosome reaction; this inhibition was relieved by the calcium ionophore A23187. The kit ligand **stem cell factor (SCF)** significantly increased the percentage of **sperm** undergoing acrosome reaction. This increase was partially inhibited by the calcium channel inhibitor (verapamil), the PI3k inhibitor (wortmannin), and the PLC inhibitor (U-73122). **ACK2** predominantly recognized **c-kit** proteins of 33, 48, and 150 kDa by Western blotting of mouse **sperm** exts. The 48- and 150-kDa protein bands were released into the media and tyrosine autophosphorylated at low basal levels during acrosome reaction. On stimulation with **SCF**, the level of **c-kit** phosphorylation increased significantly. These findings suggest that **c-kit** is present in mature **sperm**, and its binding to **SCF** may result in the activation of PLC.gamma.1 and PI3K, leading to receptor autophosphorylation, and ultimately may play a role in capacitation and/or the acrosome reaction.
 ST **c kit** receptor acrosome signal transduction;
stem cell factor ckit receptor acrosome
 IT Acrosome
 Calcium transport (biological)
 Receptor phosphorylation
 Signal transduction (biological)
 (**c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)
 IT **c-Kit** (protein)
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)
 IT Calcium channel
Stem cell factor
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (**c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)
 IT 115926-52-8, Phosphatidylinositol-3 kinase
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (**c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)
 IT 7440-70-2, Calcium, biological studies
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (**c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)
 IT 9001-86-9, Phospholipase C

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (.gamma.1; **c-kit** receptor and possible signaling transduction pathway in mouse **spermatozoa**)

- L67 ANSWER 15 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1998:80821 HCAPLUS
 DN 128:165683
 TI **Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors**
 AU Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshiro; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko
 CS USA
 SO Science (Washington, D. C.) (1998), 279(5350), 577-580
 CODEN: SCIEAS; ISSN: 0036-8075
 PB American Association for the Advancement of Science
 DT Journal
 LA English
 CC 14-1 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 3
 AB **Gastrointestinal stromal tumors (GISTs)** are the most common mesenchymal tumors in the human **digestive** tract, but their mol. etiol. and cellular origin are unknown. Sequencing of **c-kit** complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains. All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, **stem cell factor (SCF)**. Stable transfection of the mutant **c-kit** complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid **cells**, suggesting that the mutations contribute to tumor development. GISTs may originate from the interstitial **cells** of Cajal (ICCs) because the development of ICCs is dependent on the **SCF-KIT** interaction and because, like GISTs, these **cells** express both KIT and CD34.
 ST **gastrointestinal stromal tumor ckit** mutation
 constitutive; gain function mutation **ckit**
gastrointestinal tumor
 IT Missense mutation
 (K550I V559D; gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors**)
 IT **c-Kit** (protein)
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors**)
 IT **c-kit** gene (animal)
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors**)
 IT Autophosphorylation
 Receptor phosphorylation
 (gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors** in relation to)
 IT CD34 (antigen)
 RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
 (gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors** in relation to)
 IT **Stem cell factor**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gain-of-function mutations of **c-kit** in human

- IT **gastrointestinal stromal tumors in relation to)**
Mutation
(gain-of-function; gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors**)
- IT **Digestive system tumors**
(**gastrointestinal stromal tumors (GISTs)**;
gain-of-function mutations of **c-kit** in human
gastrointestinal stromal tumors)
- IT Deletion (mutation)
(in-frame, 6-bp and 15-bp and 27-bp; gain-of-function mutations of
c-kit in human **gastrointestinal stromal tumors**)
- IT **Intestine**
(interstitial cell of Cajal; gain-of-function mutations of **c-kit** in human **gastrointestinal stromal tumors in relation to**)
- IT Protein motifs
(transmembrane and tyrosine kinase domains; gain-of-function mutations
of **c-kit** in human **gastrointestinal stromal tumors**)
- IT 138359-29-2
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BOC (Biological occurrence); PRP (Properties);
BIOL (Biological study); OCCU (Occurrence)
(gain-of-function mutations of **c-kit** in human
gastrointestinal stromal tumors)
- L67 ANSWER 16 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1997:768305 HCAPLUS
DN 128:21279
TI **Stem cell factor** suppresses apoptosis in
neuroblastoma **cell lines**
- AU Timeus, Fabio; Crescenzo, Nicoletta; Valle, Paola; Pistamiglio, Paola;
Piglione, Matilde; Garelli, Emanuela; Ricotti, Emanuela; Rocchi, Paola;
Strippoli, Pierluigi; Di Montezemolo, Luca Cordero; Madon, Enrico;
Ramenghi, Ugo; Basso, Giuseppe
- CS Dipartimento di Scienze Pediatriche, University of Torino, Turin, 10126,
Italy
- SO Exp. Hematol. (Charlottesville, Va.) (1997), 25(12), 1253-1260
CODEN: EXHMA6; ISSN: 0301-472X
- PB Carden Jennings Publishing
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
- AB **Stem cell factor (SCF)** is a
glycoprotein growth **factor** produced by marrow stromal
cells that acts after binding to its sp. surface receptor, which
is the protein encoded by the protooncogene **c-kit**.
SCF synergizes with specific lineage **factors** in
promoting the proliferation of primitive hematopoietic progenitors, and
has been administered to expand the pool of these progenitors in
cancer patients treated with high-dose chemotherapy. **SCF**
and its **c-kit** receptor are expressed by some
tumor cells, including myeloid leukemia, breast
carcinoma, small **cell lung carcinoma**,
melanoma, **gynecol. tumors**, and testicular
germ cell tumors. Previous studies of
SCF in neuroblastoma have produced conflicting conclusions. To
explore the role of **SCF** in neuroblastoma, we studied five
neuroblastoma lines (IMR-S, SK-N-SH, SK-N-BE, AF8, and SJ-N-KP) and the
neuroepithelioma line CHP-100. All lines expressed mRNA for **c-**
kit and **c-kit** protein at low intensity as
measured by flow cytometry, and secreted **SCF** in medium culture
as shown by ELISA. Exogenous **SCF** did not modify 3H thymidine
uptake in the neuroblastoma and neuroepithelioma **cell lines**.

After 6 days' culture in the presence of anti-c-kit, the no. of viable neuroblastoma cells was significantly lower than the control, and terminal deoxynucleotidyl transferase assay showed a substantial increase of apoptotic cells: The percentage of pos. cells was 1-3% in the control lines, whereas in the presence of anti c-kit it varied from 29% of SK-N-BE to 92% of CHP-100. After 9 days' culture in the presence of anti-c-kit, no viable cells were detectable. These data indicate that SCF is produced by some neuroblastoma cell lines via an autocrine loop to protect them from apoptosis.

ST neuroblastoma apoptosis stem cell factor

IT Apoptosis

Neuroblastoma

(stem cell factor suppresses apoptosis in neuroblastoma cell lines)

IT Stem cell factor

RL: BAC (Biological activity or effector, except adverse); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(stem cell factor suppresses apoptosis in neuroblastoma cell lines)

IT c-Kit (protein)

RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(stem cell factor suppresses apoptosis in neuroblastoma cell lines)

L67 ANSWER 17 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1997:669383 HCAPLUS

DN 127:314963

TI Stem cell factor in nasal

polyposis and allergic rhinitis: increased expression by structural cells is suppressed by in vivo topical corticosteroids

AU Kim, Young-Ki; Nakagawa, Noriaki; Nakano, Koichi; Sulakvelidze, Irakly; Dolovich, Jerry; Denburg, Judah

CS Department of Medicine and Pediatrics, McMaster University, Hamilton, ON, L8N 3Z5, Can.

SO J. Allergy Clin. Immunol. (1997), 100(3), 389-399

CODEN: JACIBY; ISSN: 0091-6749

PB Mosby-Year Book

DT Journal

LA English

CC 2-4 (Mammalian Hormones)

AB Mast cells are increased in nasal polyp (Np) and allergic rhinitis (AR) tissue and are suppressed by topical corticosteroid treatment. Stem cell factor (SCF), a mast cell growth and survival factor, may explain these phenomena. We investigated structural cell gene expression and prodn. of SCF in nasal tissues in patients who had received and who had not received in vivo intranasal corticosteroid therapy. Northern blot analyses for mRNA and ELISA for biol. active SCF protein from cultured Np epithelial cells and fibroblasts were performed. Immunostaining for SCF in cultured and tissue nasal structural cells in the presence or absence of steroid treatment was also performed. We detected significant expression of SCF mRNA and protein by cultured Np epithelial cells and Np fibroblasts; Np fibroblast SCF supported the differentiation of mast cells in vitro. There were more immunoreactive SCF-pos. Np epithelial cells in patients with AR than in control subjects (97.2 vs. 45.6%). SCF that could be immunostained was significantly diminished overall in Np structural cells in the group given in vivo steroid treatment, with a modest (trend to significant) effect on any given cell type analyzed. In vitro treatment with budesonide of SCF-producing fibroblasts demonstrated inhibition of unstimulated, primary Np fibroblasts but not of

IL-1-stimulated fibroblasts or transformed **cell** lines. Human Np and AR tissue structural **cells** express and produce increased **SCF**. Our in vitro studies suggest that **intranasal** steroids blunt **SCF** expression in Nps, an effect that may be responsible for a decrease in mast **cells** and symptoms.

ST **stem cell factor nose disease**
corticosteroid; **nasal polyposis corticosteroid stem cell factor; allergic rhinitis**
corticosteroid **stem cell factor**

IT Tumors (animal)
(**nasal polyp; topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT **Nose diseases**
(**polyp; topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT **Allergic rhinitis**
Cell differentiation
Fibroblast
Gene expression
Mast cell
Transcription (genetic)
(**topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT **Corticosteroids, biological studies**
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT **Interleukin 1**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT **Stem cell factor**
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(**topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

IT 51333-22-3, Budesonide
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**topical corticosteroid suppression of increased structural cell stem cell factor** expression in **nasal polyposis and allergic rhinitis**)

L67 ANSWER 18 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1997:428244 HCAPLUS
DN 127:134026
TI Growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor is inhibited by TGF- β .1
AU Bellone, Graziella; Silvestri, Stefania; Artusio, Elisa; Tibaudi, Daniela; Turletti, Anna; Geuna, Massimo; Giachino, Claudia; Valente, Guido; Emanuelli, Giorgio; Rodeck, Ulrich
CS Department of Clinical Physiopathology, University of Torino, Turin, 10126, Italy
SO J. Cell. Physiol. (1997), 172(1), 1-11
CODEN: JCLLAX; ISSN: 0021-9541
PB Wiley-Liss
DT Journal

LA English
 CC 14-1 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 2
 AB Activation of the receptor tyrosine kinase **c-kit** by the kit-ligand, also known as **stem cell factor (SCF)**, is essential to melanocyte and **germ cell** development and during the early stages of hematopoiesis. Deregulated expression of **c-kit** has been reported in malignancies affecting these lineages, i.e., myeloid leukemias, melanomas, and **germ cell tumors**. In addn., **c-kit** and **SCF** are coexpressed in some breast and colorectal **cancer (CRC) cells**, raising the question of whether **c-kit** serves an autocrine role in normal or malignant epithelial tissues. In this study, we demonstrate that human colorectal **carcinomas**, but not normal colorectal mucosa **cells**, coexpress **SCF** and **c-kit** in situ. Expression of **c-kit** was also obsd. in mucosa adjacent to colorectal **tumor** tissue. Consistent with a growth-regulatory role of **SCF** in CRC **cells**, exogenous **SCF** stimulated anchorage-dependent and anchorage-independent growth in four out of five CRC **cell** lines. Exogenous transforming growth factor (TGF)- β .1 added at nanomolar concns. to HT-29 CRC **cells**, which express the type I, II, and III TGF- β . receptors, downregulated **c-kit** expression to background levels and inhibited **c-kit**-dependent proliferation. Similarly, TGF- β .1 inhibited **SCF**-dependent proliferation of three first-passage CRC **cell** lines. In summary, expression of the potential autocrine **SCF/c-kit** axis is a **tumor**-assocd. phenomenon in colorectal **cancer** that can be suppressed by TGF- β .1 in TGF- β .-responsive CRC **cells**.

ST colorectal **carcinoma stem cell factor** TGF

IT Cell proliferation
 Colorectal **carcinoma**
 HT-29 cell
 Proliferation inhibition
 (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β .1)

IT Transforming growth factor β .1
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β .1)

IT **Stem cell factor**
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (growth stimulation of colorectal **carcinoma cells** via the **c-kit** receptor inhibition by TGF- β .1)

IT Transforming growth factor β . type I receptors
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β .1)

IT Transforming growth factor β . type II receptors
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β .1)

IT **c-kit** gene (animal)
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β .1)

IT **c-Kit** (protein)
 RL: BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

- (growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β 1)
- IT Transforming growth factor β receptors
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (type III; growth stimulation of colorectal **carcinoma** cells via the **c-kit** receptor inhibition by TGF- β 1)
- L67 ANSWER 19 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1997:413373 HCAPLUS
 DN 127:79429
 TI **Gain-of-function** mutation of **c-kit** gene in human **gastrointestinal stromal** tumors
 AU Hirota, Seiichi; Kitamura, Yukihiko
 CS Igakubu, Osaka Daigaku, Suita, 565, Japan
 SO Mol. Med. (Tokyo) (1997), 34(6), 698-704
 CODEN: MOLMEL; ISSN: 0918-6557
 PB Nakayama Shoten
 DT Journal; General Review
 LA Japanese
 CC 14-0 (Mammalian Pathological Biochemistry)
 AB A review with 27 refs. Constitutive activation of **c-kit** receptor without binding to its ligand, **stem cell factor (SCF)**, induces carcinogenesis of mast cells. The functions of **C-kit** are reported. Interstitial cells of Cajal require **SCF-C-kit** system for differentiation and proliferation, and **c-kit** receptor expression is detected on the cells. Function-gaining type mutations occurs in **c-kit** in **gastrointestinal stromal** tumors (GIST).
- ST review **ckit** receptor mutation **gastrointestinal** neoplasm
- IT **Digestive** system tumors
 Mutation
 (**c-kit** gene gain-of-function mutation in human **gastrointestinal stromal** tumors)
- IT **Stem cell factor**
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**c-kit** gene gain-of-function mutation in human **gastrointestinal stromal** tumors)
- IT **c-kit** gene (animal)
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**c-kit** gene gain-of-function mutation in human **gastrointestinal stromal** tumors)
- IT **c-Kit** (protein)
 RL: BOC (Biological occurrence); BPR (Biological process); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**c-kit** gene gain-of-function mutation in human **gastrointestinal stromal** tumors)
- L67 ANSWER 20 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1996:587928 HCAPLUS
 DN 125:237980
 TI Effects of **cyclosporin A** and **FK-506** on **stem cell factor**-induced **histamine** secretion and growth of human mast cells
 AU Sperr, Wolfgang R.; Agis, Hermine; Czerwenka, Klaus; Virgolini, Irene; Bankl, Hans C.; Muller, Michael R.; Zsebo, Krisztina; Lechner, Klaus; Valent, Peter
 CS Department Internal I, University Vienna, Vienna, A-1090, Austria
 SO J. Allergy Clin. Immunol. (1996), 98(2), 389-399
 CODEN: JACIBY; ISSN: 0091-6749

DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB **Stem cell factor (SCF)** is a key regulator of human mast cells (MCs) and a potential mediator of allergy. In this study the effects of **cyclosporin A** (CSA) and **FK-506**, two potent immunosuppressive drugs, on SCF-dependent histamine release and growth of human MCs were analyzed. Preincubation of tissue MCs with CSA (3 .mu.g/mL) resulted in inhibition of histamine release provoked by either recombinant human (rh) SCF (70.3% .+- 20.6% inhibition) or anti-IgE (76.7% .+- 21.9%) or by rhSCF+ anti-IgE (77.4% .+- 13.9%). Almost the same inhibition was produced by **FK-506** (rhSCF: 82.0% .+- 18.9% inhibition,; anti-IgE: 71.5% .+- 16.7%,; rhSCF+ anti-IgE: 70.0% .+- 7.3%). The effects of CSA and **FK-506** on SCF-dependent release of histamine were dose-dependent (IC50: CSA, 1 to 10 ng/mL; **FK-506**, 0.3 to 3 ng/mL). IC50 values about three to 10 times higher were found for MCs preincubated with rhSCF before anti-IgE activation, compared with anti-IgE or SCF alone. SCF-dependent differentiation of human MCs was analyzed in a long-term suspension culture system. Unexpectedly, CSA and **FK-506** were unable to suppress, but even enhanced SCF-dependent growth of MCs and formation of MC tryptase in long-term culture. Together, CSA and **FK-506** inhibit SCF-dependent release of histamine from human MCs and even augment SCF-dependent growth of human MCs in long-term culture.

ST **cyclosporin A FK506 stem cell factor**
 ; mast cell cyclosporin A FK506

IT Immunosuppressants
 Mast cell
 (effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells)

IT Hemopoietins
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (hematopoietic cell growth factors KL, effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells)

IT 59865-13-3, Cyclosporin A 104987-11-3, FK-506
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells)

IT 51-45-6, Histamine, biological studies
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells)

L67 ANSWER 21 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1996:390429 HCAPLUS
 DN 125:77323
 TI Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen
 AU Broudy, Virginia C.; Lin, Nancy L.; Priestley, Gregory V.; Nocka, Karl; Wolf, Norman S.
 CS Division of Hematology, University of Washington, Seattle, WA, 98195, USA
 SO Blood (1996), 88(1), 75-81
 CODEN: BLOOAW; ISSN: 0006-4971
 DT Journal

LA English
 CC 2-10 (Mammalian Hormones)
 AB The phenotypes of mice that harbor a defect in the genes encoding either **stem cell factor (SCF)** or its receptor, **c-kit**, indicate that this ligand/receptor pair is necessary for maintenance of normal hematopoiesis in the adult. The objective was to det. whether **SCF**, like erythropoietin, is necessary for acute erythroid expansion during recovery from hemolytic anemia. Monoclonal antibody **ACK2**, which recognizes the murine **c-kit** receptor, was used to selectively block the hematopoietic growth-promoting effects of **SCF**. Mice were treated with phenylhydrazine on day 0 and day 1 to induce hemolytic anemia and also received no antibody, control IgG, or **ACK2** on day 0. The mice were killed on day 3 and the hematocrit (Hct), reticulocyte count, and nos. of erythroid and myeloid hematopoietic progenitor cells (colony-forming unit-erythroid [CFU-E], burst-forming unit [BFU]-E, and CFU-granulocyte-macrophage [GM]) were quantitated in the femoral marrow and spleen using hematopoietic colony-forming assays. Induction of hemolytic anemia with phenylhydrazine resulted in a drop in the Hct from approx. 50-30%, and an approx. 8-10-fold increase in the reticulocyte count. The nos. of CFU-E increased modestly in the femur, and approx. 25-50-fold in the spleen, in comparison with normal mice. BFU-E and CFU-GM values did not increase in the femur but expanded 6-10-fold in the spleen, in comparison with normal mice. This confirms that much of the erythroid expansion in response to hemolytic anemia occurs in the murine spleen. Neutralizing quantities of the **ACK2** antibody reduced femoral CFU-E, BFU-E, and CFU-GM content to less than half that found in phenylhydrazine-treated control mice and nearly totally ablated splenic hematopoiesis. These results suggest that **c-kit** receptor function may be required for optimal response to acute erythropoietic demand and that erythropoiesis in the splenic microenvironment is more dependent on **SCF/c-kit** receptor interaction than is erythropoiesis in the marrow microenvironment. Because expansion of late erythropoiesis in the spleen was preferentially blocked, the authors tested the hypothesis that homing of more primitive hematopoietic cells to the spleen was dependent on **c-kit** receptor function. Lethally irradiated mice were injected with marrow cells obtained from mice that had received phenylhydrazine plus control IgG or with marrow cells obtained from mice that had received phenylhydrazine plus **ACK2**. In parallel expts., normal murine marrow cells were treated in vitro with control IgG or with **ACK2** and were treated in vitro with control IgG or with **ACK2** and were injected into lethally irradiated mice. The fraction of BFU-E and CFU-GM retrieved from the marrow and spleen of the recipient mice 4 h later was reduced by .apprx.75% when progenitor cells had been exposed to **ACK2**, in comparison with control IgG. Apparently, interaction of **SCF** with the **c-kit** receptor affects the homing behavior of hematopoietic progenitor cells in the adult animal.

ST **stem cell factor** hematopoiesis spleen;
ckit receptor hematopoiesis spleen

IT Erythropoiesis
 Hematocrit
 Hematopoiesis
 Reticulocyte
 Spleen
 (interaction of **stem cell factor** and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic cells in murine spleen)

IT Hematopoietic precursor cell
 (erythroid burst-forming, interaction of **stem cell factor** and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic cells in murine spleen)

IT Hematopoietic precursor cell
 (erythroid colony-forming, interaction of **stem cell**

factor and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic **cells** in murine spleen)

- IT Hematopoietic precursor **cell**
(granulocyte-macrophage, interaction of **stem cell factor** and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic **cells** in murine spleen)
- IT Hemopoietin receptors
Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(hematopoietic **cell** growth **factor** KL, interaction of **stem cell factor** and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic **cells** in murine spleen)
- IT Hemopoietins
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(hematopoietic **cell** growth **factors** KL, interaction of **stem cell factor** and its receptor **c-kit** mediates lodgment and acute expansion of hematopoietic **cells** in murine spleen)

L67 ANSWER 22 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1996:372170 HCAPLUS

DN 125:55286

TI **Recombinant human stem cell factor**

(kit ligand) promotes human **mast cell** and **melanocyte** hyperplasia and functional activation in vivo

AU Costa, John J.; Demetri, George D.; Harrist, Terence J.; Dvorak, Ann M.; Hayes, Daniel F.; Merica, Elizabeth A.; Menchaca, Dora M.; Gringeri, Anthony J.; Schwartz, Lawrence B.; Galli, Stephen J.

CS Dep. Pathology and Med., Beth Israel Hosp. and Harvard Med. Sch., Boston, MA, 02215, USA

SO J. Exp. Med. (1996), 183(6), 2681-2686

CODEN: JEMEAV; ISSN: 0022-1007

DT Journal

LA English

CC 14-9 (Mammalian Pathological Biochemistry)

AB **Stem cell factor (SCF)**, also known as **mast cell growth factor**, kit ligand, and **Steel factor**, is the ligand for the **tyrosine kinase** receptor (SCFR) that is encoded by the **c-kit** proto-oncogene. We analyzed the effects of recombinant human **SCF** (r-hSCF, 5-50 .mu.g/kg/day, injected s.c.) on **mast cells** and **melanocytes** in a phase I study of 10 patients with advanced breast carcinoma. A wheal and flare reaction developed at each r-hSCF injection site; by electron microscopy, most dermal **mast cells** at these sites exhibited extensive, **anaphylactic** -type degranulation. A 14-d course of r-hSCF significantly increased dermal **mast cell** d. at sites distant to those injected with the cytokine and also increased both urinary levels of the major histamine metabolite, methyl-histamine, and serum levels of **mast cell** .alpha.-tryptase. Five subjects developed areas of persistent **hyperpigmentation** at r-hSCF injection sites; by light microscopy, these sites exhibited markedly increased epidermal **melanization** and increased nos. of **melanocytes**. The demonstration that r-hSCF can promote both the hyperplasia and the functional activation of human **mast cells** and **melanocytes** in vivo has implications for our understanding of the role of endogenous **SCF** in health and disease. These findings also indicate that the interaction between **SCF** and its receptor represents a potential therapeutic target for regulating the nos. and functional activity of both **mast cells** and cutaneous **melanocytes**.

ST **stem cell factor mast cell**

- hyperplasia; **melanocyte hyperplasia stem cell factor**
- IT **Melanocyte**
(disease, hyperplasia; recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- IT **Mast cell**
(disease, hyperplasia, recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- IT Hemopoietins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hematopoietic **cell growth factors** KL, recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- IT **Skin, disease**
(**pigmentation**, recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- IT 501-75-7
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- IT 97501-93-4, Tryptase
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(.alpha.-; recombinant human **stem cell factor** promotes human **mast cell** and **melanocyte** hyperplasia and functional activation)
- L67 ANSWER 23 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1996:334134 HCAPLUS
DN 125:31083
TI Expression of **stem-cell factor** and its receptor **c-kit** protein in normal testicular tissue and malignant **germ-cell tumors**
AU Bokemeyer, Carsten; Kuczyk, Markus A.; Dunn, Theresa; Serth, Juergen; Hartmann, Kristin; Jonasson, Jens; Pietsch, Torsten; Jonas, Udo; Schmoll, Hans-Joachim
CS Medical School, Hannover University, Hannover, D-30625, Germany
SO J. Cancer Res. Clin. Oncol. (1996), 122(5), 301-306
CODEN: JCROD7; ISSN: 0171-5216
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 2, 13
AB The proto-oncogene **c-kit** and its ligand **stem-cell factor (SCF)** may play an important role in the development of normal and malignant testicular tissue. This study investigates the presence of **SCF** and **c-kit** protein in 32 orchiectomy specimens of patients with testicular **cancer**, in 5 specimens of normal testicular tissue and in three established non-seminomatous **germ-cell cancer cell** lines (H12.1, H32, 577ML) by an immunohistochem. approach. Out of 9 testicular **cancer** specimens classified as pure seminomas, 7 (78%) showed a strong immunohistochem. reaction for both **SCF** and **c-kit** protein on the surface of the **tumor cells**. Fourteen non-seminomatous **germ-cell tumors** composed of embryonal **carcinoma** were completely neg. for both **SCF** and **c-kit** protein and only faint positivity was found in 6 **tumors** (26%). Differentiated teratomatous structures within the specimens of non-seminomatous **tumors** showed a strong

immunohistochem. reaction for **SCF** and **c-kit** protein in 8 of 11 (73%) cases. All three testicular **cancer cell** lines showed only faint staining reactions for **c-kit** protein and none for **SCF**. No secretion of **SCF** by the three lines in vitro was detected. The addn. of high concns. of **SCF** (100 ng/mL) to the testicular **cancer cell** lines in culture conditions without fetal calf serum resulted in a 1.4 to 3-fold growth stimulation compared to **cell** growth in serum-free medium alone. This effect was not detectable when the **cells** were cultured in serum-contg. media. In the normal testicular tissue the **germ-cells** displayed a strong immunohistochem. reaction for **c-kit** protein while **SCF** positivity was found at the tubular membrane and on the surface of Sertoli **cells**. The **SCF/c-kit** system may possess a regulatory function in normal testicular tissue by possibly providing the microenvironment necessary for **spermatogenesis**. With the development of testicular **cancer**, this regulatory system seems to be lost, particularly in non-seminomatous **germ-cell tumors**. A growth-stimulatory effect of high concns. of **SCF** on non-seminomatous testicular **cancer cell** lines can be detected only in culture conditions with serum-free media. The effects achievable by the combination of **SCF** with other growth **factors** need to be further studied, as well as the role of the **c-kit/SCF** regulatory system for normal **spermatogenesis** and its possible implications for the understanding and treatment of male **infertility**.

ST **stem cell factor ckit** testis **cancer**

IT **Spermatogenesis**

Testis

Testis, neoplasm

(**stem-cell factor** and receptor **c-kit** protein expression in normal human testicular tissue and malignant **germ-cell tumors**)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**c-kit, stem-cell**

factor and receptor **c-kit** protein

expression in normal human testicular tissue and malignant **germ-cell tumors**)

IT Testis, neoplasm

(**germinoma, stem-cell factor**

and receptor **c-kit** protein expression in normal

human testicular tissue and malignant **germ-cell**

tumors)

IT Hemopoietin receptors

Receptors

RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(hematopoietic **cell growth factor** KL, **stem**

-cell factor and receptor **c-kit**

protein expression in normal human testicular tissue and malignant

germ-cell tumors)

IT Hemopoietins

RL: BOC (Biological occurrence); BPR (Biological process); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(hematopoietic **cell growth factors** KL, **stem**

-cell factor and receptor **c-kit**

protein expression in normal human testicular tissue and malignant

germ-cell tumors)

IT Testis, neoplasm

(**seminoma, stem-cell factor** and

receptor **c-kit** protein expression in normal human

testicular tissue and malignant **germ-cell**

tumors)

IT Testis, **neoplasm**
 (teratoma, **stem-cell factor** and receptor
c-kit protein expression in normal human testicular
 tissue and malignant **germ-cell tumors**)

IT 138359-29-2
 RL: BOC (Biological occurrence); BPR (Biological process); BIOL
 (Biological study); OCCU (Occurrence); PROC (Process)
 (**stem-cell factor** and receptor **c**
-kit protein expression in normal human testicular tissue and
 malignant **germ-cell tumors**)

L67 ANSWER 24 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1996:284892 HCAPLUS
 DN 125:77468
 TI Effects of **SCF** removal and **ACK2** addition on the
 induction of apoptosis in cultured mouse neural crest cells
 AU Ito, Masaru; Kawa, Yoko; Baba, Takako; Kubota, Yasuo; Mizoguchi, Masako
 CS Dep. Dermatol., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
 SO Nippon Hifuka Gakkai Zasshi (1996), 106(3), 239-248
 CODEN: NHKZAD; ISSN: 0021-499X
 DT Journal
 LA Japanese
 CC 2-10 (Mammalian Hormones)
 AB The role of **stem cell factor (SCF)**
 in the **c-Kit** expression and melanogenesis in cultured
 mouse neural crest **cells** was studied. The **c-**
KIT-pos. melanoblasts appeared in the **SCF**-added medium
 when the neural tubes of 9.5-day-old mice embryos were cultivated for 7
 days. Using this culture system, we studied whether **ACK2**
 (monoclonal anti-**c-KIT** antibody) could induce
 apoptosis in melanoblasts. Apoptotic **cells** of the cultured
 neural crest **cells** were detected by using Apop Tag kit, and
 their no./well was counted. We cultured neural tubes in **SCF**
 -added medium for 7 days, divided them into 5 groups, and cultivated each
 of them for another 24 h under 1 of the following conditions: **SCF**
 group, with **SCF**; **SCF**+/- group, without **SCF**;
ACK2 group, with **SCF** and **ACK2**; **ACK2**'
 group, without **SCF** and with **ACK2**; IgG group, with
SCF and IgG. There were significantly larger nos. of apoptotic
cells in **SCF**+/-, **ACK2** and **ACK2**'
 groups as compared to the **SCF** and IgG groups. The presence of
 apoptotic **cells** was also confirmed by electron microscopic
 study. Our in vitro study shows that **ACK2** causes apoptosis in
c-Kit-pos. melanoblasts and that **SCF** promotes
 melanocyte survival and differentiation by suppressing apoptosis.

ST **stem cell factor** melanoblast apoptosis
 IT Apoptosis
 Cell differentiation
 Embryo
 Melanoblast
 Melanocyte
 (melanoblast apoptosis suppression by **stem cell**
factor and promotion of melanocyte survival and
 differentiation)

IT Hemopoietin receptors
 Receptors
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological
 process); BIOL (Biological study); PROC (Process)
 (hematopoietic **cell growth factor** KL, melanoblast
 apoptosis suppression by **stem cell factor**
 and promotion of melanocyte survival and differentiation)

IT Hemopoietins
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (hematopoietic **cell growth factors** KL, melanoblast
 apoptosis suppression by **stem cell factor**)

- and promotion of melanocyte survival and differentiation)
- IT Nervous system
(neural crest, melanoblast apoptosis suppression by **stem cell factor** and promotion of melanocyte survival and differentiation)
- L67 ANSWER 25 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1995:641162 HCAPLUS
DN 123:132909
TI The **effects of stem cell factor**,
the ligand for the c-kit receptor, on mouse and human mast **cell**
development, **survival**, and function
AU Galli, Stephen J.; Tsai, Mindy; Wershil, Barry K.; Iemura, Akihiko; Ando,
Akikazu; Tam, See-Ying; Costa, John J.
CS Department of Pathology, Beth Israel Hospital, Boston, MA, 02215, USA
SO Biol. Mol. Aspects Mast Cell Basophil Differ. Funct. (1995), 1-11.
Editor(s): Kitamura, Yukihiko. Publisher: Raven, New York, N. Y.
CODEN: 610BAK
DT Conference; General Review
LA English
CC 2-0 (Mammalian Hormones)
AB A review, with 42 refs., on some of the important effects of **stem cell factor (SCF)** in mast **cell**
biol., focusing primarily on the results of in vivo studies and on those
issues which currently appear to be of clin. relevance in humans.
Included were discussions on the identification and characterization of
SCF; effects of **SCF** in mast **cell** development
and survival; promotion of mast **cell** survival by **SCF**
by suppressing apoptosis; **SCF** regulation of mast **cell**
secretory function and mediatory release; **SCF** effects on
IGE-dependent passive **anaphylaxis** in mice; and effects of
SCF in primates and humans in vivo.
ST review **stem cell factor** mast **cell**
IT Mast **cell**
(**stem cell factor**, effects on mouse and
human mast **cell** development and survival and function)
- IT Hemopoietins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BIOL (Biological study); PROC (Process)
(hematopoietic **cell** growth **factors** KL, **stem cell factor**, effects on mouse and human mast
cell development and survival and function)
- L67 ANSWER 26 OF 30 HCAPLUS COPYRIGHT 2000 ACS
AN 1995:245385 HCAPLUS
DN 122:7833
TI **Recombinant stem cell factor**
-induced mast **cell** activation and smooth muscle contraction in
human **bronchi**
AU Undem, Bradley J.; Lichtenstein, Lawrence M.; Hubbard, Walter C.; Meeker,
Sonya; Ellis, James L.
CS Dep. Med., Johns Hopkins Univ., Baltimore, MD, USA
SO Am. J. Respir. Cell Mol. Biol. (1994), 11(6), 646-50
CODEN: AJRBEL; ISSN: 1044-1549
DT Journal
LA English
CC 15-9 (Immunochemistry)
AB The effect of human recombinant **stem cell factor (SCF)** on inflammatory mediator release and smooth
muscle contraction was evaluated in human isolated intralobar
bronchi. **Bronchi** from 21 of 26 donors contracted in
response to **SCF**. The threshold concn. was approx. 0.01
.mu.g/mL. At 1 .mu.g/mL, the tissues contracted to about 60% of the
carbamylcholine-induced max. contraction. The responses to **SCF**
mimicked those obtained with anti-IgE. Thus, the contractions to
SCF and anti-IgE were inhibited to a similar extent by a

combination of a cysteinyl-leukotriene receptor antagonist and a histamine H1 receptor antagonist. **SCF** also mimicked the effect of anti-IgE in releasing histamine, i-LTD4, and PGD2 from the **bronchi**. At a threshold concn. for contraction (0.01 μ g/mL), **SCF** had no effect on subsequent responses to anti-IgE in the **bronchi**. Apparently, human recombinant **SCF** contracts airway smooth muscle by stimulating the release of contractile mediators from **bronchial mast cells**. The data fail to support the hypothesis that **SCF** primes **bronchial mast cells** to subsequent immunol. stimuli.

ST **stem cell factor mast cell**

bronchi

IT **Bronchi**

Mast cell

(**stem cell factor**-induced mast

cell activation and smooth muscle contraction in human **bronchi**)

IT Hemopoietins

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(hematopoietic **cell** growth **factors** **KL**, **stem**

cell factor-induced mast **cell** activation

and smooth muscle contraction in human **bronchi**)

IT 51-45-6, Histamine, biological studies 41598-07-6, PGD2 73836-78-9, LTD4

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(contractile mediators release from **bronchial mast**

cells induced by **stem cell factor**

)

L67 ANSWER 27 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1994:406366 HCAPLUS

DN 121:6366

TI Coexpression of the **c-kit** receptor and the

stem cell factor in **gynecological tumors**

AU Inoue, Masaki; Kyo, Satoru; Fujita, Masami; Enomoto, Takayuki; Kondoh, Gen

CS Sch. Med., Osaka Univ., Suita, 565, Japan

SO Cancer Res. (1994), 54(11), 3049-53

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

CC 14-1 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 13, 15

AB The protooncogene **c-kit** encodes a transmembrane

receptor-type tyrosine kinase which belongs to the β -PDGER/CSF-1

receptor tyrosine kinase family. The interaction between **c-**

kit receptor and its corresponding ligand, **stem**

cell factor (SCF), has been suggested to be

involved in embryogenesis as well as **carcinogenesis** via the

autocrine/paracrine system. In the present study, **cancer**

cell lines and normal/benign/malignant tissues of the human female

genital tract were examd. for the expression of both **c-**

kit and **SCF** by Northern blot and immunohistochem.

analyses. Two of 16 **cell** lines showed mRNA expression of both

c-kit and **SCF**, while 2 and 12 **cell**

lines expressed **c-kit** and **SCF**, resp. In

tissues, several cases of malignant **tumors**, including three

cervical **cancers**, one ovarian **cancer**, and one ovarian

immature teratoma, expressed mRNA of both **c-kit** and

SCF. In normal tissues, squamous epithelium expressed **SCF**

immunohistochem., while **c-kit** protein was detected

only in melanocytes. Some tissues of malignant **tumors**, one

squamous **cell carcinoma** of the cervix, two small

cell carcinomas of the cervix, two serous

adenocarcinomas of the ovary, and two immature teratomas of the

ovary, expressed both **c-kit** and **SCF** proteins

immunohistochem. It is also notable that **c-kit** protein was expressed only in malignant **germ cells** of dysgerminous, while **SCF** was expressed in the connective tissues surrounding **germ cells**. The present study suggests that the **c-kit/SCF** system may play an important role in the **carcinogenesis** of the female genital tract.

ST gene **ckit** receptor **neoplasm** ovary cervix

IT Melanocyte

(**c-kit** receptor and **stem cell**

factor expression in, in human)

IT Ribonucleic acids, messenger

RL: BIOL (Biological study)

(for **c-kit** receptor and **stem cell**

factor, in human **gynecol. tumors**)

IT Ovary, **neoplasm**

(**adenocarcinoma**, **c-kit** receptor and

stem cell factor expression in, in human)

IT Uterus

(cervix, epithelium, **c-kit** receptor and

stem cell factor expression in, in human)

IT Uterus, **neoplasm**

(cervix, small-cell **carcinoma**, **c-**

kit receptor and **stem cell factor**

expression in, in human)

IT Uterus, **neoplasm**

(cervix, squamous cell **carcinoma**, **c-**

kit receptor and **stem cell factor**

expression in, in human)

IT Ovary, **neoplasm**

(**dysgerminoma**, **c-kit** receptor and

stem cell factor expression in, in human)

IT Hemopoietin receptors

Receptors

RL: PROC (Process)

(hematopoietic cell growth factor KL, expression

of, in human **gynecol. tumors**, **stem**

cell factor in relation to)

IT Hemopoietins

RL: BIOL (Biological study)

(hematopoietic cell growth factors KL, expression of, in human

gynecol. tumors, **c-kit** receptor

in relation to)

IT Ovary, **neoplasm**

(**teratoma**, **c-kit** receptor and **stem**

cell factor expression in, in human)

IT Reproductive tract

(vulva, epithelium of, **c-kit** receptor and

stem cell factor expression in, in human)

L67 ANSWER 28 OF 30 HCAPLUS COPYRIGHT 2000 ACS

AN 1994:183929 HCAPLUS

DN 120:183929

TI **Stem cell factor** induces outgrowth of **c-kit**-positive neurites and supports the survival of **c-kit**-positive neurons in dorsal root ganglia of mouse embryos

AU Hirata, Tatsumi; Morii, Eiichi; Morimoto, Masahiro; Kasugai, Tsutomu; Tsujimura, Tohru; Hirota, Seiichi; Kanakura, Yuzuru; Nomura, Shintaro; Kitamura, Yukihiko

CS Med. Sch., Osaka Univ., Suita, 565, Japan

SO Development (Cambridge, UK) (1993), 119(1), 49-56

CODEN: DEVPED; ISSN: 0950-1991

DT Journal

LA English

CC 2-10 (Mammalian Hormones)

- AB The **c-kit** receptor tyrosine kinase is highly expressed by about 10% of the neurons in the dorsal root ganglia (DRGs) of mouse embryos. The authors investigated the in vitro effect of **stem cell factor (SCF)**, the ligand for **c-kit** receptor, on DRGs. Recombinant murine **SCF** (rmSCF) induced the outgrowth of **c-kit**-pos. neurites from DRGs of normal (+/+) embryos. The effect of **SCF** was dose dependent and completely abolished by anti-**c-kit ACK2** monoclonal antibody (mAb). Some neurites whose outgrowth was induced by NGF were **c-kit**-pos., but anti-NGF mAb did not inhibit the rmSCF-induced neurite outgrowth. The rmSCF did not induce neurite outgrowth from DRGs of W/W embryos that did not express **c-kit** receptors on the cell surface and of W42/W42 mutant embryos that expressed **c-kit** receptors without tyrosine kinase activity. The rmSCF also had a trophic effect on **c-kit**-pos. neurons in the culture of dissociated DRG cells. Most **c-kit**-pos. neurons appeared to respond to NGF as well, and the **SCF**-responsive subpopulation represented about 10% of NGF-responsive neurons. The rmSCF did not support the survival of DRG neurons from embryos of W/W and W42/W42 genotypes. These results suggest that the stimulus through the **c-kit** receptor tyrosine kinase has an important role in development of the peripheral nervous system.
- ST **stem cell factor** nerve **c**
- IT **kit**; embryo nerve **stem cell factor**
- IT Embryo
(nerve response to **stem cell factor** in dorsal root ganglia of, gene **c-kit** receptor tyrosine kinase in relation to)
- IT Nerve
(**stem cell factor** neurotrophic action on, in dorsal root ganglia of embryo, gene **c-kit** receptor tyrosine kinase in relation to)
- IT Nerve
(axon, outgrowth of, **stem cell factor** induction of, in dorsal root ganglia of embryo, gene **c-kit** receptor tyrosine kinase in relation to)
- IT Receptors
RL: BIOL (Biological study)
(hematopoietic **cell growth factor** KL, nerve response to **stem cell factor** in dorsal root ganglia of embryo in relation to)
- IT Hemopoietins
RL: BIOL (Biological study)
(hematopoietic cell growth factors KL, nerve response to, in dorsal root ganglia of embryo, gene **c-kit** receptor tyrosine kinase in relation to)
- IT Hemopoietins
RL: BIOL (Biological study)
(hematopoietic **cell growth factors** KL, receptors, nerve response to **stem cell factor** in dorsal root ganglia of embryo in relation to)
- IT Nerve center and Ganglion
(spinal, nerve response to **stem cell factor** in, of embryo, gene **c-kit** receptor tyrosine kinase in relation to)
- IT 138359-29-2, **c-Kit** receptor tyrosine kinase
RL: BIOL (Biological study)
(nerve response to **stem cell factor** in dorsal root ganglia of embryo in relation to)
- IT 9061-61-4, Nerve growth factor
RL: BIOL (Biological study)
(nerve response to, in dorsal root ganglia of embryo, **stem cell factor** in relation to)

- AN 1994:161208 HCAPLUS
 DN 120:161208
 TI Possible role of **stem cell factor** as a serum
factor: monoclonal anti-**c-kit** antibody
 abrogates interleukin-6-dependent colony growth in serum-containing
 culture
- AU Shiohara, Masaaki; Koike, Kenichi; Kubo, Tetsuo; Amano, Yoshiro; Takagi,
 Mineo; Muraoka, Kenji; Nakao, Junji; Nakahata, Tatsutoshi; Komiyama,
 Atsushi
 CS Sch. Med., Shinshu Univ., Matsumoto, 390, Japan
 SO Exp. Hematol. (Charlottesville, Va.) (1993), 21(7), 907-12
 CODEN: EXHMA6; ISSN: 0301-472X
 DT Journal
 LA English
 CC 15-5 (Immunocytochemistry)
 Section cross-reference(s): 2
- AB The monoclonal rat anti-**c-kit** antibody (**ACK2**
), which abrogates colony growth supported by **stem cell**
factor (SCF), significantly inhibited the interleukin-6
 (IL-6)-dependent growth of hematopoietic progenitors derived from spleen
cells of normal and 5-fluorouracil (5-FU)-treated mice and from
 bone marrow **cells** of normal mice in serum-contg. culture. The
 nos. and types of colonies supported by IL-3, granulocyte-macrophage
 colony-stimulating **factor** (GM-CSF) and granulocyte
 colony-stimulating **factor** (G-CSF), however, were not influenced
 by the addn. of **ACK2** to the cultures of the bone marrow
cells from normal mice. In replating expts. with pooled blast
cells, **ACK2** caused a partial, but significant,
 inhibition of GM colony growth supported by a combination of IL-6 and
 fetal bovine serum (FBS), which suggests that FBS is one source of the
SCF activity. Conversely, the addn. of **SCF** or FBS with
 IL-6 to a serum-free culture had significant synergistic effects on the
 total no. of colonies derived from post-5-FU spleen **cells** and
 from pooled blast **cells**. The dose response study showed that
 the ability of 30% FBS to interact with IL-6 on the colony growth by
 post-5-FU spleen **cells** was equiv. to that of approx. 5 ng/mL
SCF. These findings suggest that **c-kit** plays
 an important role in the growth of hematopoietic progenitors responding to
 IL-6, and that **SCF** in the serum affects the development of
 hematopoietic progenitors in serum-contg. cultures.
- ST serum **stem cell factor** colony growth;
 interleukin 6 colony growth serum **factor**
- IT Hematopoietic precursor cell
 (**stem cell factor** in blood serum and
 interleukin 6 effect on colony growth by)
- IT Animal tissue culture
 (**stem cell factor** in blood serum and
 interleukin 6 effects on colony growth by hematopoietic precursor
 cells in)
- IT Blood serum
 (**stem cell factor** in, hematopoietic
 progenitor cells response to interleukin 6 and)
- IT Hemopoietins
 RL: BIOL (Biological study)
 (hematopoietic cell growth factors KL, of blood serum, hematopoietic
 progenitor cells response to interleukin 6 and)
- IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (interleukin 6, **stem cell factor** in blood
 serum and, colony growth by hematopoietic precursor cells
 response to)
- L67 ANSWER 30 OF 30 HCAPLUS COPYRIGHT 2000 ACS
 AN 1994:6791 HCAPLUS
 DN 120:6791
 TI Production, purification and uses of **stem cell**

proliferation factor (SCPF)
 IN Lawman, Michael J. P.; Bagwell, Charles E.; Lawman, Patricia D.
 PA University of Florida Research Foundation Inc., USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N015-00
 ICS C12N015-02; C12N005-22; C12N001-00; C07K015-28; A61K039-395;
 C07H015-00; G01N033-543
 CC 15-5 (Immunochemistry)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320197	A1	19931014	WO 1993-US3197	19930406
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9340467	A1	19931108	AU 1993-40467	19930406
	CN 1081715	A	19940209	CN 1993-105217	19930406
	EP 672128	A1	19950920	EP 1993-911591	19930406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07508640	T2	19950928	JP 1993-517758	19930406
	ZA 9302489	A	19940217	ZA 1993-2489	19930407
	AU 9745294	A1	19980212	AU 1997-45294	19971120
	AU 714492	B2	20000106		
PRAI	US 1992-863889		19920406		
	WO 1993-US3197		19930406		
AB	The autocrine growth factor is isolated from a human germ cell tumor line of neuroectodermal origin. The protein exists in two forms, i.e. a sol. form of 32 kDa polypeptide and a membrane bound form of 37 kDa polypeptide. The factor stimulates proliferation of human bone marrow stem cells and has synergistic effect with other growth factors, e.g. interleukin 3, interleukin 6, and SCF (c-kit oncogene product). Prodn. of SCPF by genetic engineering technique is also claimed. Polyclonal and monoclonal antibody are prepd. for detecting and treating SCPF-assocd. disorders, e.g. leukemia, aplastic anemia, neuronal disorder, severe combined immunodeficiency, and hypersplenism.				
ST	stem cell proliferation factor; polyclonal monoclonal antibody leukemia; aplastic anemia immunodeficiency hypersplenism treatment antibody; bone marrow stem cell stimulation				
IT	Animal cell line (of germ cell tumor, stem cell proliferation factor purifn. from)				
IT	Genetic engineering (prodn. of stem cell proliferation factor by)				
IT	Lymphokines and Cytokines RL: BIOL (Biological study) (stem cell proliferation factor, isolation and prodn. and uses of)				
IT	Leukemia Nerve, disease (stem cell proliferation factor-assocd., detection and treatment of, antibody to stem cell proliferation factor for)				
IT	Antibodies RL: PREP (Preparation) (to stem cell proliferation factor, prepn. of, for detecting and treating leukemia, etc.)				
IT	Anemia (disease)				

(aplastic, **stem cell** proliferation **factor**
 -assocd., detection and treatment of, antibody to **stem**
cell proliferation **factor** for)

IT Gene, animal
 RL: BIOL (Biological study)
 (c-kit, protein product of, synergism of
stem cell proliferation **factor** and, for
 stimulating bone marrow **stem cells** proliferation)

IT Spleen, disease
 (hypersplenism, **stem cell** proliferation
factor-assocd., detection and treatment of, antibody to
stem cell proliferation **factor** for)

IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (interleukin 3, synergism of **stem cell**
 proliferation **factor** and, for stimulating bone marrow
stem cells proliferation)

IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (interleukin 6, synergism of **stem cell**
 proliferation **factor** and, for stimulating bone marrow
stem cells proliferation)

IT Antibodies
 RL: PREP (Preparation)
 (monoclonal, to **stem cell** proliferation
factor, prepn. of, for detecting and treating leukemia, etc.)

IT Gamete and **Germ cell**
 (neoplasm, **stem cell** proliferation
factor purifn. from **cell** line of)

IT Nucleotides, polymers
 RL: BIOL (Biological study)
 (poly-, encoding gene sequence of **stem cell**
 proliferation **factor**, for prodn.)

IT Immunodeficiency
 (severe combined, **stem cell** proliferation
factor-assocd., detection and treatment of, antibody to
stem cell proliferation **factor** for)

=> fil medline

FILE 'MEDLINE' ENTERED AT 10:21:40 ON 28 JUN 2000

FILE LAST UPDATED: 22 JUN 2000 (20000622/UP). FILE COVERS 1960 TO DATE.

MEDLINE has been reloaded to reflect the annual MeSH changes made by
 the National Library of Medicine for 2000. Enter HELP RLOAD for details.

OLDMEDLINE, data from 1960 through 1965 from the Cumulated Index
 Medicus (CIM), has been added to MEDLINE. See HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the
 Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
 SUBSTANCE IDENTIFICATION.

=> d his 168-

(FILE 'HCAPLUS' ENTERED AT 09:49:49 ON 28 JUN 2000)

FILE 'MEDLINE' ENTERED AT 09:50:27 ON 28 JUN 2000

L68 2619 S STEM CELL FACTOR
 L69 56 S L68 AND SKIN+NT/CT
 L70 69 S L68 AND SKIN DISEASES+NT/CT

L71 4 S L68 AND SKIN PIGMENTATION+NT/CT
 L72 12 S L68 AND PIGMENTATION+NT/CT
 L73 8 S L68 AND SKIN PHYSIOLOGY+NT/CT
 L74 9 S L68 AND ASTHMA+NT/CT
 L75 4 S L68 AND ANAPHYLAXIS+NT/CT
 L76 0 S L68 AND BRONCHIAL SPASM+NT/CT
 L77 29 S L68 AND MASTOCYTOSIS+NT/CT
 L78 0 S L68 AND URTICARIA+NT/CT
 L79 32 S L68 AND HYPERSENSITIVITY+NT/CT
 L80 20 S L68 AND (A3. OR C6.)/CT AND STROM?
 L81 5 S L68 AND (A3. OR C6.)/CT AND STROMAL CELLS+NT/CT
 L82 3 S L80,L81 AND C4./CT
 L83 57 S L68 AND GERM CELLS+NT/CT
 L84 1 S L83 AND C4./CT
 L85 54 S L68 AND "NEOPLASMS, GERM CELL AND EMBRYONAL"+NT/CT
 L86 13 S L68 AND ACK2
 L87 60 S L68 AND ?DIMER?
 L88 39 S L87 AND KIT
 L89 36 S L87 AND PROTO ONCOGENE PROTEIN C KIT
 L90 108 S L68 AND LIGAND (L) BIND?
 L91 111 S L68 AND (PREGNANCY+NT OR FERTILITY+NT OR INFERTILITY+NT OR CO
 L92 125 S L68 AND A5./CT
 L93 158 S L68 AND EPITHELIAL CELLS+NT/CT
 L94 18 S L68 AND (MELANINS+NT OR KERATIN+NT OR KERATINOCYTES+NT)/CT
 E PROTEIN-TYROSINE KINASE/CT
 E E3+ALL/CT
 L95 915 S D8./CT AND L68
 L96 296 S L95 AND L69-L94
 L97 289 S L69-L94,L96 AND STEM CELL FACTOR/CT
 L98 448 S L69-L94,L96 AND STEM CELL FACTOR/CN
 L99 448 S L97,L98
 L100 37 S L99 AND SIGNAL TRANSDUCTION+NT/CT
 L101 172 S L69-L94,L96 NOT L99
 L102 6 S L101 AND SIGNAL TRANSDUCTION+NT/CT
 L103 43 S L100,L102
 L104 112 S L99,L101 AND SIGNAL?
 L105 69 S L104 NOT L103
 L106 17 S L105 AND PATHWAY
 L107 3 S L105 AND (DOWNSTREAM? OR UPSTREAM?)
 L108 1 S L106 AND LUNG NEOPLASMS/CT
 L109 44 S L103,L108
 L110 687 S L68 AND (AI/CT OR INHIBIT? OR BLOCK? OR ANTAGON?)
 L111 166 S L110 AND L99,L101
 L112 5 S L111 AND ((STEM CELL FACTOR) (L)AI)/CT
 L113 47 S L109,L112

FILE 'MEDLINE' ENTERED AT 10:21:40 ON 28 JUN 2000

=> d all tot

L113 ANSWER 1 OF 47 MEDLINE
 AN 2000134033 MEDLINE
 DN 20134033
 TI c-Kit and c-kit mutations in mastocytosis and other
 hematological diseases.
 AU Boissan M; Feger F; Guillosson J J; Arock M
 CS Cellular and Molecular Hematology Unit, Faculty of Pharmacy, Paris,
 France.
 SO JOURNAL OF LEUKOCYTE BIOLOGY, (2000 Feb) 67 (2) 135-48. Ref: 129
 Journal code: IWY. ISSN: 0741-5400.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English

FS Priority Journals; Cancer Journals
 EM 200004
 EW 20000404
 AB Mast cells (MC) are tissue elements derived from hematopoietic stem cells. Their differentiation and proliferation processes are under the influence of cytokines, including one of utmost importance known as **stem cell factor** (SCF). SCF receptor is encoded by the protooncogene **c-kit**, belongs to the type III receptor tyrosine kinase subfamily, and is also expressed on other hematopoietic or non-hematopoietic cells. Ligation of **c-kit** receptor by SCF induces its **dimerization**, followed by induction of multiple intracellular signaling pathways leading to cell proliferation and activation. Mastocytosis, a relatively rare group of diseases characterized by accumulation of MC in various tissues, are found isolated or sometimes associated with other hematological malignancies in humans. Although the initial events leading to mastocytosis are not yet unraveled, alterations of the **c-kit** gene have been described. Particularly interesting are acquired mutations resulting in a constitutively activated receptor, possibly involved in the increased numbers of MC in tissues. For this reason, future strategies might be envisaged to target specifically the mutated **c-kit** and/or its intracellular signaling.

CT Check Tags: Animal; Human
 Amino Acid Substitution
 Cell Differentiation
 Cell Division
 Cell Transformation, Neoplastic
Dimerization
 Hematologic Diseases: GE, genetics
 *Hematologic Diseases: ME, metabolism
 Hematologic Neoplasms: GE, genetics
 Hematologic Neoplasms: ME, metabolism
 Leukemia: GE, genetics
 Leukemia: ME, metabolism
Mastocytosis: GE, genetics
 ***Mastocytosis: ME, metabolism**
 Mice
 Neoplasm Proteins: GE, genetics
 Neoplasm Proteins: PH, physiology
 Phosphorylation
 Point Mutation
 Protein Processing, Post-Translational
 Protein Structure, Tertiary
Proto-Oncogene Protein c-kit: CH, chemistry
Proto-Oncogene Protein c-kit: GE, genetics
 ***Proto-Oncogene Protein c-kit: PH, physiology**
 Proto-Oncogenes
 Rats
 Sequence Deletion
Signal Transduction
Stem Cell Factor: PH, physiology
 Tumor Cells, Cultured

CN EC 2.7.11.- (**Proto-Oncogene Protein c-kit**); 0 (Neoplasm Proteins); 0 (**Stem Cell Factor**)

L113 ANSWER 2 OF 47 MEDLINE
 AN 2000120715 MEDLINE
 DN 20120715
 TI Kit/**stem cell factor** receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.
 AU Blume-Jensen P; Jiang G; Hyman R; Lee K F; O'Gorman S; Hunter T
 CS Molecular Biology and Virology Laboratory, The Salk Institute, La Jolla, California, USA.. blume@salk.edu
 SO NATURE GENETICS, (2000 Feb) 24 (2) 157-62.
 Journal code: BRO. ISSN: 1061-4036.

CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200005
 EW 20000501
 AB The c-kit-encoded transmembrane tyrosine kinase receptor for **stem cell factor** (Kit/SCF-R) is required for normal haematopoiesis, melanogenesis and gametogenesis. However, the roles of individual Kit/SCF-R-induced signalling pathways in the control of developmental processes in the intact animal are completely unknown. To examine the function of SCF-induced phosphatidylinositol (PI) 3'-kinase activation in vivo, we employed the Cre-loxP system to mutate the codon for Tyr719, the PI 3'-kinase binding site in Kit/SCF-R, to Phe in the genome of mice by homologous recombination. Homozygous (Y719F/Y719F) mutant mice are viable. The mutation completely disrupted PI 3'-kinase binding to Kit/SCF-R and reduced SCF-induced PI 3'-kinase-dependent activation of Akt by 90%. The mutation induced a gender- and tissue-specific defect. Although there are no haematopoietic or pigmentation defects in homozygous mutant mice, males are sterile due to a block in spermatogenesis, with initially decreased proliferation and subsequent extensive apoptosis occurring at the spermatogonial stem-cell level. In contrast, female homozygotes are fully fertile. This is the first report so far demonstrating the role of an individual signalling pathway downstream of Kit/SCF-R in the intact animal. It provides the first in vivo model for male sterility caused by a discrete signalling pathway defect affecting early germ cells.
 CT Check Tags: Animal; Female; Male; Support, U.S. Gov't, P.H.S.
 Amino Acid Substitution
 Apoptosis
 Codon
 Enzyme Activation
 Exons
 *Fertility: GE, genetics
 Fetal Development
 Genomic Library
 Heterozygote
 Homozygote
 Introns
 Mice
 Mice, Mutant Strains
 Mutagenesis, Site-Directed
 Proto-Oncogene Protein c-kit: CH, chemistry
 *Proto-Oncogene Protein c-kit: GE, genetics
 *Proto-Oncogene Protein c-kit: ME, metabolism
 Signal Transduction: DE, drug effects
 Stem Cell Factor: PD, pharmacology
 Stem Cell Factor: PH, physiology
 *1-Phosphatidylinositol 3-Kinase: ME, metabolism
 CN EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Codon); 0 (Stem Cell Factor)
 L113 ANSWER 3 OF 47 MEDLINE
 AN 2000076250 MEDLINE
 DN 20076250
 TI Distinct signals control the hematopoiesis of lymphoid-related dendritic cells.
 AU Galy A; Christopherson I; Ferlazzo G; Liu G; Spits H; Georgopoulos K
 CS Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.. galya@kci.wayne.edu
 SO BLOOD, (2000 Jan 1) 95 (1) 128-37.
 Journal code: A8G. ISSN: 0006-4971.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 200004
EW 20000401
AB The molecular and cellular requirements for the development of different populations of human dendritic cells (DC) were studied. Conditions were defined that support DC production from lymphoid progenitors but that fail to induce DC formation from peripheral monocytes. The production of these lymphoid-related DC was severely blocked when hematopoietic progenitors overexpressed Ik7, a mutant dominant-negative Ikaros protein. In contrast, Ik7 did not block the formation of DC in conditions supporting the development of monocyte-derived DC. Furthermore, Ik7 did not block the formation of monocyte/macrophages and enhanced granulopoiesis. One of the molecular mechanisms mediated by Ik7 appears to be down-regulation of the flt3-receptor mRNA. Thus, distinct signals control the formation of DC demonstrating that some aspects of DC diversity are determined in part by distinct molecular cues at the hematopoietic level. (Blood. 2000;95:128-137)

CT Check Tags: Human; Support, Non-U.S. Gov't
Adult
Antigens, CD: AN, analysis
Antigens, CD34: AN, analysis
Bone Marrow Cells: CY, cytology
Cell Differentiation: DE, drug effects
Cells, Cultured
*Cytokines: PD, pharmacology
Dendritic Cells: CY, cytology
Dendritic Cells: DE, drug effects
*Dendritic Cells: PH, physiology
Down-Regulation (Physiology)
Flow Cytometry
Granulocyte Macrophage Colony-Stimulating Factors, Recombinant: PD, pharmacology
Hematopoiesis: DE, drug effects
*Hematopoiesis: PH, physiology
Hematopoietic Stem Cells: CY, cytology
Hematopoietic Stem Cells: DE, drug effects
*Hematopoietic Stem Cells: PH, physiology
Interleukins: PD, pharmacology
Lymphocytes: CY, cytology
Lymphocytes: DE, drug effects
*Lymphocytes: PH, physiology
Macrophages: CY, cytology
Monocytes: CY, cytology
Neprilysin: AN, analysis
Proto-Oncogene Proteins: GE, genetics
Receptor Protein-Tyrosine Kinases: GE, genetics
Receptors, Cell Surface: GE, genetics
Recombinant Proteins: ME, metabolism
Recombinant Proteins: PD, pharmacology
Reverse Transcriptase Polymerase Chain Reaction
*Signal Transduction
Stem Cell Factor: PD, pharmacology
T-Lymphocytes: CY, cytology
T-Lymphocytes: DE, drug effects
*T-Lymphocytes: PH, physiology
Transcription Factors: GE, genetics
Transcription Factors: ME, metabolism
Tumor Necrosis Factor: PD, pharmacology
Zinc Fingers

RN 148971-36-2 (Ikaros protein)
CN EC 2.7.1.- (fetal liver kinase-2); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); EC 3.4.24.11 (Neprilysin); 0 (Antigens, CD); 0 (Antigens, CD34); 0 (Cytokines); 0 (Granulocyte Macrophage Colony-Stimulating Factors, Recombinant); 0 (Interleukins); 0 (Proto-Oncogene Proteins); 0 (Receptors, Cell Surface); 0 (Recombinant Proteins); 0 (Stem Cell Factor); 0 (Transcription Factors); 0 (Tumor Necrosis Factor)

L113 ANSWER 4 OF 47 MEDLINE

AN 2000059822 MEDLINE

DN 20059822

TI **Stem cell factor** protects germ cells from apoptosis in vitro.

AU Yan W; Suominen J; Toppari J

CS Departments of Physiology and Pediatrics, University of Turku, Kiinamyllynkatu 10, Turku, Finland.

SO JOURNAL OF CELL SCIENCE, (2000 Jan) 113 (Pt 1) 161-8.

Journal code: HNK. ISSN: 0021-9533.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200005

EW 20000501

AB **Stem cell factor** (SCF) plays an important role in migration, adhesion, proliferation, and survival of primordial germ cells and spermatogonia during testicular development. However, the function of SCF in the adult testis is poorly described. We have previously shown that, in the presence of SCF, there were more type A spermatogonia incorporating thymidine at stage XII of rat seminiferous tubules cultured in vitro than in the absence of SCF, implying that the increased DNA synthesis might result from enhanced survival of spermatogonia. To explore the potential pro-survival function of SCF during spermatogenesis, the seminiferous tubules from stage XII were cultured in the presence or absence of SCF (100 ng/ml) for 8, 24, 48, and 72 hours, respectively, and apoptosis was analyzed by DNA laddering and in situ 3'-end labeling (ISEL) staining. Surprisingly, not only spermatogonia, but also spermatocytes and spermatids, were protected from apoptosis in the presence of SCF. Apoptosis took place much later and was less severe in the SCF-treated tubules than in the controls. Based on previous studies showing that FSH prevents germ cells from undergoing apoptosis in vitro, and that SCF level is increased dramatically in response to FSH stimulation, we also tested if the pro-survival effect of FSH is mediated through SCF by using a function-blocking monoclonal antibody, ACK-2, to block SCF/c-kit interaction. After 24 hours of blockade, the protective effect of FSH was partially abolished, as manifested by DNA laddering and ISEL analyses. The present study demonstrates that SCF acts as an important survival factor for germ cells in the adult rat testis and FSH pro-survival effect on germ cells is mediated partially through the SCF/c-kit pathway.

CT Check Tags: Animal; Male; Support, Non-U.S. Gov't

Antibodies, Monoclonal: PD, pharmacology

*Apoptosis: DE, drug effects

Cell Survival: DE, drug effects

DNA: BI, biosynthesis

DNA: GE, genetics

DNA Fragmentation: DE, drug effects

FSH: PD, pharmacology

In Situ Nick-End Labeling

Protein Binding: DE, drug effects

Proto-Oncogene Protein c-kit: ME, metabolism

Rats

Rats, Sprague-Dawley

Seminiferous Tubules: CY, cytology

Seminiferous Tubules: DE, drug effects

Seminiferous Tubules: GD, growth & development

Seminiferous Tubules: ME, metabolism

Signal Transduction: DE, drug effects

*Spermatozoa: CY, cytology

*Spermatozoa: DE, drug effects

Spermatozoa: ME, metabolism

Stem Cell Factor: AI, antagonists & inhibitors

***Stem Cell Factor**: PD, pharmacology

Time Factors

Tissue Culture
 RN 9002-68-0 (FSH); 9007-49-2 (DNA)
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Antibodies, Monoclonal);
 0 (Stem Cell Factor)

L113 ANSWER 5 OF 47 MEDLINE
 AN 2000049052 MEDLINE
 DN 20049052
 TI Early signaling pathways activated by c-Kit in hematopoietic cells.
 AU Linnekin D
 CS Basic Research Laboratory, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201, USA..
 dlinnekin@mail.ncifcrf.gov
 SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, (1999 Oct) 31 (10) 1053-74. Ref: 171
 Journal code: CDK. ISSN: 1357-2725.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English
 FS Priority Journals
 EM 200004
 EW 20000403
 AB c-Kit is a receptor tyrosine kinase that binds **stem cell factor** (SCF). Structurally, c-Kit contains five immunoglobulin-like domains extracellularly and a catalytic domain divided into two regions by a 77 amino acid insert intracellularly. Studies in white spotting and steel mice have shown that functional SCF and c-Kit are critical in the survival and development of stem cells involved in hematopoiesis, pigmentation and reproduction. Mutations in c-Kit are associated with a variety of human diseases. Interaction of SCF with c-Kit rapidly induces receptor **dimerization** and increases in autophosphorylation activity. Downstream of c-Kit, multiple signal transduction components are activated, including phosphatidylinositol-3-kinase, Src family members, the JAK/STAT pathway and the Ras-Raf-MAP kinase cascade. Structure-function studies have begun to address the role of these signaling components in SCF-mediated responses. This review will focus on the biochemical mechanism of action of SCF in hematopoietic cells.

CT Check Tags: Animal; Human
 ras Proteins: ME, metabolism
 Dimerization
 DNA-Binding Proteins: ME, metabolism
 *Hematopoietic Stem Cells: ME, metabolism
 Mice
 Mitogen-Activated Protein Kinases: ME, metabolism
 Phosphorylation
 Protein-Tyrosine Kinase: ME, metabolism
 *Proto-Oncogene Protein c-kit: ME, metabolism
 Proto-Oncogene Proteins c-raf: ME, metabolism
 *Signal Transduction
 *Stem Cell Factor: ME, metabolism
 Structure-Activity Relationship
 Trans-Activators: ME, metabolism
 1-Phosphatidylinositol 3-Kinase: ME, metabolism

CN EC 2.7.1.- (Janus kinase 1); EC 2.7.1.- (Mitogen-Activated Protein Kinases); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.10.- (Proto-Oncogene Proteins c-raf); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 3.6.1.- (ras Proteins); 0 (gamma-activated factor, 91-kD); 0 (DNA-Binding Proteins); 0 (Stem Cell Factor); 0 (Trans-Activators)

L113 ANSWER 6 OF 47 MEDLINE

AN 2000047616 MEDLINE
 DN 20047616
 TI **Stem cell factor/c-kit system in spermatogenesis.**
 AU Mauduit C; Hamamah S; Benahmed M
 CS INSERM U407, Faculte de Medecine Lyon-Sud, Oullins, France..
 mauduit@lsgrisl.univ-lyon1.fr
 SO HUMAN REPRODUCTION UPDATE, (1999 Sep-Oct) 5 (5) 535-45. Ref: 92
 Journal code: CUH. ISSN: 1355-4786.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 200003
 EW 20000302
 AB One of the major unresolved questions with male infertility is the identification of the molecular origin of a great majority of the spermatogenetic arrests currently diagnosed as idiopathic male infertility. During the past years, several families of regulating factors have been implicated in spermatogenesis defects observed essentially in animal models. Among these factors are signalling molecules, and particularly the **stem cell factor** (SCF)/c-kit system. The SCF and its receptor c-kit are an appropriate example to illustrate the role of signalling molecules in the physiology and pathology of spermatogenesis. The SCF/c-kit regulates primordial germ cell migration, proliferation and apoptosis during fetal gonadal development. The SCF/c-kit also regulates spermatogonia proliferation in the adult animal. In mutant mice, abnormalities of the SCF/c-kit gene expression, such as gene deletion, point mutation, alternative splicing defect, lead to different types of spermatogenesis alterations (e.g. decrease in primordial germ cell migration, decrease in spermatogonia proliferation). More recently, defects in SCF/c-kit gene expression have also been shown in human testicular dysfunctions. Indeed, a reduction in SCF/c-kit expression has been evidenced in oligozoospermia/azoospermia associated with an increase in the germ cell apoptosis process. In addition, c-kit seems to be a good marker of seminoma testicular tumours. This review reports a large number of data--obtained essentially in animal models--that suggest an important role for the SCF/c-kit system in spermatogenesis and, as a corollary, its potential involvement in spermatogenic defects.
 CT Check Tags: Animal; Human; Male; Support, Non-U.S. Gov't
 Apoptosis
 Cell Division
 Cell Movement
 Gene Expression Regulation
 *Infertility, Male: PP, **physiopathology**
 Mice
 Mice, Mutant Strains
 Proto-Oncogene Protein c-kit: GE, **genetics**
 *Proto-Oncogene Protein c-kit: PH, **physiology**
 Rats
 *Signal Transduction: PH, **physiology**
 *Spermatogenesis: PH, **physiology**
 Stem Cell Factor: GE, **genetics**
 *Stem Cell Factor: PH, **physiology**
 Testis: CY, **cytology**
 Testis: EM, **embryology**
 Yolk Sac: CY, **cytology**
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (**Stem Cell Factor**)
 L113 ANSWER 7 OF 47 MEDLINE
 AN 1999455234 MEDLINE
 DN 99455234
 TI Isoforms of c-KIT differ in activation of signalling pathways and

- transformation of NIH3T3 fibroblasts.
- AU Caruana G; Cambareri A C; Ashman L K
- CS Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia.
- SO ONCOGENE, (1999 Sep 30) 18 (40) 5573-81.
Journal code: ONC. ISSN: 0950-9232.
- CY ENGLAND: United Kingdom
- DT Journal; Article; (JOURNAL ARTICLE)
- LA English
- FS Priority Journals; Cancer Journals
- EM 200001
- EW 20000104
- AB Alternate splicing of mRNA encoding c-KIT results in isoforms which differ in the presence or absence of four amino acids (GNNK) in the juxtamembrane region of the extracellular domain of the receptor. In this study we show that these isoforms of human c-KIT, expressed at similar levels in NIH3T3 cells, display differential effects on various attributes of transformation. The GNNK- isoform strongly promoted anchorage independent growth (colony formation in semi-solid medium), loss of contact inhibition (focus formation), and led to tumorigenicity in nude mice. In contrast, the GNNK+ isoform elicited colony formation but relatively poor focus formation and no tumorigenicity. Saturation **binding** analysis indicated that the isoforms do not differ significantly in their affinity for the KIT **ligand**, Steel Factor (SLF). Negligible **ligand**-independent receptor phosphorylation was observed in either case but, after **ligand** stimulation, the GNNK- isoform displayed more rapid and extensive tyrosine autophosphorylation and faster internalization. Both isoforms recruited the p85 subunit of phosphatidylinositol 3-kinase and led to similar phosphorylation of its downstream effector c-Akt, but the GNNK- isoform gave rise to more MAP kinase phosphorylation. Thus the c-KIT isoforms display different signalling characteristics and have different transforming activity in NIH3T3 cells.
- CT Check Tags: Animal; Comparative Study; Human; Support, Non-U.S. Gov't
Amino Acid Sequence
Cell Adhesion
*Cell Transformation, Neoplastic: ME, metabolism
DNA, Complementary: GE, genetics
Mice
Mice, Nude
Protein Isoforms: GE, genetics
*Protein Isoforms: PH, physiology
***Proto-Oncogene Protein c-kit: PH, physiology**
Recombinant Fusion Proteins: GE, genetics
Recombinant Fusion Proteins: PH, physiology
*RNA Splicing
***Signal Transduction: PH, physiology**
Stem Cell Factor: PH, physiology
Transfection
Tumor Stem Cell Assay
1-Phosphatidylinositol 3-Kinase: PH, physiology
3T3 Cells: PA, pathology
3T3 Cells: TR, transplantation
- CN EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (DNA, Complementary); 0 (Protein Isoforms); 0 (Recombinant Fusion Proteins); 0 (**Stem Cell Factor**)
- L113 ANSWER 8 OF 47 MEDLINE
- AN 1999408738 MEDLINE
- DN 99408738
- TI Signaling via Src family kinases is required for normal internalization of the receptor c-Kit.
- AU Broudy V C; Lin N L; Liles W C; Corey S J; O'Laughlin B; Mou S; Linnekin D
- CS Divisions of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA.. vcbroudy@u.washington.edu
- NC DK44194 (NIDDK)

DK43719 (NIDDK)
CA31615 (NCI)
+

SO BLOOD, (1999 Sep 15) 94 (6) 1979-86.
Journal code: A8G. ISSN: 0006-4971.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199912

AB **Stem cell factor** (SCF) exerts its biological effects by **binding** to a specific receptor, the tyrosine kinase c-Kit, which is expressed on the cell surface. Although normal cellular trafficking of growth factor receptors may play a critical role in the modulation of receptor function, the mechanisms that regulate the distribution of c-Kit on the cell surface and the internalization of c-Kit have not been fully defined. We investigated whether signal transduction via Src family kinases is required for normal c-Kit trafficking. Treatment of the SCF-responsive human hematopoietic cell line MO7e with the inhibitor of Src family kinases PP1 blocked SCF-induced capping of c-Kit and internalization of c-Kit. c-Kit was able to associate with clathrin in the presence of PP1, suggesting that entry of c-Kit into clathrin-coated pits occurs independently of Src family kinases. SCF-induced internalization of c-Kit was also diminished in the D33-3 lymphoid cell line in which expression of Lyn kinase was disrupted by homologous recombination. These results indicate that Src family kinases play a role in **ligand**-induced trafficking of c-Kit.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.
src-Family Kinases: AI, antagonists & inhibitors
src-Family Kinases: GE, genetics
***src-Family Kinases: ME, metabolism**
Cell Membrane: PH, physiology
Chemotaxis: DE, drug effects
Chemotaxis: PH, physiology
Clathrin: ME, metabolism
***Coated Pits, Cell-Membrane: PH, physiology**
Gene Expression Regulation, Enzymologic
Kinetics
Leukemia
Proto-Oncogene Protein c-kit: DE, drug effects
***Proto-Oncogene Protein c-kit: ME, metabolism**
Pyrroles: PD, pharmacology
Pyrimidines: PD, pharmacology
Recombination, Genetic
***Signal Transduction: PH, physiology**
Stem Cell Factor: PD, pharmacology
***Stem Cell Factor: PH, physiology**
Tumor Cells, Cultured

CN EC 2.7.11.- (src-Family Kinases); EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Clathrin); 0 (Pyrroles); 0 (Pyrimidines); 0 (**Stem Cell Factor**); 0 (4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine)

L113 ANSWER 9 OF 47 MEDLINE

AN 1999348687 MEDLINE

DN 99348687

TI SCF-KIT pathway in human epidermal melanocyte homeostasis [letter].

AU Longley B J; Carter E L

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1999 Jul) 113 (1) 139-40.
Journal code: IHZ. ISSN: 0022-202X.

CY United States

DT Letter

LA English

FS Priority Journals; Cancer Journals

EM 199910

CT Check Tags: Human

Epidermis: CY, cytology
 Epidermis: PH, physiology
 *Homeostasis
 Melanocytes: CY, cytology
 *Melanocytes: PH, physiology
 *Proto-Oncogene Protein c-kit: PH, physiology
 Signal Transduction
 *Stem Cell Factor: PH, physiology

CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Stem Cell Factor)

L113 ANSWER 10 OF 47 MEDLINE

AN 1999317075 MEDLINE

DN 99317075

TI Defective expression of the SHP-1 phosphatase in polycythemia vera.

AU Wickrema A; Chen F; Namin F; Yi T; Ahmad S; Uddin S; Chen Y H; Feldman L;
 Stock W; Hoffman R; Platanias L C

CS Department of Medicine, University of Illinois at Chicago, USA..
 awickrem@uic.edu

SO EXPERIMENTAL HEMATOLOGY, (1999 Jul) 27 (7) 1124-32.

Journal code: EPR. ISSN: 0301-472X.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199909

AB The SHP-1 phosphatase associates with the receptors for erythropoietin, **stem cell factor**, and interleukin-3, and negatively regulates the mitogenic signals generated during engagement by their respective **ligands**. The erythroid progenitors of patients with polycythemia vera are hypersensitive to the mitogenic effects of these growth factors despite the fact that the numbers and **binding** affinities for their receptors are not increased. To determine whether post-receptor signaling defects may account for growth factor-hypersensitivity in polycythemia vera, we determined the expression of SHP-1 in highly purified erythroid progenitors from polycythemia vera patients. Our data demonstrate that in approximately 60% of the patients, expression of SHP-1 in the colony forming unit-erythroid population is diminished. The decreased expression of the protein may result from a transcriptional defect, as suggested by the diminished SHP-1 mRNA expression in the erythroid progenitors of these patients. Studies to determine the level of maturation of polycythemia vera and normal cells indicated that there was no difference between the two at early colony forming unit-erythroid stage of differentiation although polycythemia vera cells showed retarded differentiation kinetics at late colony forming unit-erythroid stage of differentiation. Furthermore, SHP-1 expression in normal colony forming unit-erythroid demonstrated downregulation of mRNA and protein levels during terminal differentiation, suggesting that its function is required for growth control during the early stages of erythropoiesis. These results indicate an important role for SHP-1 in the regulation of normal human erythroid progenitors and suggest that defective expression of the protein may contribute to the pathogenesis of polycythemia vera.

CT Check Tags: Human; Support, Non-U.S. Gov't

Cell Differentiation

Colony-Forming Units Assay

Enzyme Induction

Erythroid Progenitor Cells: DE, drug effects

Erythroid Progenitor Cells: EN, enzymology

Erythroid Progenitor Cells: PA, pathology

Erythropoiesis: DE, drug effects

Erythropoiesis: PH, physiology

Erythropoietin: PD, pharmacology

Heme: BI, biosynthesis

Phosphorylation

*Polycythemia Vera: EN, enzymology

Polycythemia Vera: GE, genetics

Polycythemia Vera: PA, pathology
 Protein Processing, Post-Translational
Protein-Tyrosine-Phosphatase: BI, biosynthesis
***Protein-Tyrosine-Phosphatase: DF, deficiency**
Protein-Tyrosine-Phosphatase: GE, genetics
Protein-Tyrosine-Phosphatase: PH, physiology
Proto-Oncogene Protein c-kit: ME, metabolism
 Receptors, Erythropoietin: ME, metabolism
 Receptors, Interleukin-3: ME, metabolism
 RNA, Messenger: BI, biosynthesis
Signal Transduction
 Transcription, Genetic
 RN 11096-26-7 (Erythropoietin); 14875-96-8 (Heme)
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 3.1.3.- (SH
 protein-tyrosine phosphatase); EC 3.1.3.48 (Protein-Tyrosine-Phosphatase);
 0 (Receptors, Erythropoietin); 0 (Receptors, Interleukin-3); 0 (RNA,
 Messenger)

 L113 ANSWER 11 OF 47 MEDLINE
 AN 1999287893 MEDLINE
 DN 99287893
 TI STAT protein recruitment and activation in c-Kit deletion
 mutants.
 AU Brizzi M F; Dentelli P; Rosso A; Yarden Y; Pegoraro L
 CS Department of Internal Medicine, University of Turin, Turin 10126, Italy.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 Jun 11) 274 (24) 16965-72.
 Journal code: HIV. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199909
 AB **Stem cell factor (SCF)** and its tyrosine
 kinase receptor, c-Kit, play a crucial role in regulating
 migration and proliferation of melanoblasts, germ cells, and hemopoietic
 cell progenitors by activating a number of intracellular signaling
 molecules. Here we report that SCF stimulation of myeloid cells or
 fibroblasts ectopically expressing c-Kit induces physical
 association with and tyrosine phosphorylation of three signal transducers
 and activators of transcription (STATs) as follows: STAT1alpha, STAT5A,
 and STAT5B. Other STAT proteins are not recruited upon SCF stimulation.
 Recruitment of STATs leads to their **dimerization**, nuclear
 translocation, and binding to specific promoter-responsive elements.
 Whereas STAT1alpha, possibly in the form of **homodimers**, binds to
 the sis-inducible DNA element, STAT5 proteins, either as STAT5A/STAT5B or
 STAT5/STAT1alpha **heterodimers**, bind to the prolactin-inducible
 element of the beta-casein promoter. The tyrosine kinase activity of
 Kit appears essential for STAT activation since a kinase-defective
 mutant lacking a kinase insert domain was inactive in STAT signaling.
 However, another mutant that lacked the carboxyl-terminal region retained
 STAT1alpha activation and nuclear translocation but was unable to fully
 activate STAT5 proteins, although it mediated their transient
 phosphorylation. These results indicate that different intracellular
 domains of c-Kit are involved in activation of the various STAT
 proteins.
 CT Check Tags: Support, Non-U.S. Gov't
 Binding Sites
 Biological Transport
 Bone Marrow Cells: CY, cytology
 Bone Marrow Cells: ME, metabolism
 Cell Compartmentation
 Cell Nucleus: ME, metabolism
Dimerization
 *DNA-Binding Proteins: ME, metabolism
 *Mutation
 Phosphorylation

Protein Binding

*Proto-Oncogene Protein c-kit: GE, genetics

Response Elements

Sequence Deletion

Signal Transduction

*Stem Cell Factor: PD, pharmacology

*Trans-Activators: ME, metabolism

*Transcription Factors: ME, metabolism

Tyrosine: ME, metabolism

RN 55520-40-6 (Tyrosine)

CN EC 2.7.11.- (Proto-Oncogene Protein

c-kit); 0 (gamma interferon activation factor); 0

(mammary gland-specific nuclear factor); 0 (DNA-Binding Proteins); 0

(Stem Cell Factor); 0 (Trans-Activators); 0 (Transcription Factors)

L113 ANSWER 12 OF 47 MEDLINE

AN 1999252441 MEDLINE

DN 99252441

TI **Stem cell factor**-induced airway
hyperreactivity in allergic and normal mice.

AU Campbell E; Hogaboam C; Lincoln P; Lukacs N W

CS University of Michigan Medical School, Department of Pathology, Ann Arbor,
Michigan 48109-0602, USA.

NC AI36302 (NIAID)

HL59178 (NHLBI)

SO AMERICAN JOURNAL OF PATHOLOGY, (1999 Apr) 154 (4) 1259-65.

Journal code: 3RS. ISSN: 0002-9440.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199908

EW 19990802

AB The induction of airway hyperreactivity during allergic responses involves multiple ill-defined mechanisms. Recently a role for **stem cell factor** (SCF) in the development of allergic eosinophilic airway inflammation has been identified. In the present study we demonstrate that SCF has a role in both the inflammatory response and airway hyperreactivity. Neutralization of SCF or examination of SCF-mutant mice, which were deficient in SCF and pulmonary mast cells, demonstrated significant alterations in the allergen-induced airway hyperreactive responses. The reduced hyperreactivity response was accompanied by a significant reduction in eosinophil accumulation. To examine the direct role of SCF on airway hyperreactivity, we administered SCF into the airways of normal mice via intratracheal injections and demonstrated a dose dependent increase in airway hyperreactivity at 4 hours that was maintained at 24 hours after administration. Instillation of SCF into SCF-deficient (mast cell deficient) mice demonstrated significantly lower increases in airway hyperreactivity compared with the littermate controls with normal mast cell numbers. These studies demonstrate that locally expressed SCF can induce changes in airway physiology via mast cell activation, verifying the role of SCF in allergic airway inflammation and hyperreactivity.

CT Check Tags: Animal; Female; Support, U.S. Gov't, P.H.S.

Airway Resistance: DE, drug effects

Antigens, Helminth: PD, pharmacology

Bronchial Provocation Tests

Dose-Response Relationship, Drug

Eosinophils: DE, drug effects

IgG: PD, pharmacology

Mast Cells: DE, drug effects

Mast Cells: IM, immunology

Methacholine Chloride: PD, pharmacology

Mice

Mice, Inbred CBA

Mice, Mutant Strains

***Respiratory Hypersensitivity: IM, immunology**
Stem Cell Factor: AI, antagonists & inhibitors
***Stem Cell Factor: IM, immunology**
***Stem Cell Factor: PD, pharmacology**
 Time Factors
 Trachea: DE, drug effects

***Trachea: IM, immunology**
 RN 62-51-1 (Methacholine Chloride)
 CN 0 (Antigens, Helminth); 0 (IgG); 0 (Stem Cell Factor)

L113 ANSWER 13 OF 47 MEDLINE

AN 199208021 MEDLINE

DN 99208021

TI Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development.

AU Kos L; Aronzon A; Takayama H; Maina F; Ponzetto C; Merlino G; Pavan W
 CS Laboratory for Genetic Disease Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-4472, USA.

SO PIGMENT CELL RESEARCH, (1999 Feb) 12 (1) 13-21.
 Journal code: PIG. ISSN: 0893-5785.

CY Denmark

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199908

AB The mechanisms governing development of neural crest-derived melanocytes, and how alterations in these pathways lead to hypopigmentation disorders, are not completely understood. Hepatocyte growth factor/scatter factor (HGF/SF) signaling through the tyrosine-kinase receptor, MET, is capable of promoting the proliferation, increasing the motility, and maintaining high tyrosinase activity and melanin synthesis of melanocytes in vitro. In addition, transgenic mice that ubiquitously overexpress HGF/SF demonstrate hyperpigmentation in the skin and leptomenigenes and develop melanomas. To investigate whether HGF/ SF-MET signaling is involved in the development of neural crest-derived melanocytes, transgenic embryos, ubiquitously overexpressing HGF/SF, were analyzed. In HGF/SF transgenic embryos, the distribution of melanoblasts along the characteristic migratory pathway was not affected. However, additional ectopically localized melanoblasts were also observed in the dorsal root ganglia and neural tube, as early as 11.5 days post coitus (p.c.). We utilized an in vitro neural crest culture assay to further explore the role of HGF/SF-MET signaling in neural crest development. HGF/SF added to neural crest cultures increased melanoblast number, permitted differentiation into pigmented melanocytes, promoted melanoblast survival, and could replace mast-cell growth factor/Steel factor (MGF) in explant cultures. To examine whether HGF/SF-MET signaling is required for the proper development of melanocytes, embryos with a targeted Met null mutation (Met-/-) were analysed. In Met-/- embryos, melanoblast number and location were not overtly affected up to 14 days p.c. These results demonstrate that HGF/SF-MET signaling influences, but is not required for, the initial development of neural crest-derived melanocytes in vivo and in vitro.

CT Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Cell Differentiation: DE, drug effects

Cell Division

Cells, Cultured

Embryo: DE, drug effects

Gestational Age

Hepatocyte Growth Factor: GE, genetics

***Hepatocyte Growth Factor: ME, metabolism**

Hepatocyte Growth Factor: PD, pharmacology

Melanocytes: DE, drug effects

***Melanocytes: PH, physiology**

Mice

Mice, Transgenic

***Neural Crest: CY, cytology**

*Neural Crest: EM, embryology
 Neural Crest: ME, metabolism
 *Proto-Oncogene Protein c-met: ME, metabolism
 *Signal Transduction: PH, physiology
 Stem Cell Factor: ME, metabolism
 Stem Cell Factor: PD, pharmacology
 RN 67256-21-7 (Hepatocyte Growth Factor)
 CN EC 2.7.11.- (Proto-Oncogene Protein c-met); 0 (Stem Cell Factor)

L113 ANSWER 14 OF 47 MEDLINE

AN 1999027821 MEDLINE

DN 99027821

TI [Oocyte apoptosis: when, how, why?].
 L'apoptose ovocytaire: quand, comment, pourquoi?.

AU Driancourt M A; Fair T; Reynaud K

CS INRA-URA CNRS 1291, Monnaie, France.

SO CONTRACEPTION, FERTILITE, SEXUALITE, (1998 Jul-Aug) 26 (7-8) 522-7.
 Journal code: BUD. ISSN: 1165-1083.

CY France

DT Journal; Article; (JOURNAL ARTICLE)

LA French

EM 199901

EW 19990104

AB The store of primordial follicles used for folliculogenesis is formed during oogenesis. Its size is the consequence of three processes: oogonia multiplication, time of meiosis initiation and extent of loss of germ cells (atretic oogonia, oocytes at the pachytene stage and newly formed primordial follicles). Apoptosis is causing this loss but its mechanisms are poorly documented. Both death signals (TNF alpha, Fas ligand) and survival signals (LIF, kit ligand) are present in the embryonic gonad. The apoptotic cascade then involves bcl2, bax and caspases since knock out of these genes alters the store of primordial follicles. Apoptosis also exists within primordial follicles in adult ovaries and involves oocyte death. Its control has not been extensively studied.

CT Check Tags: Female; Human
 Adult

Antigens, CD95: PH, physiology

*Apoptosis: PH, physiology

English Abstract

Mitosis

*Oocytes: PH, physiology

*Oogenesis: PH, physiology

Ovarian Follicle: PH, physiology

Signal Transduction

Stem Cell Factor: PH, physiology

Transcription Factors: PH, physiology

Tumor Necrosis Factor: PH, physiology

CN 0 (Antigens, CD95); 0 (Stem Cell Factor); 0 (Transcription Factors); 0 (Tumor Necrosis Factor)

L113 ANSWER 15 OF 47 MEDLINE

AN 1999025939 MEDLINE

DN 99025939

TI Growth and differentiation of human **stem cell factor**/erythropoietin-dependent erythroid progenitor cells in vitro.

AU Panzenbock B; Bartunek P; Mapara M Y; Zenke M

CS Max-Delbrück-Centre for Molecular Medicine, MDC, Berlin, Germany; and the Humboldt University Berlin, Virchow Klinikum, Robert-Rossle-Klinik, Berlin, Germany.

SO BLOOD, (1998 Nov 15) 92 (10) 3658-68.
 Journal code: A8G. ISSN: 0006-4971.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199902
EW 19990204
AB **Stem cell factor** (SCF) and erythropoietin (Epo) effectively support erythroid cell development in vivo and in vitro. We have studied here an SCF/Epo-dependent erythroid progenitor cell from cord blood that can be efficiently amplified in liquid culture to large cell numbers in the presence of SCF, Epo, insulin-like growth factor-1 (IGF-1), dexamethasone, and estrogen. Additionally, by changing the culture conditions and by administration of Epo plus insulin, such progenitor cells effectively undergo terminal differentiation in culture and thereby faithfully recapitulate erythroid cell differentiation in vitro. This SCF/Epo-dependent erythroid progenitor is also present in CD34(+) peripheral blood stem cells and human bone marrow and can be isolated, amplified, and differentiated in vitro under the same conditions. Thus, highly homogenous populations of SCF/Epo-dependent erythroid progenitors can be obtained in large cell numbers that are most suitable for further biochemical and molecular studies. We demonstrate that such cells express the recently identified adapter protein p62(dok) that is involved in signaling downstream of the c-kit/SCF receptor. Additionally, cells express the cyclin-dependent kinase (CDK) inhibitors p21(cip1) and p27(kip1) that are highly induced when cells differentiate. Thus, the in vitro system described allows the study of molecules and signaling pathways involved in proliferation or differentiation of human erythroid cells.

CT Check Tags: Comparative Study; Human
Blood Cells: CY, cytology
Blood Cells: DE, drug effects
Bone Marrow Cells: CY, cytology
Bone Marrow Cells: DE, drug effects
Cell Differentiation: DE, drug effects
Cell Division: DE, drug effects
Cells, Cultured
Cyclins: BI, biosynthesis
Cyclins: GE, genetics
Dexamethasone: PD, pharmacology
Enzyme Induction
*Erythroid Progenitor Cells: CY, cytology
Erythroid Progenitor Cells: DE, drug effects
*Erythropoiesis: DE, drug effects
Erythropoietin: PD, pharmacology
Estrogens: PD, pharmacology
Fetal Blood: CY, cytology
Insulin: PD, pharmacology
Insulin-Like Growth Factor I: PD, pharmacology
Microtubule-Associated Proteins: BI, biosynthesis
Microtubule-Associated Proteins: GE, genetics
Organ Specificity
Phosphoproteins: BI, biosynthesis
Phosphoproteins: GE, genetics
Signal Transduction
Stem Cell Factor: PD, pharmacology

RN 11061-68-0 (Insulin); 11096-26-7 (Erythropoietin); 147604-94-2 (KIP1 protein); 50-02-2 (Dexamethasone); 67763-96-6 (Insulin-Like Growth Factor I)

CN 0 (p62(dok) protein); 0 (Cip1 protein); 0 (Cyclins); 0 (Estrogens); 0 (Microtubule-Associated Proteins); 0 (Phosphoproteins); 0 (**Stem Cell Factor**)

L113 ANSWER 16 OF 47 MEDLINE
AN 1999011376 MEDLINE
DN 99011376
TI Signaling events during male germ cell differentiation: bases and perspectives.
AU Berruti G
CS Dipartimento di Biologia, Universit'a di Milano, via Celoria 26, 20133 Milano, Italy.

SO FRONTIERS IN BIOSCIENCE, (1998 Nov 1) 3 D1097-108. Ref: 117
 Journal code: CUE. ISSN: 1093-4715.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199901

AB In all species, reproductive function depends on the ability of the individual to produce functional differentiated gametes. Spermatogenesis is a cyclic process in which diploid spermatogonia differentiate into mature haploid spermatozoa. Thus from a genetic point of view, spermatogenesis can be divided into two phases, namely the diploid and haploid phase. Indeed, this complex differentiation process is still more intriguing since primary spermatocytes, if genetically diploid, are functionally tetraploid, while elongating spermatids, the germ cells undergoing the most dramatic morphological changes, if genetically haploid, become functionally anucleate due to ongoing condensation of chromatin resulting in an inactive nuclear DNA. This multi-step differentiative pathway is dependent on a specific environment provided by the anatomical and cellular relationships that take place in the testis and more specifically within the seminiferous tubules. Already, early anatomists (mind comes to Enrico Sertoli and Gustaf Retzius) were fascinated by the mixed cellular composition of the testis correctly deciphered as a whole of interacting and interdependent cell types despite the fact these belong to two well-established and different cell lineages, i.e, the somatic and germinal line. Since their time (the XIX century) up to-day a conspicuous bulk of experimental work and a relative massive bibliographic documentation have been provided. From this it stands out : a) a sophisticated role played by the cyclic hormonal control elicited by the hypothalamic-pituitary axis; b) the structural membrane specializations of Sertoli-germ cell communications; c) the existence and action of a paracrine and autocrine testicular regulative secretion; d) a regulation of germ cell gene expression, highly specialized both at transcriptional, posttranscriptional, and translational level; e) an active participation of the haploid genome in the final steps of cell differentiation. Each of these points has been the matter of several more and less recent reviews to which the present author hands back in the course of this note. However all these points, although topics of separate and extensive treatises, are conceptually jointed by a 'leit-motiv', that is, the intracellular transduction of an exogenous signal evoking a specific stimulatory/inhibitory, proliferative/differentiative event. The spirit with which the present author interpreted this minireview was to recall some points to which to draw attention having as a scenario the complex process of male germ cell differentiation in mammals.

CT Check Tags: Animal; Human; Male; Support, Non-U.S. Gov't
 *Cell Differentiation
 DNA-Binding Proteins: PH, physiology
 Estrogens: PH, physiology
 Heat-Shock Proteins 70: PH, physiology
 Models, Biological
 Progesterone: PH, physiology
 Proto-Oncogene Protein c-kit: PH, physiology
 Receptors, Estrogen: PH, physiology
 Receptors, Progesterone: PH, physiology
 *Signal Transduction
 *Spermatozoa: PH, physiology
 Stem Cell Factor: PH, physiology
 Testis: PH, physiology

RN 135844-64-3 (CREM protein); 57-83-0 (Progesterone)

CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (heat shock protein 70.2); 0 (DNA-Binding Proteins); 0 (Estrogens); 0 (Heat-Shock Proteins 70); 0 (Receptors, Estrogen); 0 (Receptors, Progesterone); 0 (Stem Cell Factor)

L113 ANSWER 17 OF 47 MEDLINE

AN 1999002668 MEDLINE

DN 99002668

TI Lck associates with and is activated by Kit in a small cell lung cancer cell line: **inhibition** of SCF-mediated growth by the Src family kinase **inhibitor** PP1.

AU Krystal G W; DeBerry C S; Linnekin D; Litz J

CS Department of Medicine, Medical College of Virginia Commonwealth University, McGuire Veterans Affairs Medical Center, Richmond 23249, USA.. GKRYSTAL@GEMS.VCU.edu

SO CANCER RESEARCH, (1998 Oct 15) 58 (20) 4660-6.

Journal code: CNF. ISSN: 0008-5472.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199901

AB At least 70% of small cell lung cancers (SCLCs) express the Kit receptor tyrosine kinase and its ligand, **stem cell factor** (SCF). In an effort to define the signal transduction pathways activated by Kit in SCLC, we focused on Src family kinases and, in particular, Lck, a Src-related tyrosine kinase that is expressed in hemopoietic cells and certain tumors, including SCLC. SCF treatment of the H526 cell line induced a physical association between Kit and Lck that, in vitro, was dependent on phosphorylation of the juxtamembrane domain of Kit. Stimulation of Kit with recombinant SCF resulted in a rapid 3-6-fold increase in the specific activity of Lck, which was similar in magnitude to the activation of Lck resulting from the cross-linking of the T-cell receptor complex of Jurkat cells. Lck activity peaked by 5 min after SCF addition, and the elevated activity persisted for at least 30 min in the presence of SCF, with kinetics similar to the activation of mitogen-activated protein kinase. PP1, an **inhibitor** of Src family kinases with selectivity for Lck, completely **inhibited** SCF-mediated growth but had little effect on insulin-like growth factor-I-mediated growth. PP1 **antagonized** both SCF-mediated proliferation and **inhibition** of apoptosis. PP1 had no effect on Kit kinase activity but was shown to **block** total Lck activity by at least 90% by immune complex kinase assay. Low levels of Src, Hck, and Yes were also expressed in the H526 cell line; only Yes showed a consistent increase in specific activity, which was also **inhibited** by PP1 following SCF treatment. These data demonstrate that, in the H526 SCLC cell line, Lck and, possibly, Yes are downstream of Kit in a signal transduction pathway; the **inhibition** by PP1 of SCF-mediated proliferation and **inhibition** of apoptosis suggests that Src family kinases are intermediates in the signaling pathways that regulate these processes.

CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S.

*src-Family Kinases: AI, antagonists & inhibitors

*Carcinoma, Small Cell: DT, drug therapy

Carcinoma, Small Cell: ME, metabolism

*Enzyme Inhibitors: PD, pharmacology

Jurkat Cells

*Lung Neoplasms: DT, drug therapy

Lung Neoplasms: ME, metabolism

*Lymphocyte Specific Protein Tyrosine Kinase p56(lck): PH, physiology

*Proto-Oncogene Protein c-kit: PH, physiology

Pyrazoles: PD, pharmacology

Pyrimidines: PD, pharmacology

Signal Transduction

*Stem Cell Factor: AI, antagonists & inhibitors

Stem Cell Factor: PD, pharmacology

CN EC 2.7.11.- (src-Family Kinases); EC 2.7.11.- (Lymphocyte Specific Protein Tyrosine Kinase p56(lck)); EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Enzyme Inhibitors); 0 (Pyrazoles); 0 (Pyrimidines); 0 (Stem Cell Factor); 0 (4-amino-5-(4-methylphenyl)-7-(tert-

butyl)pyrazolo(3,4-d)pyrimidine)

L113 ANSWER 18 OF 47 MEDLINE

AN 1998430685 MEDLINE

DN 98430685

TI **Stem cell factor** augments Fc epsilon

RI-mediated TNF-alpha production and stimulates MAP kinases via a different pathway in MC/9 mast cells.

AU Ishizuka T; Kawasome H; Terada N; Takeda K; Gerwins P; Keller G M; Johnson G L; Gelfand E W

CS Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.

NC AI HL-36577 (NIAID)

AI 4224B (NIAID)

DK-37871 (NIDDK)

SO JOURNAL OF IMMUNOLOGY, (1998 Oct 1) 161 (7) 3624-30.

Journal code: IFB. ISSN: 0022-1767.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199812

AB Mast cells express the receptor tyrosine kinase **kit/stem**

cell factor receptor (SCFR) which is encoded by the proto-oncogene c-kit. Ligation of SCFR induces its **dimerization** and activation of its intrinsic tyrosine kinase activity leading to activation of Raf-1, phospholipases, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinases. However, little is known about the downstream signals initiated by SCFR ligation except for activation of extracellular signal-regulated kinases. The murine mast cell line, MC/9, synthesizes and secretes TNF-alpha following the aggregation of high affinity Fc receptors for IgE (Fc epsilonRI). Ligation of SCFR or Fc epsilonRI on MC/9 cells resulted in the activation of all three MAP kinase family members, extracellular signal-regulated kinases, c-Jun amino-terminal kinase (JNK), and p38.

Stem cell factor (SCF)-induced activation of JNK and p38 was insensitive to wortmannin, cyclosporin A, and FK506 whereas activation of these kinases through Fc epsilonRI was sensitive to these drugs. Coligation of SCFR augmented Fc epsilonRI-mediated activation of MAP kinases, especially JNK activation, and SCF augmented Fc epsilonRI-mediated TNF-alpha production in MC/9 cells, although SCF alone did not induce TNF-alpha production. This augmentation by SCF was regulated at the level of transcription, at least in part, since the promoter activity of TNF-alpha was enhanced following addition of SCF. These results demonstrate that SCF can augment Fc epsilonRI-mediated JNK activation and cytokine gene transcription but via pathways that are regulated differently than the ones activated through Fc epsilonRI.

CT Check Tags: Animal; Support, U.S. Gov't, P.H.S.

*Adjuvants, Immunologic: PH, physiology

Amino Acid Sequence

Androstadienes: PD, pharmacology

Antigens: PD, pharmacology

Ca(2+)-Calmodulin Dependent Protein Kinase: DE, drug effects

***Ca(2+)-Calmodulin Dependent Protein Kinase: ME, metabolism**

Cell Line

Cyclosporine: PD, pharmacology

Enzyme Activation: DE, drug effects

Enzyme Activation: IM, immunology

Gene Expression Regulation: IM, immunology

*Mast Cells: EN, enzymology

Mast Cells: IM, immunology

Mast Cells: ME, metabolism

Mice

Molecular Sequence Data

Ovalbumin: IM, immunology

Ovalbumin: PD, pharmacology

Polyenes: PD, pharmacology
 Promoter Regions (Genetics): IM, immunology
Protein-Serine-Threonine Kinases: AI, antagonists & inhibitors
Protein-Serine-Threonine Kinases: ME, metabolism
Proto-Oncogene Protein c-kit: ME, metabolism
 Receptors, IgE: DE, drug effects
 Receptors, IgE: ME, metabolism
 *Receptors, IgE: PH, physiology
Signal Transduction: IM, immunology
Stem Cell Factor: DE, drug effects
Stem Cell Factor: ME, metabolism
 ***Stem Cell Factor: PH, physiology**
 Tacrolimus: PD, pharmacology
 *Tumor Necrosis Factor: BI, biosynthesis
 Tumor Necrosis Factor: GE, genetics
 RN 109581-93-3 (Tacrolimus); 19545-26-7 (wortmannin); 53123-88-9 (Sirolimus);
 59865-13-3 (Cyclosporine); 9006-59-1 (Ovalbumin)
 CN EC 2.7.10 (Protein-Serine-Threonine Kinases); EC 2.7.10.- (c-Jun
 amino-terminal kinase); EC 2.7.10.- (mitogen-activated protein kinase
 p38); EC 2.7.10.- (p42 MAP Kinase); EC 2.7.10.- (AKT1 protein kinase); EC
 2.7.10.- (Ca(2+)-Calmodulin Dependent Protein Kinase); EC 2.7.11.- (
Proto-Oncogene Protein c-kit
); 0 (Adjuvants, Immunologic); 0 (Androstadienes); 0 (Antigens); 0
 (Polyenes); 0 (Receptors, IgE); 0 (**Stem Cell Factor**); 0 (Tumor
 Necrosis Factor)

L113 ANSWER 19 OF 47 MEDLINE
 AN 1998413782 MEDLINE
 DN 98413782
 TI Morphological alterations in rat peritoneal mast cells by **stem
 cell factor**.
 AU Kim H M; Shin H Y; Lee E H
 CS Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University,
 Iksan, Chonbuk, South Korea.
 SO IMMUNOLOGY, (1998 Jun) 94 (2) 242-6.
 Journal code: GH7. ISSN: 0019-2805.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199812
 EW 19981202
 AB **Stem cell factor** (SCF) stimulates mast cell
 adhesion and, because SCF is produced normally in tissues, it may be a
 major factor responsible for the adhesion of mast cells to connective
 tissue matrix. We found that the morphology of rat peritoneal mast cells
 (RPMC) altered after the addition of recombinant murine SCF (rmSCF) in
 vitro. The ability of rmSCF to enhance morphological alteration was dose
 dependent and completely abolished by anti-c-kit **ACK2** monoclonal
 antibody. Exposure of RPMC to transforming growth factor-beta 1,
 wortmannin, genistein, herbimycin A, staurosporine, indomethacin and
 cytochalasin D before the addition of rmSCF **antagonized**
 rmSCF-induced morphological alteration. However, nordihydroguaiaretic acid
 had no effect. Many RPMC appeared to respond also to nerve growth factor
 (NGF) but the total number of cells with altered morphology was much
 greater when the culture was stimulated by rmSCF than by NGF. We suggest
 that morphological alterations of mast cells by rmSCF is an important step
 for the participation in adhesion to tissue under resident physiological
 conditions.
 CT Check Tags: Animal; Support, Non-U.S. Gov't
 Cell Culture
 Dose-Response Relationship, Drug
 *Mast Cells: CY, cytology
 Nerve Growth Factors: PD, pharmacology
 *Peritoneal Cavity: CY, cytology
 Rats

Rats, Wistar
 Recombinant Proteins: PD, pharmacology
Stem Cell Factor: AI, antagonists & inhibitors
***Stem Cell Factor: PD, pharmacology**
 Transforming Growth Factor beta: PD, pharmacology
 CN 0 (Nerve Growth Factors); 0 (Recombinant Proteins); 0 (**Stem Cell Factor**); 0 (Transforming Growth Factor beta)

L113 ANSWER 20 OF 47 MEDLINE
 AN 1998324991 MEDLINE
 DN 98324991
 TI Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia.
 AU Price E R; Ding H F; Badalian T; Bhattacharya S; Takemoto C; Yao T P; Hemesath T J; Fisher D E
 CS Pediatric Hematology/Oncology, Dana Farber Cancer Research Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 Jul 17) 273 (29) 17983-6.
 Journal code: HIV. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199810
 AB During melanocyte development, the cytokine Steel factor activates its receptor c-Kit, initiating a signal transduction cascade, which is vital for lineage determination via unknown downstream nuclear targets. c-Kit has recently been found to trigger mitogen-activated protein kinase-mediated phosphorylation of Microphthalmia (Mi), a lineage-restricted transcription factor, which, like Steel factor and c-Kit, is essential for melanocyte development. This cascade results in increased Mi-dependent transcriptional reporter activity. Here we examine the mechanism by which Mi is activated by this pathway. Phosphorylation does not significantly alter Mi's nuclear localization, DNA binding, or **dimerization**. However, the transcriptional coactivator p300/CBP selectively associates with mitogen-activated protein kinase-phosphorylated Mi, even under conditions in which non-MAPK phospho-Mi is more abundant. Moreover, p300/CBP coactivates Mi transcriptional activity in a manner dependent upon this phosphorylation. Mi thus joins CREB as a transcription factor whose signal-responsive phosphorylation regulates coactivator recruitment, in this case modulating lineage development in melanocytes.
 CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Ca(2+)-Calmodulin Dependent Protein Kinase: ME, metabolism
Dimerization
 DNA-Binding Proteins: GE, genetics
***DNA-Binding Proteins: PH, physiology**
 Enzyme Activation
 Hamsters
***Melanocytes: PH, physiology**
 Mice
***Nuclear Proteins: PH, physiology**
 Phosphorylation
 Protein Binding
Proto-Oncogene Protein c-kit: PH, physiology
 Rabbits
***Signal Transduction**
Stem Cell Factor: PH, physiology
 Trans-Activation (Genetics)
***Trans-Activators: PH, physiology**
***Transcription Factors: PH, physiology**
 Tumor Cells, Cultured
 CN EC 2.7.10.- (Ca(2+)-Calmodulin Dependent Protein Kinase); EC 2.7.11.- (**Proto-Oncogene Protein c-kit**); 0 (CREB-binding protein); 0 (DNA-Binding Proteins); 0 (E1A-associated

p300 protein); 0 (Mi protein); 0 (Nuclear Proteins); 0 (Stem Cell Factor); 0 (Trans-Activators); 0 (Transcription Factors)

L113 ANSWER 21 OF 47 MEDLINE

AN 1998234426 MEDLINE

DN 98234426

TI Role of **dimerization** of the membrane-associated growth factor **kit** ligand in juxtacrine signaling: the S117H mutation affects **dimerization** and stability-phenotypes in hematopoiesis.

AU Tajima Y; Huang E J; Vosseller K; Ono M; Moore M A; Besmer P

CS Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

SO JOURNAL OF EXPERIMENTAL MEDICINE, (1998 May 4) 187 (9) 1451-61.
Journal code: I2V. ISSN: 0022-1007.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199808

EW 19980801

AB The **Kit** ligand (KL)/**Kit** receptor pair functions in hematopoiesis, gametogenesis, and melanogenesis. KL is encoded at the murine steel (Sl) locus and encodes a membrane growth factor which may be proteolytically processed to produce soluble KL. The membrane-associated form of KL is critical in mediating **Kit** function in vivo. Evidence for a role of cytoplasmic domain sequences of KL comes from the S117H mutation, a splice site mutation that replaces the cytoplasmic domain with extraneous amino acids. Using deletion mutants and the S117H allele, we have investigated the role of the cytoplasmic domain sequences of KL in biosynthetic processing and cell surface presentation. The normal KL protein products are processed for cell surface expression, where they form **dimers**. Both S117H and the cytoplasmic deletion mutants of KL were processed to the cell surface; however, the rate of transport and protein stability were affected by the mutations. Deletion of cytoplasmic domain sequences of KL did not affect **dimerization** of KL. In contrast, **dimerization** of the S117H protein was reduced substantially. In addition, we have characterized the hematopoietic cell compartment in S117H mutant mice. The S117H mutation has only minor effects on hematopoiesis. Tissue and peritoneal mast cell numbers were reduced in mutant mice as well as in myeloid progenitors. Interestingly, long-term bone marrow cultures from S117H mice did not sustain the long-term production of hematopoietic cells. In addition, homing of normal hematopoietic progenitors to the spleen of irradiated S117H/S117H recipient mice was diminished in transplantation experiments, providing evidence for a role of **Kit** in homing or lodging. These results demonstrate that the membrane forms of KL exist as **homodimers** on the cell surface and that **dimerization** may play an important role in KL/**Kit**-mediated juxtacrine signaling.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Amino Acid Sequence

Bone Marrow Cells: ME, metabolism

COS Cells

Dimerization

Flow Cytometry

Hematopoiesis: GE, genetics

*Hematopoiesis: PH, physiology

Mast Cells: ME, metabolism

Mice

Microscopy, Fluorescence

Molecular Sequence Data

Mutation: GE, genetics

RNA Splicing: GE, genetics

Sequence Deletion: GE, genetics

Signal Transduction: PH, physiology

*Stem Cell Factor: CH, chemistry

Stem Cell Factor: PH, physiology

Stem Cells: ME, metabolism

CN 0 (**Stem Cell Factor**)

L113 ANSWER 22 OF 47 MEDLINE

AN 1998152084 MEDLINE

DN 98152084

TI The c-kit receptor and its possible signaling transduction pathway in mouse spermatozoa.

AU Feng H; Sandlow J I; Sandra A

CS Department of Urology, University of Iowa, Iowa City 52242-1089, USA.

SO MOLECULAR REPRODUCTION AND DEVELOPMENT, (1998 Mar) 49 (3) 317-26.

Journal code: AN7. ISSN: 1040-452X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199806

AB The presence and role of the c-kit protein was investigated in the mature sperm of the mouse. The c-kit monoclonal antibody (mAb) **ACK2** reacted specifically with the acrosomal region and the principal piece of fixed noncapacitated sperm but did not react with the acrosome region in acrosome-reacted sperm. **ACK2** significantly inhibited the acrosome reaction; this inhibition was relieved by the calcium ionophore A23187. The kit ligand stem cell factor (SCF) significantly increased the percentage of sperm undergoing acrosome reaction. This increase was partially inhibited by the calcium channel inhibitor (verapamil), the PI3k inhibitor (wortmannin), and the PLC inhibitor (U-73122). **ACK2** predominantly recognized c-kit proteins of 33, 48, and 150 kDa by Western blotting of mouse sperm extracts. The 48- and 150-kDa protein bands were released into the media and tyrosine autophosphorylated at low basal levels during acrosome reaction. On stimulation with SCF, the level of c-kit phosphorylation increased significantly. These findings suggest that c-kit is present in mature sperm, and its binding to SCF may result in the activation of PLC gamma 1 and PI3K, leading to receptor autophosphorylation, and ultimately may play a role in capacitation and/or the acrosome reaction.

CT Check Tags: Animal; Male; Support, Non-U.S. Gov't

Antibodies, Monoclonal: PD, pharmacology

Blotting, Western

Enzyme Inhibitors: PD, pharmacology

Immunoenzyme Techniques

Isoenzymes: ME, metabolism

Mice

Phospholipase C: ME, metabolism

Phosphorylation

Protein Kinase C: ME, metabolism

***Proto-Oncogene Protein c-kit: ME, metabolism**

Rabbits

Rats

***Signal Transduction**

Spermatozoa: DE, drug effects

***Spermatozoa: ME, metabolism**

Stem Cell Factor: PD, pharmacology

Tyrosine: ME, metabolism

1-Phosphatidylinositol 3-Kinase: ME, metabolism

RN 55520-40-6 (Tyrosine)

CN EC 2.7.1.- (Protein Kinase C); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 3.1.4.- (phospholipase C gamma); EC 3.1.4.3 (Phospholipase C); 0 (Antibodies, Monoclonal); 0 (Enzyme Inhibitors); 0 (Isoenzymes); 0 (**Stem Cell Factor**)

L113 ANSWER 23 OF 47 MEDLINE

AN 1998070948 MEDLINE

DN 98070948
 TI Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo.
 AU Mackenzie M A; Jordan S A; Budd P S; Jackson I J
 CS MRC Human Genetics Unit, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom.
 SO DEVELOPMENTAL BIOLOGY, (1997 Dec 1) 192 (1) 99-107.
 Journal code: E7T. ISSN: 0012-1606.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199803
 AB The development of neural crest-derived melanocytes, as well as haematopoietic and germ cells, is affected by mutations of the Kit and Mgf genes, which lead to dominant spotting (W) or steel (Sl) phenotypes. Mgf codes for the ligand of the receptor tyrosine kinase encoded by the Kit locus. KitW-v, a point mutation exerting a dominant negative effect, causes a substantial reduction in tyrosine kinase activity of the Kit receptor and leads to a characteristic pigmentation phenotype, namely dilute coat colour and a white ventral and head spot with reduced pigmentation of the feet and tail in the heterozygous animal, as well as slight anaemia. Homozygous animals lack coat pigmentation and are severely anaemic and infertile. Dct is a marker for cells of the melanoblast lineage. In order to study these cells in detail we have generated transgenic mouse lines carrying the lacZ reporter under the control of the Dct promoter and have used the embryonic expression of the reporter to identify early melanoblasts before they begin to produce pigment. Our transgenic lines have simplified the study of melanoblasts in the mouse embryo, and by crossing our mice with KitW-v mutants we have been able to identify the midgestation stages at which melanoblasts rely critically on Mgf/Kit interactions. We conclude that the survival of immature melanoblasts depends crucially upon Kit signalling up until E11, and later in development Kit plays a vital role in melanoblast proliferation. Our data do not describe a dependence upon Kit for melanoblast migration or differentiation. Copyright 1997 Academic Press.
 CT Check Tags: Animal; Female; Male; Support, Non-U.S. Gov't
 Base Sequence
 Cell Differentiation: GE, genetics
 Cell Division: GE, genetics
 Cell Movement: GE, genetics
 Crosses, Genetic
 DNA Primers: GE, genetics
 Enzyme Activation
 Gene Expression Regulation, Developmental
 Genetic Markers
 Lac Operon
 *Melanocytes: CY, cytology
 *Melanocytes: EN, enzymology
 Mice
 Mice, Transgenic
 Phenotype
 Pigmentation Disorders: EM, embryology
 Pigmentation Disorders: GE, genetics
 Point Mutation
 Proto-Oncogene Protein c-kit: GE, genetics
 *Proto-Oncogene Protein c-kit: ME, metabolism
 Signal Transduction: GE, genetics
 Stem Cell Factor: GE, genetics
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (DNA Primers); 0 (Genetic Markers); 0 (Stem Cell Factor)
 L113 ANSWER 24 OF 47 MEDLINE
 AN 1998008115 MEDLINE
 DN 98008115
 TI Signal transduction in human hematopoietic cells by vascular endothelial

growth factor related protein, a novel ligand for the FLT4 receptor.

AU Wang J F; Ganju R K; Liu Z Y; Avraham H; Avraham S; Groopman J E
 CS Division of Experimental Medicine, Beth Israel Deaconess Medical Center,
 Harvard Medical School, Boston, MA 02115, USA.

NC HL 53745-02 (NHLBI)
 HL 43510-07 (NHLBI)
 HL 55187-01 (NHLBI)
 +

SO BLOOD, (1997 Nov 1) 90 (9) 3507-15.
 Journal code: A8G. ISSN: 0006-4971.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199801

AB We have recently identified a novel **ligand** of the vascular
 endothelial growth factor (VEGF) family termed VEGF-related protein (VRP),
 which specifically **binds** to the FLT4 receptor. To characterize
 the signaling events after VRP engagement of its cognate receptor in
 hematopoietic cells, a population of human erythroleukemia (HEL) cells,
 termed HEL-JW, expressing high levels of FLT4 receptor was isolated.
 Stimulation of HEL-JW cells with VRP alone and in combination with the
 c-kit **ligand/stem cell factor**
 increased cell growth. VRP induced tyrosine phosphorylation of various
 proteins, including the FLT4 receptor. Further characterization of these
 tyrosine phosphorylated molecules revealed that Shc, Grb2, and SOS form a
 complex with the activated FLT4 receptor. HEL-JW cells also expressed
 RAFTK, a recently identified member of the focal adhesion kinase family.
 RAFTK was phosphorylated and activated upon VRP treatment, and there was
 an enhanced association of this kinase with the adaptor protein Grb2.
 Furthermore, the c-Jun NH2-terminal kinase (JNK), involved in growth
 activation and shown to mediate RAFTK signaling in other cell types, was
 activated by VRP stimulation. We also observed that VRP treatment of
 HEL-JW cells resulted in the phosphorylation of the cytoskeletal protein
 paxillin. This treatment resulted in an increased association of paxillin
 with RAFTK, which was mediated by the C-terminal region of RAFTK. These
 studies indicate that VRP stimulation induced the formation of a signaling
 complex at its activated receptor as well as activation of RAFTK.
 VRP-mediated activation of RAFTK may facilitate signal transduction to the
 cytoskeleton and downstream to the JNK pathway in FLT4-expressing blood
 cells.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.
 *Carrier Proteins: PH, physiology
 Cells, Cultured
 *Hematopoietic Stem Cells: PH, physiology
 Ligands
 *Receptor Protein-Tyrosine Kinases: PH, physiology
 *Receptors, Cell Surface: PH, physiology
 *Signal Transduction

RN 144638-77-7 (FLT4 protein)

CN EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Carrier Proteins); 0
 (Ligands); 0 (Receptors, Cell Surface); 0 (VEGF-related protein)

L113 ANSWER 25 OF 47 MEDLINE

AN 97359263 MEDLINE

DN 97359263

TI A new strategy for treating small cell lung cancer.

AU Ueda R; Takashi T

CS Department of Internal Medicine II, Nagoya City University Medical School.

SO NIHON KYOBU SHIKKAN GAKKAI ZASSHI. JAPANESE JOURNAL OF THORACIC DISEASES,
 (1996 Dec) 34 Suppl 111-4. Ref: 7
 Journal code: KQD. ISSN: 0301-1542.

CY Japan

DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)

LA Japanese
EM 199711
AB Recent results from molecular biology have shown that lung cancer is characterized by multiple, sequentially appearing molecular changes that include genetic and epigenetic alterations. Among all types of lung cancer, small cell lung cancer (SCLC) is associated with the lowest rate of 5-year survival. In this symposium, we introduce our findings regarding the c-kit oncogenes in SCLC. We found that the c-kit gene is strongly expressed in SCLC. The c-kit gene was not expressed in normal bronchial epithelial cells, which indicates that this gene is aberrantly transcribed in SCLC. In addition, c-kit-positive cases of SCLC showed autophosphorylation in response to recombinant human **stem cell factor**. Furthermore, adding rh **stem cell factor** of SCLC cell lines induced a significant chemotactic response and moderate in vitro cell growth. These results strongly suggest that abnormal expression of the c-kit gene may be involved in the pathogenesis of SCLC by autocrine/paracrine stimulation via the c-kit/SCF **signal pathway**. To overcome drug resistance, we assessed the efficacy of a chimeric toxin targeted to c-kit receptors.

CT Check Tags: Human
 Carcinoma, Small Cell: GE, genetics
 ***Carcinoma, Small Cell: TH, therapy**
 English Abstract
 Gene Expression Regulation, Neoplastic
 ***Immunotoxins: TU, therapeutic use**
 Lung Neoplasms: GE, genetics
 ***Lung Neoplasms: TH, therapy**
 Proto-Oncogene Protein c-kit: GE, genetics
 Stem Cell Factor: ME, metabolism

CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Immunotoxins); 0 (**Stem Cell Factor**)

L113 ANSWER 26 OF 47 MEDLINE
AN 97334241 MEDLINE
DN 97334241
TI The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression.
AU Reichel M; Nelson B H; Greenberg P D; Rothman P B
CS Department of Dermatology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
NC AI33540-04 (NIAID)
AI36613 (NIAID)
CA18029 (NCI)
SO JOURNAL OF IMMUNOLOGY, (1997 Jun 15) 158 (12) 5860-7.
Journal code: IFB. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199709
AB The common gamma-chain (gamma(c)) is a functional component of the IL-4R, yet cells lacking gamma(c) are able to respond to IL-4. This has led to the suggestion that a surrogate gamma'-chain, which can interact with the IL-4R alpha chain to mediate signaling, is expressed on cells lacking gamma(c). An alternative possibility is that in the absence of gamma(c), the IL-4R alpha chain is able to transduce signals by **homodimerization**. To test this latter possibility, a chimeric receptor containing the extracellular domain of c-kit (the **stem cell factor** (SCF) receptor) and the cytoplasmic and transmembrane domains of the IL-4R alpha chain was generated. Treatment of cells expressing the chimeric receptor **kit** /IL-4R alpha with SCF induces activation of the IL-4R alpha-associated kinase JAK-1 and the transcription factor STAT6. However, tyrosine phosphorylation of JAK-3, which associates with gamma(c), is not induced

by SCF in these cells. SCF-mediated ligation of kit/IL-4R alpha is sufficient to elicit IL-4-specific gene expression, including up-regulation of CD23 and synthesis of germ-line epsilon transcripts. In the T cell line CTLL2, ligation of kit/IL-4R alpha induces cellular proliferation. Finally, in JAK-1-deficient HeLa cells, STAT6 activation by IL-4 is completely abolished. Together, these data demonstrate that the IL-4R alpha cytoplasmic domain is sufficient to activate JAK-1 and STAT6 and to induce expression of IL-4 target genes, thus identifying a mechanism by which IL-4 signaling can proceed in the absence of JAK-3 and gamma(c).

CT Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

*Antigens, CD: AN, analysis

Base Sequence

Cells, Cultured

Enzyme Activation

*Gene Expression

*Interleukin-4

Lymphocyte Transformation

Molecular Sequence Data

Phosphorylation

*Protein-Tyrosine Kinase: ME, metabolism

Proto-Oncogene Protein c-kit: AN, analysis

*Receptors, Interleukin: AN, analysis

*Signal Transduction

T-Lymphocytes: IM, immunology

*Trans-Activators: ME, metabolism

Tyrosine: ME, metabolism

RN 168115-60-4 (Stat6 protein); 55520-40-6 (Tyrosine)

CN EC 2.7.1.- (Janus kinase 1); EC 2.7.1.- (Janus kinase 3); EC 2.7.1.112

(Protein-Tyrosine Kinase); EC 2.7.11.- (**Proto-Oncogene**

Protein c-kit); 0 (Antigens, CD); 0

(Interleukin-4); 0 (Receptors, Interleukin); 0 (Receptors, Interleukin-4);

0 (Trans-Activators)

L113 ANSWER 27 OF 47 MEDLINE

AN 97329531 MEDLINE

DN 97329531

TI Cross-linking of integrins induces tyrosine phosphorylation of the proto-oncogene product Vav and the protein tyrosine kinase Syk in human factor-dependent myeloid cells.

AU Gotoh A; Takahira H; Geahlen R L; Broxmeyer H E

CS Department of Microbiology and Immunology, Indiana University, School of Medicine, Indianapolis 46202-5121, USA.

NC R01 HL56416 (NHLBI)

R01 HL54037 (NHLBI)

P01 HL53586 (NHLBI)

+

SO CELL GROWTH AND DIFFERENTIATION, (1997 Jun) 8 (6) 721-9.

Journal code: AYH. ISSN: 1044-9523.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199709

AB Attachment to extracellular matrix is important in the regulation of proliferation and differentiation of hematopoietic stem and progenitor cells. Post-ligand occupancy events of integrin receptors in myeloid cells are largely unknown. We examined early signaling events after stimulation of integrin receptors (outside-in signal) using a cross-linking system in a growth factor-dependent myeloid cell line, M07e, alpha 4, alpha 5, and beta 1 integrin cross-linking induced a similar pattern of transient tyrosine phosphorylation of cellular proteins. The approximate molecular weights of these phosphoproteins were M(r) 150,000, M(r) 120,000-125,000, M(r) 95,000, M(r) 70,000, M(r) 60,000, and M(r) 40,000-50,000. Vav, Syk, and Erk2 were identified as some of the tyrosine-phosphorylated proteins, and their weights were M(r) 95,000, M(r)

70,000, and M(r) 40,000-50,000, respectively. Erk2 and Vav were also tyrosine-phosphorylated by stimulation with Steel factor (SLF) and granulocyte macrophage colony-stimulating factor, whereas tyrosine phosphorylation of Syk was not induced by stimulation with these cytokines. The degree of tyrosine phosphorylation of Vav through integrin engagement was almost equal to that by SLF stimulation, whereas that of Erk2 was much weaker than with SLF stimulation. Upon integrin engagement, antibodies raised against Syk coprecipitated several tyrosine-phosphorylated proteins. In vitro **binding** assays demonstrated that, among these Syk-associated proteins, pp40, which differed from Erks, Crk, and Crkl, **binds** Syk through SH2 domains of Syk and is a prominent tyrosine-phosphorylated protein in integrin cross-linked cells. These results suggest that tyrosine phosphorylation of Vav and Erk2 in myeloid cells might be regulated by both integrins and cytokines in the bone marrow microenvironment, whereas Syk might be involved in a distinct pathway from the shared between integrins and cytokines in myeloid cells.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.

Blotting, Western

Ca(2+)-Calmodulin Dependent Protein Kinase: ME, metabolism

Cell Adhesion

Cell Line

Cytokines: ME, metabolism

***Enzyme Precursors: ME, metabolism**

Growth Substances: ME, metabolism

***Hematopoietic Stem Cells: ME, metabolism**

***Integrins: ME, metabolism**

Phosphorylation

***Protein-Tyrosine Kinase: ME, metabolism**

***Proto-Oncogene Proteins: ME, metabolism**

Receptors, Fibronectin: ME, metabolism

Recombinant Fusion Proteins

Signal Transduction

Stem Cell Factor: ME, metabolism

Tyrosine: ME, metabolism

RN 55520-40-6 (Tyrosine)

CN EC 2.7.1.- (myelin basic protein kinase); EC 2.7.1.- (p72syk); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.10.- (Ca(2+)-Calmodulin Dependent Protein Kinase); 0 (proto-oncogene protein vav); 0 (Cytokines); 0 (Enzyme Precursors); 0 (Growth Substances); 0 (Integrins); 0 (Proto-Oncogene Proteins); 0 (Receptors, Fibronectin); 0 (Recombinant Fusion Proteins); 0 (**Stem Cell Factor**)

L113 ANSWER 28 OF 47 MEDLINE

AN 97303716 MEDLINE

DN 97303716

TI Cytokines involved in B-cell differentiation and their sites of action.

AU Takatsu K

CS Department of Immunology, University of Tokyo, Japan.

SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1997 Jun) 215 (2) 121-33. Ref: 171

Journal code: PXZ. ISSN: 0037-9727.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LA English

FS Priority Journals; Cancer Journals

EM 199708

AB B cells originate from pluripotent hematopoietic stem cells and differentiate in the bone marrow into mature B cells. The differentiation of a stem cell into a mature B cell can be subdivided into five steps: early pro-B cells, late pro-B cell stage, pre-B cell stage, immature B cells, and mature B cells. Each differentiation step appears to be regulated by co-receptor and cytokines. The earliest B-cell progenitors are bound to the stromal cell surface by adhesive interactions through cell surface molecules to promote the **binding** of c-kit to

stem cell factor (SCF). At the late pro-B cell stage, interleukin-7 (IL-7) induces proliferation and differentiation of pro-B cells to pre-B cells. Surface Ig-expressing mature B cells leave bone marrow and circulate into peripheral lymphoid organs in which they can be activated to proliferate and to differentiate into antibody-secreting cells by encountering antigens and "helper" T (TH) cells. TH cells activate B cells by their products, cytokines such as IL-4, IL-5, and IL-6, and membrane-bound stimulatory molecules including **CD40 ligand**. Each cytokine has pleiotropic activity on B cells and other cell types, and acts through a specific receptor. Abnormal expression of a cytokine receptor and aberrant signal transduction causes functional abnormality of B cells.

CT Check Tags: Animal; Human
 Antigens, CD: PH, physiology
 Antigens, Differentiation: PH, physiology
 *B-Lymphocytes: CY, cytology
 Cell Differentiation
 Cell Division
 *Cytokines: PH, physiology
 Interleukin-4: PH, physiology
 Interleukin-5: PH, physiology
 Interleukin-6: PH, physiology
 Lymphocyte Transformation
Nucleosidases: PH, physiology
 Receptors, Antigen, B-Cell: PH, physiology
 Receptors, Interleukin: PH, physiology
Signal Transduction
 T-Lymphocytes, Helper-Inducer: PH, physiology

CN EC 3.2.2. (Nucleosidases); EC 3.2.2.- (T10 antigen); 0 (Antigens, CD); 0 (Antigens, Differentiation); 0 (Cytokines); 0 (Interleukin-4); 0 (Interleukin-5); 0 (Interleukin-6); 0 (Receptors, Antigen, B-Cell); 0 (Receptors, Interleukin); 0 (Receptors, Interleukin-6)

L113 ANSWER 29 OF 47 MEDLINE

AN 96290410 MEDLINE

DN 96290410

TI Interaction of **stem cell factor** and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen.

AU Broudy V C; Lin N L; Priestley G V; Nocka K; Wolf N S

CS Department of Medicine University of Washington, Seattle 98195, USA.

NC DK44194 (NIDDK)

AG07724 (NIA)

SO BLOOD, (1996 Jul 1) 88 (1) 75-81.

Journal code: A8G. ISSN: 0006-4971.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals

EM 199611

AB The phenotypes of mice that harbor a defect in the genes encoding either **stem cell factor (SCF)** or its receptor, c-kit, indicate that this ligand/receptor pair is necessary for maintenance of normal hematopoiesis in the adult. Our objective was to determine whether SCF, like erythropoietin, is necessary for acute erythroid expansion during recovery from hemolytic anemia. Monoclonal antibody **ACK2**, which recognizes the murine c-kit receptor, was used to selectively **block** the hematopoietic growth-promoting effects of SCF. Mice were treated with phenylhydrazine on day 0 and day 1 to induce hemolytic anemia and also received no antibody, control IgG, or **ACK2** on day 0. The mice were killed on day 3 and the hematocrit (Hct), reticulocyte count, and numbers of erythroid and myeloid hematopoietic progenitor cells (colony-forming unit-erythroid [CFU-E], burst-forming unit [BFU]-E, and CFU-granulocyte-macrophage [GM]) were quantitated in the femoral marrow and spleen using hematopoietic colony-forming assays. Induction of hemolytic anemia with phenylhydrazine resulted in a drop in the Hct from

approximately 50% to 30%, and an approximate 8- to 10-fold increase in the reticulocyte count. The numbers of CFU-E increased modestly in the femur, and approximately 25- to 50-fold in the spleen, in comparison with normal mice. BFU-E and CFU-GM values did not increase in the femur but expanded 6- to 10-fold in the spleen, in comparison with normal mice. This confirms that much of the erythroid expansion in response to hemolytic anemia occurs in the murine spleen. Neutralizing quantities of the **ACK2** antibody reduced femoral CFU-E, BFU-E, and CFU-GM content to less than half that found in phenylhydrazine-treated control mice and nearly totally ablated splenic hematopoiesis. These results suggest that c-kit receptor function may be required for optimal response to acute erythropoietic demand and that erythropoiesis in the splenic microenvironment is more dependent on SCF/c-kit receptor interaction than is erythropoiesis in the marrow microenvironment. Because expansion of late erythropoiesis in the spleen was preferentially **blocked**, we tested the hypothesis that homing of more primitive hematopoietic cells to the spleen was dependent on c-kit receptor function. Lethally irradiated mice were injected with marrow cells obtained from mice that had received phenylhydrazine plus control IgG or with marrow cells obtained from mice that had received phenylhydrazine plus **ACK2**. In parallel experiments, normal murine marrow cells were treated in vitro with control IgG or with **ACK2** and were injected into lethally irradiated mice. The fraction of BFU-E and CFU-GM retrieved from the marrow and spleen of the recipient mice 4 hours later was reduced by approximately 75% when progenitor cells had been exposed to **ACK2**, in comparison with control IgG. These data suggest that interaction of SCF with the c-kit receptor affects the homing behavior of hematopoietic progenitor cells in the adult animal.

CT Check Tags: Animal; Comparative Study; Female; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
 Anemia, Hemolytic: CI, chemically induced
 Anemia, Hemolytic: PA, pathology
 Antibodies, Monoclonal: PD, pharmacology
 Bone Marrow: PA, pathology
 Cell Movement: PH, physiology
 Colony-Forming Units Assay
 Erythropoiesis: PH, physiology
 Hematopoietic Stem Cells: ME, metabolism
 *Hematopoietic Stem Cells: PA, pathology
 IgG: PD, pharmacology
 Mice
 Mice, Inbred C57BL
 Mice, Inbred DBA
 Phenotype
 Phenylhydrazines: TO, toxicity
Proto-Oncogene Protein c-kit: DE, drug effects
***Proto-Oncogene Protein c-kit: PH, physiology**
 Radiation Chimera
 Rats
 *Spleen: PA, pathology
Stem Cell Factor: AI, antagonists & inhibitors
***Stem Cell Factor: PH, physiology**
 RN 100-63-0 (phenylhydrazine)
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); 0 (Antibodies, Monoclonal); 0 (IgG); 0 (Phenylhydrazines); 0 (Stem Cell Factor)

L113 ANSWER 30 OF 47 MEDLINE

AN 96202494 MEDLINE

DN 96202494

TI The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells.

AU Rusten L S; Dybedal I; Blomhoff H K; Blomhoff R; Smeland E B; Jacobsen S E
 CS Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo.

SO BLOOD, (1996 Mar 1) 87 (5) 1728-36.

Journal code: A8G. ISSN: 0006-4971.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
 EM 199609
 AB Previous studies have shown that retinoic acid (RA), similar to tumor necrosis factor-alpha (TNF-alpha), can act as a bifunctional regulator of the growth of bone marrow progenitors, in that it can stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF)- or interleukin-3 (IL-3)-induced GM colony formation, but potentially inhibit G-CSF-induced growth. The present study, using highly enriched human CD34+ as well as Lin- murine bone marrow progenitor cells, demonstrates a potent inhibitory effect of 9-cis-RA on burst-forming unit-erythroid (BFU-E) colony formation regardless of the cytokine stimulating growth. Specifically, 9-cis-RA potentially inhibited the growth of BFU-E response to erythropoietin (Epo) (100%), **stem cell factor** (SCF) + Epo (92%), IL-3 + Epo (97%), IL-4 + Epo (88%), and IL-9 + Epo (100%). Erythroid colony growth was also inhibited when CD34+ progenitors were seeded at one cell per well, suggesting a direct action of RA. Using synthetic **ligands** to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) that selectively **bind and activate** RAR-RXR or RXR-RXR **dimers**, respectively, we dissected the involvement of the two retinoid response pathways in the regulation of normal myeloid and erythroid progenitor cell growth. Transactivation studies showed that both the RAR (Ro 13-7410) and RXR (Ro 25-6603 and Ro 25-7386) **ligands** were highly selective at 100 nmol/L. At this concentration, Ro 13-7410 potentially inhibited G-CSF-stimulated myeloid as well as SCF + Epo-induced erythroid colony growth. At the same concentration, Ro 25-6603 and Ro 25-7386 had little or no effect on G-CSF-induced colony formation, whereas they inhibited 75% and 53%, respectively, of SCF + Epo-stimulated BFU-E colony growth. Thus, the RAR-RXR response pathway can signal growth inhibition of normal bone marrow myeloid and erythroid progenitor cells. In addition, we demonstrate a unique involvement of the RXR-RXR pathway in mediating growth inhibition of erythroid but not myeloid progenitor cells.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't
 Antigens, CD34
 Base Sequence
 Benzoates: PD, pharmacology
 Consensus Sequence
 Cyclohexanes: PD, pharmacology
 Depression, Chemical
 *Erythroid Progenitor Cells: CY, cytology
 Erythroid Progenitor Cells: DE, drug effects
 *Erythropoiesis: DE, drug effects
 Erythropoietin: PD, pharmacology
 Hematopoietic Cell Growth Factors: PD, pharmacology
 Interleukins: PD, pharmacology
 Mice
 Mice, Inbred BALB C
 Molecular Sequence Data
 Pentanoic Acids: PD, pharmacology
 Rats
 Receptors, Retinoic Acid: AG, agonists
 Receptors, Retinoic Acid: DE, drug effects
 *Receptors, Retinoic Acid: PH, physiology
 Recombinant Proteins: PD, pharmacology
 Retinoids: PD, pharmacology
 *Signal Transduction: PH, physiology
 Stem Cell Factor: PD, pharmacology
 Transcription Factors: DE, drug effects
 *Transcription Factors: PH, physiology
 Tretinoin: PD, pharmacology

RN 11096-26-7 (Erythropoietin); 302-79-4 (Tretinoin); 71441-28-6 (Ro 13-7410)
 CN 0 (retinoic acid receptor alpha); 0 (retinoid X receptor); 0 (Antigens, CD34); 0 (Benzoates); 0 (Cyclohexanes); 0 (Hematopoietic Cell Growth Factors); 0 (Interleukins); 0 (Pentanoic Acids); 0 (Receptors, Retinoic Acid); 0 (Recombinant Proteins); 0 (Retinoids); 0 (Ro 25-6603); 0

(Stem Cell Factor); 0 (Transcription Factors)

L113 ANSWER 31 OF 47 MEDLINE

AN 96195144 . MEDLINE

DN 96195144

TI Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes.

AU Imokawa G; Yada Y; Kimura M

CS Institute for Fundamental Research, Kao Corporation, Tochigi, Japan.

SO BIOCHEMICAL JOURNAL, (1996 Feb 15) 314 (Pt 1) 305-12.

Journal code: 9YO. ISSN: 0264-6021.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Cancer Journals; Priority Journals

EM 199610

AB To understand the signalling mechanisms involved in the dual stimulatory effects of endothelin-1 (ET-1) on DNA synthesis and melanization in cultured human melanocytes, we analysed the biological profile of ET-1 receptor and determined the effects of ET-1 on the protein kinase C, cyclic AMP system and mitogen-activated protein kinase (MAP kinase) in comparison with their relevant stimulants. The photoaffinity labelling of ET-1 receptors with Denny-Jaff reagents revealed an ET-1 receptor with a molecular mass of 51 kDa in human melanocytes. The ET(A) receptor subtype-sensitive antagonist BQ123 (50 nM) or pertussis toxin (100 ng/ml) significantly suppressed the ET-1-induced intracellular calcium mobilization, indicating the presence of pertussis toxin-sensitive G-protein-coupled ET(A) receptors. An assay of protein kinase C activity revealed that 10nM ET-1 translocated cytosolic protein kinase C to membrane-bound protein kinase C within 5 min of the start of incubation. In contrast, receptor-mediated melanocyte activation by ET-1 was accompanied by an elevated level of cyclic AMP (4-fold over control) after 10-60 min of incubation, whereas 60 min of incubation of human melanocytes with c-Kit or c-Met ligands such as **stem cell factor** (10 nM) or basic fibroblast growth factor (10 nM) did not elevate the cyclic AMP level. We have also demonstrated that a specific tyrosine kinase inhibitor, tyrphostin B-42 (10 microM), inhibited the ET-1-induced growth stimulation, suggesting the involvement of the tyrosine kinase pathway in growth stimulation. Consistently, an assay of MAP kinase revealed that ET-1 caused a 10-fold activation of MAP kinase after 5 min of incubation with human melanocytes in a similar way to tyrosine kinase ligands such as **stem cell factor** and hepatocyte growth factor. Further, the DNA synthesis stimulated by the c-Kit ligand **stem cell factor** at a concentration of 1 nM was synergistically enhanced by 5 nM ET-1. These results suggest that ET-induced dual cellular events in human melanocytes are closely associated with cross-talk between the protein kinase C and A and tyrosine kinase pathways.

CT Check Tags: Human

Amino Acid Sequence

Ca(2+)-Calmodulin Dependent Protein Kinase: ME, metabolism

Cholera Toxin: PD, pharmacology

Cyclic AMP: ME, metabolism

DNA: BI, biosynthesis

DNA: DE, drug effects

*Endothelins: PD, pharmacology

*Melanins: BI, biosynthesis

Melanocytes: CY, cytology

*Melanocytes: ME, metabolism

Molecular Sequence Data

Peptides, Cyclic: PD, pharmacology

Pertussis Toxins: PD, pharmacology

Phosphodiesterase Inhibitors: PD, pharmacology

Protein Kinase C: AI, antagonists & inhibitors

Protein Kinase C: ME, metabolism

Protein-Tyrosine Kinase: ME, metabolism

Receptors, Endothelin: AI, antagonists & inhibitors
 Receptors, Endothelin: CH, chemistry
 *Receptors, Endothelin: ME, metabolism

***Signal Transduction**

Stem Cell Factor: PD, pharmacology

Thiouracil: ME, metabolism

1-Methyl-3-isobutylxanthine: PD, pharmacology

RN 136553-81-6 (BQ 123); 141-90-2 (Thiouracil); 28822-58-4
 (1-Methyl-3-isobutylxanthine); 60-92-4 (Cyclic AMP); 70323-44-3 (Pertussis
 Toxins); 9007-49-2 (DNA); 9012-63-9 (Cholera Toxin)
 CN EC 2.7.1.- (Protein Kinase C); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC
 2.7.10.- (extracellular signal-regulated kinase 1); EC 2.7.10.- (p42 MAP
 Kinase); EC 2.7.10.- (Ca(2+)-Calmodulin Dependent Protein Kinase); 0
 (endothelin A receptor); 0 (Endothelins); 0 (Melanins); 0 (Peptides,
 Cyclic); 0 (Phosphodiesterase Inhibitors); 0 (Receptors, Endothelin);
 0 (**Stem Cell Factor**)

L113 ANSWER 32 OF 47 MEDLINE

AN 96019555 MEDLINE

DN 96019555

TI Biology of flt3 ligand and receptor.

AU Lyman S D

CS Immunex Corporation, Seattle, WA 98101, USA.

SO INTERNATIONAL JOURNAL OF HEMATOLOGY, (1995 Aug) 62 (2) 63-73. Ref: 42
 Journal code: A7F. ISSN: 0925-5710.

CY Ireland

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LA English

EM 199606

AB The flt3 ligand is a member of a small family of growth factors
 that stimulate the proliferation of hematopoietic cells; other members of
 this family include Steel factor (also known as mast cell growth factor,
stem cell factor, and kit ligand)
 and colony stimulating factor 1. These proteins function by
binding to and activating unique tyrosine kinase receptors.
 Expression of the flt3 receptor is primarily restricted among
 hematopoietic cells to the most primitive progenitor cells. The flt3
ligand is similar to Steel factor in that both proteins stimulate
 the proliferation of early progenitor or stem cells. Neither of these
 factors has much proliferative activity on its own, but each factor can
 synergize with a wide range of other colony stimulating factors and
 interleukins (ILs) to stimulate proliferation. One major difference
 between the two factors appears to be their effect on mast cells, which
 Steel factor stimulates but flt3 ligand does not. Although flt3
ligand and Steel factor each act on early hematopoietic cells,
 differences in their activities suggest that they are not redundant and
 both are required for normal hematopoiesis. There are a number of clinical
 settings in which the flt3 ligand may potentially prove quite
 useful.

CT Check Tags: Animal; Human

Amino Acid Sequence

Cell Line

Cloning, Molecular

*Hematopoietic Stem Cells: PH, physiology

Leukemia: GE, genetics

Leukemia: PA, pathology

Liver: CY, cytology

Liver: EM, embryology

*Membrane Proteins: PH, physiology

Membrane Proteins: TU, therapeutic use

Mice

Molecular Sequence Data

Multigene Family

Phosphorylation

Protein Conformation
 Protein Processing, Post-Translational
Proto-Oncogene Protein c-kit: PH, physiology
 *Proto-Oncogene Proteins: PH, physiology
 *Receptor Protein-Tyrosine Kinases: PH, physiology
 Receptor, Macrophage Colony-Stimulating Factor: PH, physiology
 Signal Transduction
 Stem Cell Factor: PH, physiology
 Tumor Cells, Cultured

CN EC 2.7.1.- (fetal liver kinase-2); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); EC 2.7.11.- (Receptor, Macrophage Colony-Stimulating Factor); 0 (flt3 ligand protein); 0 (Membrane Proteins); 0 (Proto-Oncogene Proteins); 0 (Stem Cell Factor)

L113 ANSWER 33 OF 47 MEDLINE
 AN 95294029 MEDLINE
 DN 95294029
 TI Identification of the major phosphorylation sites for protein kinase C in **kit/stem cell factor** receptor in vitro and in intact cells.
 AU Blume-Jensen P; Wernstedt C; Heldin C H; Ronnstrand L
 CS Ludwig Institute for Cancer Research, Uppsala Branch, Biomedical Center, Sweden.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Jun 9) 270 (23) 14192-200.
 Journal code: HIV. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199509
 AB The c-**kit**-encoded tyrosine kinase receptor for **stem cell factor** (**Kit/SCFR**) is crucial for the development of hematopoietic cells, melanoblasts, and germ cells. Ligand stimulation of **Kit/SCFR** leads to receptor **dimerization** and autophosphorylation on tyrosine residues. We recently showed, that protein kinase C (PKC) acts in an SCF-stimulated negative feedback loop, which controls **Kit/SCFR** tyrosine kinase activity and modulates the cellular responses to SCF (Blume-Jensen, P., Siegbahn, A., Stabel, S., Heldin, C.-H., and Ronnstrand, L. (1993) EMBO J. 12, 4199-4209). We present here the identification of the major phosphorylation sites for PKC in **Kit/SCFR**. Two serine residues in the kinase insert, Ser-741 and Ser-746, are PKC-dependent phosphorylation sites in vivo and account for all phosphorylation by PKC in vitro. Together they comprise more than 60% of the total SCF-stimulated receptor phosphorylation in living cells and 85-90% of its phosphorylation in resting cells. Two additional serine residues, Ser-821 close to the major tyrosine autophosphorylation site in the kinase domain and Ser-959 in the carboxyl terminus are SCF-stimulated PKC-dependent phosphorylation sites. However, they are not phosphorylated directly by PKC-alpha in vitro. Both specific receptor tyrosine autophosphorylation and specific receptor-associated phosphatidylinositide 3'-kinase activity was increased approximately 2-fold in response to SCF in PAE cells stably expressing **Kit/SCFR**(S741A/S746A). Furthermore, the kinase activity of **Kit/SCFR**(S741A/S746A) toward an exogenous substrate was increased, which was reflected as a decreased Km and an increased Vmax, in accordance with the negative regulatory role of PKC on **Kit/SCFR** signaling.

CT Check Tags: Support, Non-U.S. Gov't
 Base Sequence
 Hematopoietic Cell Growth Factors: PD, pharmacology
 Molecular Sequence Data
 Phosphorylation
Phosphotransferases (Alcohol Group Acceptor): ME, metabolism
 Polycyclic Hydrocarbons: PD, pharmacology
 *Protein Kinase C: PH, physiology
 *Proto-Oncogene Proteins: ME, metabolism

*Receptor Protein-Tyrosine Kinases: ME, metabolism
 *Receptors, Colony-Stimulating Factor: ME, metabolism
 Signal Transduction

Tetradecanoylphorbol Acetate: PD, pharmacology
 Transfection

RN 121263-19-2 (calphostin C); 16561-29-8 (Tetradecanoylphorbol Acetate)
 CN EC 2.7.1 (Phosphotransferases (Alcohol Group Acceptor)); EC 2.7.1.-
 (Protein Kinase C); EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC
 2.7.11.- (Proto-Oncogene Protein c
 -kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0
 (Hematopoietic Cell Growth Factors); 0 (Polycyclic Hydrocarbons); 0
 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor);
 0 (Stem Cell Factor)

L113 ANSWER 34 OF 47 MEDLINE

AN 95211033 MEDLINE

DN 95211033

TI The flt3 ligand: a hematopoietic stem cell
 factor whose activities are distinct from steel factor.

AU Lyman S D; Brasel K; Rousseau A M; Williams D E

CS Immunex Research and Development Corporation, Seattle, Washington.

SO STEM CELLS, (1994) 12 Suppl 1 99-107; discussion 108-10. Ref: 28

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199507

AB A number of growth factors have been described that affect the
 hematopoietic system. Among this group are Steel factor (also known as
 mast cell growth factor, stem cell factor
 and kit ligand), and the more recently described flt3
 ligand. These factors have been shown to function by
 binding to and activating the c-kit and flt3 tyrosine kinase
 receptors, respectively. Both of these factors stimulate the growth of
 mouse and human hematopoietic progenitor cells. These factors therefore
 differ from such later acting hematopoietic factors as colony-stimulating
 factor (CSF)-1, which regulates the growth, survival and differentiation
 of monocytic cells through the c-fms tyrosine kinase receptor. Like Steel
 factor, the flt3 ligand has little biological activity on its
 own, but synergizes well with a number of other colony stimulating factors
 and interleukins. One major difference between the two factors appears to
 be their effect on mast cells. Steel factor stimulates both the
 proliferation and activation of mast cells, while preliminary data with
 the flt3 ligand suggests that it has no effect on mast cells.
 Although the flt3 ligand and Steel factor each act on early
 hematopoietic cells, differences in their activities suggest that they are
 not redundant and are both required for normal hematopoiesis.

CT Check Tags: Animal; Female; Human; Male

Cloning, Molecular
 Gene Expression

*Hematopoiesis: PH, physiology

Hematopoietic Cell Growth Factors: CH, chemistry

Hematopoietic Cell Growth Factors: GE, genetics

*Hematopoietic Cell Growth Factors: PH, physiology

Hematopoietic Stem Cells: CY, cytology

Leukemia: PP, physiopathology

Mast Cells: CY, cytology

Membrane Proteins: CH, chemistry

Membrane Proteins: GE, genetics

*Membrane Proteins: PH, physiology

Molecular Structure

Proto-Oncogene Proteins: CH, chemistry

Proto-Oncogene Proteins: GE, genetics

Proto-Oncogene Proteins: PH, physiology
 Receptor Protein-Tyrosine Kinases: CH, chemistry
 Receptor Protein-Tyrosine Kinases: GE, genetics
 Receptor Protein-Tyrosine Kinases: PH, physiology
 Signal Transduction

CN EC 2.7.1.- (fetal liver kinase-2); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (flt3 ligand protein); 0 (Hematopoietic Cell Growth Factors); 0 (Membrane Proteins); 0 (Proto-Oncogene Proteins); 0 (Stem Cell Factor)

L113 ANSWER 35 OF 47 MEDLINE

AN 95151825 MEDLINE

DN 95151825

TI Steel factor and c-kit protooncogene: genetic lessons in signal transduction.

AU Lev S; Blechman J M; Givol D; Yarden Y

CS Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

SO CRITICAL REVIEWS IN ONCOGENESIS, (1994) 5 (2-3) 141-68. Ref: 166
 Journal code: ALY. ISSN: 0893-9675.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LA English

FS Priority Journals

EM 199505

AB Despite extensive research on the molecular mechanisms of signal transduction by growth factors and their oncogenic receptor tyrosine kinases, the physiological relevance of these pathways, especially in mammals, remains largely unknown. A unique exception is the Steel factor (SLF) and its c-kit-encoded receptor, because many natural germ line mutations of both the ligand and the receptor exist in mice. The protooncogene c-kit encodes a cell surface receptor that belongs to the immunoglobulin gene family and carries an intrinsic tyrosine kinase activity in its cytoplasmic portion. The precursor of the Kit ligand, SLF, is also a transmembrane protein that exists as a soluble factor as well as a cell surface protein. The interaction of Kit with SLF leads to receptor dimerization, kinase activation, and tyrosine phosphorylation of cytoplasmic proteins that contain Src homology 2 motifs. Various mutations in Kit and SLF result in a defective signaling pathway and underly the complex phenotypes of W and Sl mice, respectively. The early development of at least four cell lineages is affected. These are erythrocytes, melanocytes, germ cells, and mast cells. Correlation between the behavior of these lineages and specific mutations uncovered interesting physiological aspects of the mechanism of signal transduction by a polypeptide growth factor. These include the different degrees of severity of affected lineages, indications for distinct functions during early embryonic development and at late phases, the significance of synergy between a growth factor and lymphokines, the interaction between mutant and wild-type proteins in heterozygous animals, and the possibility that a surface-anchored ligand may act differently than a soluble factor. Predictably, the lessons learned with Kit and Sl mice will be widely relevant to other pairs of ligands and receptors that control the function of different cell lineages and physiological processes.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

*Hematopoietic Cell Growth Factors: GE, genetics
 Mice

*Mutation

*Proto-Oncogene Proteins: GE, genetics

*Receptor Protein-Tyrosine Kinases: GE, genetics

*Receptors, Colony-Stimulating Factor: GE, genetics

*Signal Transduction: GE, genetics

CN EC 2.7.11.- (Proto-Oncogene Protein

c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases);
 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0
 (Receptors, Colony-Stimulating Factor); 0 (**Stem Cell Factor**)

L113 ANSWER 36 OF 47 MEDLINE

AN 95112336 MEDLINE

DN 95112336

TI The fourth immunoglobulin domain of the **stem cell factor** receptor couples **ligand binding** to signal transduction.

AU Blechman J M; Lev S; Barg J; Eisenstein M; Vaks B; Vogel Z; Givol D; Yarden Y

CS Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

SO CELL, (1995 Jan 13) 80 (1) 103-13.
 Journal code: CQ4. ISSN: 0092-8674.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199504

AB Receptor **dimerization** is ubiquitous to the action of all receptor tyrosine kinases, and in the case of **dimeric ligands**, such as the **stem cell factor** (SCF), it was attributed to **ligand** bivalency. However, by using a **dimerization**-inhibitory monoclonal antibody to the SCF receptor, we confined a putative **dimerization** site to the nonstandard fourth immunoglobulin-like domain of the receptor. Deletion of this domain not only abolished **ligand**-induced **dimerization** and completely inhibited signal transduction, but also provided insights into the mechanism of the coupling of **ligand binding** to **dimer** formation. These results identify an intrinsic receptor **dimerization** site and suggest that similar sites may exist in other receptors.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

Antibodies, Monoclonal: IM, immunology

Base Sequence

Binding Sites

Cells, Cultured

Enzyme Activation

Epitope Mapping

*Hematopoietic Cell Growth Factors: ME, metabolism

Ligands

Mice

Models, Molecular

Molecular Sequence Data

Mutation

Proto-Oncogene Proteins: CH, chemistry

Proto-Oncogene Proteins: IM, immunology

*Proto-Oncogene Proteins: ME, metabolism

Receptor Protein-Tyrosine Kinases: CH, chemistry

Receptor Protein-Tyrosine Kinases: IM, immunology

***Receptor Protein-Tyrosine Kinases: ME, metabolism**

Receptors, Colony-Stimulating Factor: CH, chemistry

Receptors, Colony-Stimulating Factor: IM, immunology

*Receptors, Colony-Stimulating Factor: ME, metabolism

***Signal Transduction**

Solubility

CN EC 2.7.11.- (**Proto-Oncogene Protein**

c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases);

0 (Antibodies, Monoclonal); 0 (Hematopoietic Cell Growth Factors); 0

(Ligands); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating

Factor); 0 (**Stem Cell Factor**)

L113 ANSWER 37 OF 47 MEDLINE

AN 95081116 MEDLINE

DN 95081116
 TI Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase.
 AU Brizzi M F; Zini M G; Aronica M G; Blechman J M; Yarden Y; Pegoraro L
 CS Dipartimento di Scienze Biomediche e Oncologia Umana, Universit`a di Torino, Italy.
 SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1994 Dec 16) 269 (50) 31680-4. Journal code: HIV. ISSN: 0021-9258.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199503
 AB Mast cell growth factor (MGF) (also called **stem cell factor**) synergizes with several lymphokines, including interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF), to promote proliferation and differentiation of certain hemopoietic progenitor cells. Although similar patterns of tyrosine-phosphorylated proteins characterize cells stimulated by MGF, IL-3, and GM-CSF, only the MGF receptor is a tyrosine kinase, and the **heterodimeric** receptors for IL-3 and GM-CSF share a common beta subunit that is devoid of enzymatic activity. Here we show that signaling pathways utilized by all three cytokines include the cytoplasmic tyrosine kinase JAK2. Analysis of several factor-dependent myeloid cell lines indicated that JAK2 is physically associated with the common beta subunit and with MGF receptor (c-Kit) even prior to **ligand binding**. However, each of the **ligands** induced elevated tyrosine phosphorylation of JAK2 and a consequent increase in its catalytic activity. These results demonstrate for the first time the convergence within the same myeloid cells of signaling pathways originating in two distinct lymphokine receptors and a tyrosine kinase receptor on activation of a cytoplasmic tyrosine kinase.
 CT Check Tags: Human; In Vitro; Support, Non-U.S. Gov't
 Amino Acid Sequence
 *Granulocyte-Macrophage Colony-Stimulating Factor: PH, physiology
 *Hematopoietic Cell Growth Factors: PH, physiology
 *Interleukin-3: PH, physiology
 Molecular Sequence Data
 Peptides: CH, chemistry
 Peptides: IM, immunology
 *Protein-Tyrosine Kinase: ME, metabolism
 *Proto-Oncogene Proteins: ME, metabolism
 *Receptor Protein-Tyrosine Kinases: ME, metabolism
 *Receptors, Colony-Stimulating Factor: ME, metabolism
 Signal Transduction
 Tyrosine: AA, analogs & derivatives
 Tyrosine: ME, metabolism
 RN 21820-51-9 (Phosphotyrosine); 55520-40-6 (Tyrosine); 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
 CN EC 2.7.1.- (Janus kinase 2); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Hematopoietic Cell Growth Factors); 0 (Interleukin-3); 0 (Peptides); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Stem Cell Factor)
 GEN c-kit
 L113 ANSWER 38 OF 47 MEDLINE
 AN 95014303 MEDLINE
 DN 95014303
 TI The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells.
 AU Tauchi T; Feng G S; Marshall M S; Shen R; Mantel C; Pawson T; Broxmeyer H E
 CS Department of Medicine (Hematology/Oncology), Indiana University School of

Medicine, Indianapolis 46202.

NC R37 CA36464 (NCI)
R01 HL46549 (NHLBI)
R01 HL49202 (NHLBI)

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1994 Oct 7) 269 (40) 25206-11.
Journal code: HIV. ISSN: 0021-9258.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199501

AB The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor, which is important for the normal development of hematopoietic cells, melanoblasts, and germ cells. Autophosphorylation of c-kit receptor on tyrosine creates **binding** sites for cellular src homology 2 (SH2)-containing signaling molecules. The discovery of phosphotyrosine phosphatases that contain SH2 domains suggests roles for these molecules in growth factor signaling pathways. We found that Syp, a phosphotyrosine phosphatase widely expressed in all the tissues in mammals, associates with c-kit receptor after activation with its **ligand**, steel factor, in the factor-dependent cell line, M07e. Both NH2-terminal and COOH-terminal SH2 domains of Syp, made as glutathione S-transferase fusion proteins, were able to **bind** to the activated c-kit receptor in vitro. Furthermore, Syp became marginally phosphorylated on tyrosine upon c-kit receptor activation, and tyrosine-phosphorylated Syp was found to be complexed with Grb2 in steel factor-stimulated M07e cells. Direct **binding** between Syp and Grb2 was also observed in vitro. Last, Ras and Raf interacts in vitro as a result of steel factor-stimulated Ras activation. These results suggest that Syp may be an important signaling component downstream of the c-kit receptor and involved in activation of the Ras signaling pathway in hematopoietic cells.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.
Cell Line
Hematopoietic Cell Growth Factors: PD, pharmacology
Phosphorylation
Protein-Serine-Threonine Kinases: ME, metabolism
***Protein-Tyrosine-Phosphatase: ME, metabolism**
***Proteins: ME, metabolism**
Proto-Oncogene Protein p21(ras): ME, metabolism
***Proto-Oncogene Proteins: ME, metabolism**
***Receptor Protein-Tyrosine Kinases: ME, metabolism**
***Receptors, Colony-Stimulating Factor: ME, metabolism**
Signal Transduction

CN EC 2.7.10 (Protein-Serine-Threonine Kinases); EC 2.7.10.- (Proto-Oncogene Proteins c-raf); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); EC 3.1.3.- (Syp protein); EC 3.1.3.48 (Protein-Tyrosine-Phosphatase); EC 3.6.1.- (Proto-Oncogene Protein p21(ras)); 0 (growth factor receptor-bound protein-2); 0 (Hematopoietic Cell Growth Factors); 0 (Proteins); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (**Stem Cell Factor**)

L113 ANSWER 39 OF 47 MEDLINE

AN 94325604 MEDLINE

DN 94325604

TI The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis.

AU Besmer P; Manova K; Duttlinger R; Huang E J; Packer A; Gyssler C; Bachvarova R F

CS Molecular Biology Program Sloan-Kettering Institute, New York, NY.

SO DEVELOPMENT. SUPPLEMENT, (1993) 125-37. Ref: 91
Journal code: A8Z. ISSN: 0950-1991.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)

LA English

FS Priority Journals

EM 199411

AB The c-kit receptor tyrosine kinase belongs to the PDGF/CSF-1/c-kit receptor subfamily. The kit-ligand, KL, also called steel factor, is synthesized from two alternatively spliced mRNAs as transmembrane proteins that can either be proteolytically cleaved to produce soluble forms of KL or can function as cell-associated molecules. The c-kit receptor kinase and KL are encoded at the white spotting (W) and steel (Sl) loci of the mouse, respectively. Mutations at both the W and the Sl locus cause deficiencies in gametogenesis, melanogenesis and hematopoiesis. The c-kit receptor is expressed in the cellular targets of W and Sl mutations, while KL is expressed in their microenvironment. In melanogenesis, c-kit is expressed in melanoblasts from the time they leave the neural crest and expression continues during embryonic development and in the melanocytes of postnatal animals. In gametogenesis c-kit is expressed in primordial germ cells, in spermatogonia, and in primordial and growing oocytes, implying a role at three distinct stages of gametogenesis. Many mutant alleles are known at W and Sl loci and their phenotypes vary in the degree of severity in the different cellular targets of the mutations. While many W and Sl alleles severely affect primordial germ cells (PGC), several mild Sl alleles have weak effects on PGCs and exhibit differential male or female sterility. Steel Panda (Sl(pan)) is a KL expression mutation in which KL RNA transcript levels are reduced in most tissues analyzed. In female Sl(pan)/Sl(pan) mice, ovarian follicle development is arrested at the one layered cuboidal stage as a result of reduced KL expression in follicle cells, indicating a role for c-kit in oocyte growth. Wsh is a c-kit expression mutation, which affects mast cells and melanogenesis. While the mast cell defect results from lack of c-kit expression, the pigmentation deficiency appears to stem from ectopic c-kit receptor expression in the somitic dermatome at the time of migration of melanoblasts from the neural crest to the periphery. It is proposed that the ectopic c-kit expression in Wsh mice affects early melanogenesis in a dominant fashion. The "sash" or white belt of Wsh/+ animals and some other mutant mice is explained by the varying density of melanoblasts along the body axis of wild-type embryos.

CT Check Tags: Animal; Female; Human; Male; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

*Gametogenesis: GE, genetics

*Hematopoietic Cell Growth Factors: GE, genetics
Mice

Mutation: PH, physiology
Phenotype

*Pigmentation: GE, genetics

*Proto-Oncogene Proteins: GE, genetics

*Receptor Protein-Tyrosine Kinases: GE, genetics

*Receptors, Colony-Stimulating Factor: GE, genetics

*Signal Transduction: GE, genetics

CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Stem Cell Factor)

L113 ANSWER 40 OF 47 MEDLINE

AN 94239532 MEDLINE

DN 94239532

TI Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation.

AU Nelson B H; Lord J D; Greenberg P D

CS Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.

SO NATURE, (1994 May 26) 369 (6478) 333-6.

Journal code: NSC. ISSN: 0028-0836.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199408

- AB The interleukin-2 receptor (IL-2R) consists of three distinct chains (alpha, beta, gamma) which bind IL-2 and generate a proliferative signal in T cells. To define the mechanism of receptor activation, chimaeric receptors were constructed from the intracellular region of either IL-2R beta or IL-2R gamma and the extracellular region of c-kit, a receptor tyrosine kinase that **homodimerizes** on binding **stem cell factor** (SCF). We report here that binding of SCF to the beta-chain chimaera induced proliferation of the pro-B-cell line BA/F3, but not T cells. But in T cells expressing both the beta- and gamma-chain chimaeras, SCF induced proliferation and tyrosine phosphorylation characteristic of the native IL-2R signal. Chimaeric IL-2 receptor beta and gamma chains constructed with the **heterodimeric** extracellular regions of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) also provided the IL-2R signal. Thus, **heterodimerization** of the cytoplasmic domains of IL-2R beta and -gamma appears necessary and sufficient for signalling in T cells.
- CT Check Tags: Animal; Human
 B-Lymphocytes: PH, physiology
 Base Sequence
 Biopolymers
 Cell Line
 Chimeric Proteins
 Granulocyte-Macrophage Colony-Stimulating Factor: ME, metabolism
 Hematopoietic Cell Growth Factors: ME, metabolism
 Lymphocyte Transformation: IM, immunology
 Mice
 Molecular Sequence Data
 Phosphorylation
 Proto-Oncogene Proteins: PH, physiology
Receptor Protein-Tyrosine Kinases: PH, physiology
 Receptors, Colony-Stimulating Factor: PH, physiology
 *Receptors, Interleukin-2: CH, chemistry
 *Receptors, Interleukin-2: PH, physiology
 *Signal Transduction: IM, immunology
 *T-Lymphocytes: PH, physiology
 Tyrosine: ME, metabolism
- RN 55520-40-6 (Tyrosine); 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
- CN EC 2.7.11.- (**Proto-Oncogene Protein c-kit**); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Biopolymers); 0 (Chimeric Proteins); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Receptors, Interleukin-2); 0 (**Stem Cell Factor**)
- L113 ANSWER 41 OF 47 MEDLINE
- AN 94171899 MEDLINE
- DN 94171899
- TI Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1.
- AU Ashman L K; Buhning H J; Aylett G W; Broudy V C; Muller C
- CS Leukaemia Research Unit, Hanson Centre for Cancer Research, Adelaide, South Australia.
- NC DK 44194 (NIDDK)
- SO JOURNAL OF CELLULAR PHYSIOLOGY, (1994 Mar) 158 (3) 545-54.
 Journal code: HNB. ISSN: 0021-9541.
 United States
- CY Journal; Article; (JOURNAL ARTICLE)
- DT English
- LA English
- FS Priority Journals; Cancer Journals
- EM 199406
- AB Three monoclonal antibodies (MAbs) to the human c-kit receptor tyrosine kinase (P145c-kit), derived in independent laboratories, have been extensively used in studies of c-kit expression and the role of its **ligand**, steel factor (SLF), in hemopoiesis and mast cell differentiation and function. In this study, the relationship between the epitopes they identify, and their effects on SLF **binding**,

receptor internalization, and signal transduction are compared. Epitope mapping studies carried out on the high P145c-kit-expressing cell line HEL-DR showed that SR-1 identifies an epitope independent of those bound by YB5.B8 and 17F11, while the latter two antibodies bound to distinct but interacting epitopes. SR-1 potentially blocked the binding of SLF to P145c-kit on these cells and also on cells of the factor-dependent line MO7e. In contrast, YB5.B8 and 17F11 had minimal effects on ligand binding. Conversely, SLF partially blocked the binding of SR-1 and YB5.B8 to cells, while binding of 17F11 was actually enhanced by SLF on some target cells. Preincubation of HEL-DR and MO7e cells with MAbs prior to exposure to SLF revealed that 17F11 itself brought about partial down-regulation of P145c-kit and did not inhibit SLF-mediated down-regulation. SR-1 caused minimal down-regulation and inhibited SLF-mediated receptor internalization. YB5.B8 had minimal effects on either cell line in this assay. To determine whether the antibodies had any agonist activity, they were compared with SLF for their ability to bring about receptor phosphorylation in intact MO7e cells. All three antibodies induced detectable tyrosine phosphorylation with 17F11 being the most effective, while YB5.B8 was the least effective. Finally, the ability of the antibodies to influence the proliferation of the MO7e cells was examined. As expected, SR-1 potentially inhibited the proliferative response to SLF, while 17F11 weakly inhibited and YB5.B8 had negligible effect. In the absence of SLF both 17F11 and YB5.B8 displayed very weak but reproducible agonist activity.

CT Check Tags: Animal; Comparative Study; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

*Antibodies, Monoclonal: IM, immunology
 Antibodies, Monoclonal: ME, metabolism
 Antibodies, Monoclonal: PD, pharmacology
 Binding Sites, Antibody
 Binding, Competitive
 Bone Marrow: CY, cytology
 Bone Marrow: ME, metabolism
 Bone Marrow: UL, ultrastructure
 Cells, Cultured
 CHO Cells
 Endocytosis
 *Epitopes: IM, immunology
 Flow Cytometry
 Fluorescent Antibody Technique
 Hamsters
 Hematopoietic Cell Growth Factors: ME, metabolism
 Leukemia, Erythroblastic, Acute: ME, metabolism
 Leukemia, Erythroblastic, Acute: PA, pathology
 Leukemia, Megakaryocytic, Acute: ME, metabolism
 Leukemia, Megakaryocytic, Acute: PA, pathology
 *Peptide Mapping
 Phosphorylation
 *Proto-Oncogene Proteins: IM, immunology
 Proto-Oncogene Proteins: ME, metabolism
 *Proto-Oncogene Proteins: PH, physiology
 *Receptor Protein-Tyrosine Kinases: IM, immunology
 Receptor Protein-Tyrosine Kinases: ME, metabolism
 *Receptor Protein-Tyrosine Kinases: PH, physiology
 *Receptors, Colony-Stimulating Factor: IM, immunology
 Receptors, Colony-Stimulating Factor: ME, metabolism
 *Receptors, Colony-Stimulating Factor: PH, physiology
 Signal Transduction: PH, physiology
 Tumor Cells, Cultured

CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Antibodies, Monoclonal); 0 (Binding Sites, Antibody); 0 (Epitopes); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Stem Cell Factor)

AN 94105123 MEDLINE
 DN 94105123
 TI Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases.
 AU Ohashi H; Maruyama K; Liu Y C; Yoshimura A
 CS Pharmaceutical Laboratories, Kirin Brewery Co. LTD., Gunma, Japan.
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1994 Jan 4) 91 (1) 158-62.
 Journal code: PV3. ISSN: 0027-8424.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199404
 AB Ligand-induced **dimerization** is a key step in the activation of receptor tyrosine kinases, including the epidermal growth factor receptor, **stem cell factor** receptor (c-kit), and colony-stimulating factor 1 receptor (c-fms). The erythropoietin receptor (EPOR), a member of the cytokine receptor family, contains no kinase motif and its activation mechanism remains unclear. Here we show that chimeric receptors carrying the extracellular domain of the epidermal growth factor receptor or c-kit linked to the cytoplasmic domain of the EPOR, transmitted epidermal growth factor or **stem cell factor**-dependent proliferation signals in an interleukin 3-dependent cell line. The chimeric receptors as well as the wild-type EPOR also mediated the ligand-induced tyrosine phosphorylation of a set of similar proteins. Moreover, erythropoietin triggered mitogenic signals of chimeric receptors carrying the extracellular domain of the EPOR linked to the tyrosine kinase of c-fms. These data demonstrate the interchangeability of domains between two distinct receptor families and suggest that ligand-induced **dimerization** is a key step in activating the EPOR.
 CT Check Tags: Animal; Support, Non-U.S. Gov't
 Amino Acid Sequence
 Base Sequence
 Cell Line
 Chimeric Proteins: ME, metabolism
 Enzyme Activation
 Mice
 Mitosis
 Molecular Sequence Data
 Oligodeoxyribonucleotides: CH, chemistry
 Proto-Oncogene Proteins: CH, chemistry
 *Receptor Protein-Tyrosine Kinases: CH, chemistry
 Receptor, Epidermal Growth Factor: CH, chemistry
 Receptor, Macrophage Colony-Stimulating Factor: CH, chemistry
 Receptors, Colony-Stimulating Factor: CH, chemistry
 *Receptors, Erythropoietin: CH, chemistry
 Signal Transduction
 Structure-Activity Relationship
 Transfection
 Tyrosine: AA, analogs & derivatives
 Tyrosine: ME, metabolism
 RN 21820-51-9 (Phosphotyrosine); 55520-40-6 (Tyrosine)
 CN EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); EC 2.7.11.- (Receptor, Epidermal Growth Factor); EC 2.7.11.- (Receptor, Macrophage Colony-Stimulating Factor); 0 (Chimeric Proteins); 0 (Oligodeoxyribonucleotides); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Receptors, Erythropoietin)
 GEN EGFR; EPOR; c-kit; c-fms
 L113 ANSWER 43 OF 47 MEDLINE
 AN 94004531 MEDLINE
 DN 94004531
 TI Molecular genetic approaches to the elucidation of hematopoietic stem cell

function.

AU Bernstein A
 CS Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
 SO STEM CELLS, (1993 Jul) 11 Suppl 2 31-5. Ref: 33
 Journal code: BN2. ISSN: 1066-5099.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199401

AB The past few years have seen considerable advances in the development of the methodologies for discovering novel genes critical to hematopoietic stem cell function and for analyzing their biological role in hematopoiesis. This review briefly discusses some common themes that are emerging from the molecular genetic approaches to hematopoietic stem cell function.

CT Check Tags: Animal; Support, Non-U.S. Gov't
 Anemia: GE, genetics
Germ Cells: DE, drug effects
 *Hematopoiesis: GE, genetics
 Hematopoietic Cell Growth Factors: GE, genetics
 Hematopoietic Cell Growth Factors: PD, pharmacology
 *Hematopoietic Cell Growth Factors: PH, physiology
 Hematopoietic Stem Cells: DE, drug effects
 *Hematopoietic Stem Cells: PH, physiology
Infertility: GE, genetics
Melanocytes: DE, drug effects
 Mice
 Mice, Mutant Strains: GE, genetics
Pigmentation Disorders: GE, genetics
Protein-Tyrosine Kinase: PH, physiology
 Proto-Oncogene Proteins: GE, genetics
 *Proto-Oncogene Proteins: PH, physiology
Receptor Protein-Tyrosine Kinases: GE, genetics
***Receptor Protein-Tyrosine Kinases: PH, physiology**
 Receptors, Cell Surface: PH, physiology
 Receptors, Colony-Stimulating Factor: GE, genetics
 *Receptors, Colony-Stimulating Factor: PH, physiology
Signal Transduction

CN EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (Receptors, Cell Surface); 0 (Receptors, Colony-Stimulating Factor); 0 (**Stem Cell Factor**)

GEN S1; c-myb; c-src; c-fyn; c-kit; src; GATA-1

L113 ANSWER 44 OF 47 MEDLINE
 AN 94004519 MEDLINE
 DN 94004519
 TI Structure-function analyses of the kit receptor for the steel factor.
 AU Blechman J M; Lev S; Givol D; Yarden Y
 CS Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
 SO STEM CELLS, (1993 Jul) 11 Suppl 2 12-21. Ref: 42
 Journal code: BN2. ISSN: 1066-5099.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199401

AB **Binding** of the Steel factor (SLF) to the **product** of the **c-kit** proto-oncogene stimulates the receptor's intrinsic tyrosine kinase that phosphorylates a set of cytoplasmic signaling molecules. Germ-line mutations in the genes that encode the receptor or the **ligand** result in remarkably similar phenotypes that affect melanogenesis, erythropoiesis and gametogenesis in mice. We concentrated on the initial events of the signal transduction pathway that underlies these processes. The extracellular portion of **Kit** is comprised of five immunoglobulin-(Ig)-like domains. **Ligand binding** to this domain induces rapid and extensive **dimerization** of the receptor molecules in a mechanism that involves monovalent **binding** of the **dimeric ligand**, followed by an increase in receptors' affinity and gradual stabilization of the **dimers**. It thus appears that **Kit** has at least two functions: **ligand binding** and **ligand-induced receptor dimerization**, in addition to the kinase activity. Both functions are independent of the transmembrane and cytoplasmic domains, as a recombinant soluble ectodomain retained high affinity to SLF and **ligand-dependent dimerization**. In order to correlate these functions with specific structures, we employed **ligand-competitive monoclonal antibodies**, soluble deletion mutants of the ectodomain and chimeric human-mouse **Kit** proteins. These approaches indicated that the N-terminal three Ig-like domains constitute the **binding site**, whose core is the second domain. Further experiments suggested that a putative **dimerization site** is distinct from the **binding cleft** and may be located on the fourth Ig-like domain.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't
 Antibodies, Monoclonal: IM, immunology
 Binding Sites
 Hematopoietic Cell Growth Factors: GE, genetics
 *Hematopoietic Cell Growth Factors: ME, metabolism
 Mice
 Models, Molecular
 Polymers
 Protein Binding
 Protein Conformation
 Protein Engineering
Protein-Tyrosine Kinase: ME, metabolism
 Proto-Oncogene Proteins: CH, chemistry
 Proto-Oncogene Proteins: GE, genetics
 Proto-Oncogene Proteins: IM, immunology
 *Proto-Oncogene Proteins: ME, metabolism
 Proto-Oncogenes
Receptor Protein-Tyrosine Kinases: CH, chemistry
Receptor Protein-Tyrosine Kinases: GE, genetics
Receptor Protein-Tyrosine Kinases: IM, immunology
 ***Receptor Protein-Tyrosine Kinases: ME, metabolism**
 Receptors, Colony-Stimulating Factor: CH, chemistry
 Receptors, Colony-Stimulating Factor: GE, genetics
 Receptors, Colony-Stimulating Factor: IM, immunology
 *Receptors, Colony-Stimulating Factor: ME, metabolism
 Recombinant Fusion Proteins: ME, metabolism
Signal Transduction
 Structure-Activity Relationship

CN EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.11.- (**Proto-Oncogene Protein c-kit**); EC 2.7.11.- (Receptor Protein-Tyrosine Kinases); 0 (Antibodies, Monoclonal); 0 (Hematopoietic Cell Growth Factors); 0 (Polymers); 0 (Proto-Oncogene Proteins); 0 (Receptors, Colony-Stimulating Factor); 0 (Recombinant Fusion Proteins); 0 (**Stem Cell Factor**)

GEN c-kit; Sl; v-kit

L113 ANSWER 45 OF 47 MEDLINE

AN 92313795 MEDLINE

DN 92313795

TI The kit receptor and its ligand, steel factor, as regulators of

- hemopoiesis.
- AU Broxmeyer H E; Maze R; Miyazawa K; Carow C; Hendrie P C; Cooper S; Hangoc G; Vadhan-Raj S; Lu L
- CS Department of Medicine (Hematology/Oncology), Indiana University School of Medicine, Indianapolis 46202.
- NC R37 CA36464 (NCI)
R01 HL46549 (NHLBI)
R01 CA36740 (NCI)
+
- SO CANCER CELLS, (1991 Dec) 3 (12) 480-7. Ref: 68
Journal code: AU5. ISSN: 1042-2196.
- CY United States
- DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
- LA English
- FS Priority Journals
- EM 199210
- AB Mouse strains carrying mutations at the Dominant White Spotting (W) locus or the Steel (Sl) locus are anemic and display defects in pigmentation and gametogenesis. In W mutants the anemia is due to a deficiency of hemopoietic stem cells and, in Sl mutants, to a deficiency of supporting stromal cells in the bone marrow. The W locus encodes the c-kit proto-oncogene product, a cell surface receptor with protein-tyrosine kinase activity, and the Sl locus encodes its ligand, a hemopoietic cytokine known variously as Steel factor (SLF), mast cell growth factor, **stem cell factor**, and Kit ligand. SLF can synergize with a number of other cytokines to stimulate growth of hemopoietic progenitors in vitro and stimulates blood cell production in vivo in animals. Here we review the biological activities of SLF, with particular emphasis on its effects on hemopoietic stem and progenitor cells. We also discuss present knowledge of the molecules involved in SLF-triggered signal transduction, and speculate on potential therapeutic applications for SLF in human disease.
- CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
- Anemia: DT, drug therapy
Anemia: GE, genetics
Bone Marrow: EM, embryology
Cell Differentiation
Cell Movement
Drug Screening
Gene Expression Regulation
*Hematopoiesis: PH, physiology
Hematopoietic Cell Growth Factors: GE, genetics
Hematopoietic Cell Growth Factors: IP, isolation & purification
Hematopoietic Cell Growth Factors: PD, pharmacology
*Hematopoietic Cell Growth Factors: PH, physiology
Hematopoietic Cell Growth Factors: TU, therapeutic use
Hematopoietic Stem Cells: DE, drug effects
Leukemia: PA, pathology
Melanocytes: CY, cytology
Mice
Mice, Mutant Strains: EM, embryology
Mice, Mutant Strains: GE, genetics
Mice, Mutant Strains: PH, physiology
Protein-Tyrosine Kinase: GE, genetics
Protein-Tyrosine Kinase: ME, metabolism
Proto-Oncogene Proteins: GE, genetics
*Proto-Oncogene Proteins: PH, physiology
Proto-Oncogenes
Rats
Signal Transduction
Tumor Stem Cells: DE, drug effects
Tumor Stem Cells: PA, pathology
- CN EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.11.- (Proto-Oncogene

Protein c-kit); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (**Stem Cell Factor**)

GEN c-kit; W; Sl; c-fms; Sld; C-KIT; KIT; SLF

L113 ANSWER 46 OF 47 MEDLINE

AN 91246171 MEDLINE

DN 91246171

TI The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor.

AU Rottapel R; Reedijk M; Williams D E; Lyman S D; Anderson D M; Pawson T; Bernstein A

CS Division of Molecular and Developmental Biology, Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.

SO MOLECULAR AND CELLULAR BIOLOGY, (1991 Jun) 11 (6) 3043-51.

Journal code: NGY. ISSN: 0270-7306.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199109

AB The W/c-kit and Steel loci respectively encode a receptor tyrosine kinase (Kit) and its extracellular **ligand**, Steel factor, which are essential for the development of hematopoietic, melanocyte, and germ cell lineages in the mouse. To determine the biochemical basis of the Steel/W developmental pathway, we have investigated the response of the Kit tyrosine kinase and several potential cytoplasmic targets to stimulation with Steel in mast cells derived from normal and mutant W mice. In normal mast cells, Steel induces Kit to autophosphorylate on tyrosine and **bind** to phosphatidylinositol 3'-kinase (PI3K) and phospholipase C-gamma 1 but not detectably to Ras GTPase-activating protein. Additionally, we present evidence that Kit tyrosine phosphorylation acts as a switch to promote complex formation with PI3K. In mast cells from mice homozygous for the W42 mutant allele, Kit is not tyrosine phosphorylated and fails to **bind** PI3K following Steel stimulation. In contrast, in the transformed mast cell line P815, Kit is constitutively phosphorylated and **binds** to PI3K in the absence of **ligand**. These results suggest that Kit autophosphorylation and its physical association with a unique subset of cytoplasmic signaling proteins are critical for mammalian development.

CT Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S. Blotting, Western Cell Line

*Hematopoietic Cell Growth Factors: GE, genetics

Hematopoietic Cell Growth Factors: ME, metabolism

*Hematopoietic Stem Cells: PH, physiology

Homozygote

Mast Cells: PH, physiology

Mice

Mice, Inbred C57BL

Mice, Mutant Strains

Mutation

Phospholipase C: ME, metabolism

Phosphorylation

Phosphotransferases: ME, metabolism

Protein Binding

***Protein-Tyrosine Kinase**: GE, genetics

Protein-Tyrosine Kinase: ME, metabolism

Proteins: ME, metabolism

*Proto-Oncogene Proteins: GE, genetics

Proto-Oncogene Proteins: ME, metabolism

*Proto-Oncogenes

Recombinant Fusion Proteins: ME, metabolism

Restriction Mapping

***Signal Transduction**

CN EC 2.7 (Phosphotransferases); EC 2.7.1.112 (Protein-Tyrosine Kinase); EC

2.7.1.137 (1-Phosphatidylinositol 3-Kinase); EC 2.7.11.- (Proto-Oncogene Protein c-kit); EC 3.1.4.3 (Phospholipase C); 0 (ras GTPase-Activating Proteins); 0 (GTPase-Activating Proteins); 0 (Hematopoietic Cell Growth Factors); 0 (Proto-Oncogene Proteins); 0 (Recombinant Fusion Proteins); 0 (Stem Cell Factor)

L113 ANSWER 47 OF 47 MEDLINE

AN 91160520 MEDLINE

DN 91160520

TI A specific combination of substrates is involved in signal transduction by the kit-encoded receptor.

AU Lev S; Givol D; Yarden Y

CS Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

NC 1 RO1 CA512712 (NCI)

SO EMBO JOURNAL, (1991 Mar) 10 (3) 647-54.

Journal code: EMB. ISSN: 0261-4189.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199106

AB The kit protooncogene encodes a transmembrane tyrosine kinase related to the receptors for the platelet derived growth factor (PDGF-R) and the macrophage growth factor (CSF1-R), and was very recently shown to **bind a stem cell factor**. To compare signal transduction by the kit kinase with signaling by homologous receptors we constructed a chimeric protein composed of the extracellular domain of the epidermal growth factor receptor (EGF-R) and the transmembrane and cytoplasmic domains of kit. We have previously shown that the chimeric receptor transmits potent mitogenic and transforming signals in response to the heterologous **ligand**. Here we demonstrate that upon **ligand binding**, the **ligand**-receptor complex undergoes endocytosis and degradation and induces short- and long-term cellular effects. Examination of the signal transduction pathway revealed that the activated kit kinase strongly associates with phosphatidylinositol 3'-kinase activity and a phosphoprotein of 85 kd. In addition, the **ligand**-stimulated kit kinase is coupled to modifications of phospholipase C gamma and the Raf1 protein kinase. However, it does not lead to a significant change in the production of inositol phosphate. Comparison of our results with the known signaling pathways of PDGF-R and CSF1-R suggests that each receptor is coupled to a specific combination of signal transducers.

CT Check Tags: Animal; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Biological Transport, Active: DE, drug effects

Cell Line

Chimera

Deoxyglucose: ME, metabolism

Endocytosis

Epidermal Growth Factor: PD, pharmacology

Kinetics

Ligands

Macrophage Colony-Stimulating Factor: PD, pharmacology

Mice

Models, Biological

Platelet-Derived Growth Factor: ME, metabolism

***Protein-Tyrosine Kinase: GE, genetics**

***Proto-Oncogene Proteins: GE, genetics**

Proto-Oncogene Proteins: ME, metabolism

***Proto-Oncogenes**

***Receptors, Cell Surface: GE, genetics**

Receptors, Cell Surface: ME, metabolism

***Signal Transduction**

RN 154-17-6 (Deoxyglucose); 62229-50-9 (Epidermal Growth Factor); 81627-83-0 (Macrophage Colony-Stimulating Factor)

CN EC 2.7.1.112 (Protein-Tyrosine Kinase); EC 2.7.11.- (Proto-Oncogene

Protein c-kit); EC 2.7.11.- (Receptors, Platelet-Derived Growth Factor); 0 (Ligands); 0 (Platelet-Derived Growth Factor); 0 (Proto-Oncogene Proteins); 0 (Receptors, Cell Surface)

GEN kit

=> fil biosis

FILE 'BIOSIS' ENTERED AT 10:32:15 ON 28 JUN 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 21 June 2000 (20000621/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> d his l114-

(FILE 'MEDLINE' ENTERED AT 10:21:40 ON 28 JUN 2000)

FILE 'BIOSIS' ENTERED AT 10:22:38 ON 28 JUN 2000

L114 3059 S STEM CELL FACTOR
L115 1215 S L114 AND 00520/CC
L116 1245 S L114 AND (CONGRESS OR CONFERENCE OR POSTER OR SYMPOS? OR MEET
L117 1222 S L115, L116 AND PY<=1999
L118 1 S L117 AND LONGLEY ?/AU
L119 236 S L117 AND (185? OR *355? OR *1400? OR *1600? OR 1650?)/CC
L120 48 S L119 AND *34508/CC
L121 40 S L120 AND 150?/CC
L122 41 S L118, L121
L123 8 S L120 NOT L122
L124 49 S L122, L123

FILE 'BIOSIS' ENTERED AT 10:32:15 ON 28 JUN 2000

=> d all tot

*All are conference
rep - No abstracts
available*

L124 ANSWER 1 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1999:229797 BIOSIS

DN PREV199900229797

TI Transgenic mice expressing **stem cell factor**
in basal keratinocytes develop postinflammatory hyperpigmentation in
response to irritant and allergic contactants.

AU Carter, E. L. (1); Tigelaar, R. E.; Longley, B. J.

CS (1) Department of Dermatology, Columbia University, New York, NY USA

SO Journal of Investigative Dermatology, (April, 1999) Vol. 112,
No. 4, pp. 539.

Meeting Info.: 60th Annual Meeting of the Society for Investigative
Dermatology Chicago, Illinois, USA May 5-9, 1999
ISSN: 0022-202X.

DT Conference

LA English

CC Integumentary System - General; Methods *18501

Cytology and Cytochemistry - Animal *02506

Biochemical Studies - General *10060

Blood, Blood-Forming Organs and Body Fluids - General; Methods *15001

Immunology and Immunochemistry - General; Methods *34502

Allergy *35500

Toxicology - General; Methods and Experimental *22501

Endocrine System - General *17002

**General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520**

BC Muridae 86375
IT Major Concepts
Allergy (Clinical Immunology, Human Medicine, Medical Sciences);
Dermatology (Human Medicine, Medical Sciences)
IT Parts, Structures, & Systems of Organisms
basal keratinocyte: integumentary system; epidermis: integumentary
system
IT Diseases
postinflammatory hyperpigmentation: integumentary system disease
IT Chemicals & Biochemicals
allergic contactant: allergen; irritant contactant: toxin; keratin 14
promoter; **stem cell factor**: expression
IT Miscellaneous Descriptors
Meeting Abstract
ORGN Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
mouse (Muridae): model, transgenic
ORGN Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates;
Rodents; Vertebrates

L124 ANSWER 2 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1999:136245 BIOSIS

DN PREV199900136245

TI **Stem cell factor** (SCF) stimulates adhesion
of human intestinal mast cells to extracellular matrix proteins.

AU Lorentz, A. (1); Sellge, G. (1); Manns, M. P. (1); Schuppan, D.;
Levi-Schaffer, F.; Bischoff, S. C. (1)

CS (1) Dep. Gastroenterology and Hepatology, Med. Sch. Hannover, Hannover
Germany

SO Journal of Allergy and Clinical Immunology, (Jan., 1999) Vol.
103, No. 1 PART 2, pp. S41.

Meeting Info.: **55th Annual Meeting of the American Academy of
Allergy, Asthma and Immunology** Orlando, Florida, USA February
26-March 3, 1999 American Academy of Allergy, Asthma, and Immunology
. ISSN: 0091-6749.

DT **Conference**

LA English

CC **Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**

Cytology and Cytochemistry - Human *02508

Digestive System - Physiology and Biochemistry *14004

**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**

**General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520**

Biochemical Studies - Proteins, Peptides and Amino Acids *10064

BC Hominidae 86215

IT Major Concepts

Immune System (Chemical Coordination and Homeostasis)

IT Parts, Structures, & Systems of Organisms

intestinal mast cells: adhesion, blood and lymphatics, digestive
system, immune system

IT Chemicals & Biochemicals

extracellular matrix proteins; fibronectin: matric protein;
stem cell factor

IT Miscellaneous Descriptors

Meeting Abstract; Meeting Poster

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

human (Hominidae)

ORGN Organism Superterms

Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L124 ANSWER 3 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1999:125314 BIOSIS
 DN PREV199900125314
 TI Mast cell regulation by cytokines and nitric oxide.
 AU Coleman, J. W. (1)
 CS (1) Dep. Pharmacol., Univ. Liverpool, Liverpool L69 3GE UK
 SO Immunology, (Dec., 1998) Vol. 95, No. SUPPL. 1, pp. 19.
 Meeting Info.: **6th Annual Congress of the British Society for Immunology** Harrogate, England, UK December 1-4, 1998
 ISSN: 0019-2805.
 DT **Conference**
 LA English
 CC **Immunology and Immunochemistry - Immunopathology, Tissue Immunology**
***34508**
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Endocrine System - General *17002
Allergy *35500
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
 IT Major Concepts
 Immune System (Chemical Coordination and Homeostasis)
 IT Parts, Structures, & Systems of Organisms
 mast cells: immune system
 IT Chemicals & Biochemicals
 cytokines; nitric oxide; **stem cell factor**
 ; IFN-gamma [interferon-gamma]; IL-4 [interleukin-4]
 IT Miscellaneous Descriptors
 allergic reactions; immunity; mast cell regulation; **Meeting**
Abstract
 RN 10102-43-9 (NITRIC OXIDE)

L124 ANSWER 4 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1999:125313 BIOSIS
 DN PREV199900125313
 TI Regulation of the mucosal mast cells response following parasitic infection.
 AU Grencis, R. K. (1)
 CS (1) Sch. Biol. Sci., Stopford Build., Univ. Manchester, Oxford Road, Manchester M13 9PT UK
 SO Immunology, (Dec., 1998) Vol. 95, No. SUPPL. 1, pp. 19.
 Meeting Info.: **6th Annual Congress of the British Society for Immunology** Harrogate, England, UK December 1-4, 1998
 ISSN: 0019-2805.
 DT **Conference**
 LA English
 CC Immunology, Parasitological *35000
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Digestive System - Pathology *14006
 Endocrine System - General *17002
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
 Parasitology - General *60502
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
 BC Nematoda 51300
 IT Major Concepts
 Immune System (Chemical Coordination and Homeostasis); Parasitology
 IT Parts, Structures, & Systems of Organisms
 mast cells: immune system
 IT Diseases
 parasitic infection: parasitic disease
 IT Chemicals & Biochemicals
 interleukin-9 [IL-9]; intestinal mastocytosis: immune system disease;
stem cell factor

- IT Alternate Indexing
Parasitic Diseases (MeSH)
- IT Miscellaneous Descriptors
immunity; mucosal mast cell response: regulation; **Meeting Abstract**
- ORGN Super Taxa
Nematoda: Aschelminthes, Helminthes, Invertebrata, Animalia
- ORGN Organism Name
nematode (Nematoda): intestinal parasite
- ORGN Organism Superterms
Animals; Aschelminths; Helminths; Invertebrates
- L124 ANSWER 5 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
- AN 1998:248327 BIOSIS
- DN PREV199800248327
- TI Rapid reduction in the size of mouse cutaneous mast cell populations by apoptosis after cessation of treatment with SCF does not result in skin inflammation.
- AU Maurer, Marcus (1); Galli, Stephen J.
- CS (1) Dep. Pathol., Beth Israel Deaconess Med. Cent., Boston, MA USA
- SO Journal of Investigative Dermatology, (April, 1998) Vol. 110, No. 4, pp. 634.
- Meeting Info.: Annual Meeting of the International Investigative Dermatology Cologne, Germany May 7-10, 1998 The Society for Investigative Dermatology, Inc.
. ISSN: 0022-202X.
- DT **Conference**
- LA English
- CC **Integumentary System - Pathology *18506**
Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
- BC Muridae 86375
- IT Major Concepts
Immune System (Chemical Coordination and Homeostasis); Integumentary System (Chemical Coordination and Homeostasis)
- IT Parts, Structures, & Systems of Organisms
mast cell: immune system; skin: integumentary system
- IT Chemicals & Biochemicals
stem cell factor
- IT Miscellaneous Descriptors
apoptosis; inflammation; **Meeting Abstract;**
Meeting Poster
- ORGN Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
- ORGN Organism Name
mouse (Muridae)
- ORGN Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates
- L124 ANSWER 6 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
- AN 1998:247926 BIOSIS
- DN PREV199800247926
- TI Human **stem cells factor** does not affect the morphology and expression of functionally relevant molecules of Langerhans cells in vitro.
- AU Prignano, Francesca; Gerlini, Gianni; Pimpinelli, Nicola; Romagnoli, Paolo; Giannotti, Benvenuto
- CS Dep. Anatomy Histology, Inst. Dermatol., Univ. Florence, Florence Italy
- SO Journal of Investigative Dermatology, (April, 1998) Vol. 110, No. 4, pp. 567.
- Meeting Info.: Annual Meeting of the International Investigative

Dermatology Cologne, Germany May 7-10, 1998 The Society for
Investigative Dermatology, Inc.
. ISSN: 0022-202X.

DT **Conference**
LA English
CC **Immunology and Immunochemistry - Immunopathology, Tissue Immunology**
***34508**
Cytology and Cytochemistry - Human *02508
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
Endocrine System - General *17002
Integumentary System - Physiology and Biochemistry *18504
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Immune System (Chemical Coordination and Homeostasis); Integumentary
System (Chemical Coordination and Homeostasis)
IT Parts, Structures, & Systems of Organisms
epidermis: integumentary system; Langerhans cells: immune system, in
vitro, metabolism, morphology
IT Chemicals & Biochemicals
human **stem cell factor**
IT Miscellaneous Descriptors
Meeting Abstract; Meeting Poster
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L124 ANSWER 7 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:154607 BIOSIS
DN PREV199800154607
TI Adherence of human lung mast cells to bronchial epithelium.
AU Sanmugalingam, D.; Wardlaw, A. J.; Bradding, P.
CS Univ. Leicester, Glenfield Hosp., Leicester UK
SO Journal of Allergy and Clinical Immunology, (Jan., 1998) Vol.
101, No. 1 PART 2, pp. S216.
Meeting Info.: 54th Annual Meeting of the American Academy of
Allergy, Asthma and Immunology Washington, DC, USA March 13-18, 1998
American Academy of Allergy, Asthma, and Immunology
. ISSN: 0091-6749.

DT **Conference**
LA English
CC **Respiratory System - Pathology *16006**
Cytology and Cytochemistry - Human *02508
Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
***15004**
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
Endocrine System - General *17002
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
BC Hominidae 86215
IT Major Concepts
Immune System (Chemical Coordination and Homeostasis); Respiratory
System (Respiration)
IT Parts, Structures, & Systems of Organisms
bronchial epithelium: respiratory system; lung mast cells
IT Diseases
asthma: immune system disease, respiratory system disease

IT Chemicals & Biochemicals
alpha-4-beta-1; CD18; E-cadherin; SCF [**stem cell factor**]

IT Miscellaneous Descriptors
Meeting Abstract

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae); BEAS-2B (Hominidae): **bronchial epithelial cell**

ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L124 ANSWER 8 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:145813 BIOSIS
DN PREV199800145813
TI Cytokines and asthma.
AU Palma Carlos, A. G.; Palma Carlos, M. L.; Conceicao, Santos M.; Alcinda, Melo
CS Med. I Univ. Clinic, Immunol. Inst., Lisbon Portugal
SO Journal of Investigational Allergology & Clinical Immunology, (Sept.-Oct., 1997) Vol. 7, No. 5, pp. 270-273.
Meeting Info.: **Annual Meeting of the International Association of Asthmology, Western Europe Chapter: Interasma 97** Las Palmas de Gran Canaria, Canary Islands, Spain December 3-5, 1997 International Association of Asthmology
. ISSN: 1018-9068.

DT **Conference**
LA English
CC **Allergy *35500**
Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
Pathology, General and Miscellaneous - Therapy *12512
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Respiratory System - Pathology *16006
Endocrine System - General *17002
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520

BC Hominidae 86215
IT Major Concepts
Clinical Immunology (Human Medicine, Medical Sciences)

IT Diseases
asthma: cell recruitment, respiratory system disease, immune system disease, inflammation; atopy: immune system disease; respiratory allergy: immune system disease

IT Chemicals & Biochemicals
adhesion molecules; chemokines; cytokines: immunomodulation, production, network activation; **stem cell factor**; tumor necrosis factor alpha; IgE [**immunoglobulin E**]: synthesis

IT Methods & Equipment
immunomodulatory intervention: therapeutic method

IT Miscellaneous Descriptors
Meeting Paper

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae): patient

ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L124 ANSWER 9 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1998:67444 BIOSIS

- DN PREV199800067444
 TI Oncostatin M (OSM) supports expansion of hematopoietic progenitors derived from the aorta gonad mesonephros (AGM) region of mouse embryo.
 AU Mukoyama, Y. (1); Hara, T. (1); Xu, M.; Tamura, K.; Donovan, P. J.; Kim, H. (1); Kogo, H.; Tsuji, K.; Nakahata, T.; Miyajima, A. (1)
 CS (1) Inst. Molecular Cellular Biosciences, Univ. Tokyo, Tokyo Japan
 SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 1, pp. 258A.
 Meeting Info.: 39th Annual Meeting of the American Society of Hematology San Diego, California, USA December 5-9, 1997 The American Society of Hematology . ISSN: 0006-4971.
 DT Conference
 LA English
 CC Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies *15002
 Cytology and Cytochemistry - Animal *02506
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Reproductive System - Physiology and Biochemistry *16504
 Endocrine System - General *17002
 Developmental Biology - Embryology - General and Descriptive *25502
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 BC Muridae 86375
 IT Major Concepts
 Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation)
 IT Parts, Structures, & Systems of Organisms
 aorta gonad mesonephros: embryonic structure; bone marrow: blood and lymphatics, immune system; hematopoietic progenitor cells: blood and lymphatics, expansion
 IT Chemicals & Biochemicals
 basic fibroblast growth factor; interleukin-6; oncostatin M: expression; stem cell factor
 IT Miscellaneous Descriptors
 hematopoiesis; Meeting Abstract
 ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 mouse (Muridae): embryo
 ORGN Organism Superterms
 Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates
 RN 106956-32-5 (ONCOSTATIN M)
- L124 ANSWER 10 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1998:67249 BIOSIS
 DN PREV199800067249
 TI Cell cycling of mobilized peripheral blood stem cell subsets: Effect of mobilization regimen and impact on engraftment.
 AU Lill, M. (1); Saks-Rosenthal, E.; Turner, S. A.; Chap, L.; Crooks, G.; Glaspy, J. A.
 CS (1) Div. Hematol./Oncol., UCLA Sch. Med., Los Angeles, CA USA
 SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 1, pp. 213A.
 Meeting Info.: 39th Annual Meeting of the American Society of Hematology San Diego, California, USA December 5-9, 1997 The American Society of Hematology . ISSN: 0006-4971.
 DT Conference
 LA English
 CC Blood, Blood-Forming Organs and Body Fluids - General; Methods

*15001
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Biochemical Studies - Carbohydrates *10068
 Anatomy and Histology, General and Comparative - Regeneration and Transplantation *11107
 Movement *12100
 Pathology, General and Miscellaneous - Therapy *12512
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies *15002
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
 Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Reproductive System - General; Methods *16501
 Reproductive System - Physiology and Biochemistry *16504
 Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods *18001
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology *18006
 Pharmacology - Clinical Pharmacology *22005
 Pharmacology - Blood and Hematopoietic Agents *22008
 Pharmacology - Endocrine System *22016
 Pharmacology - Immunological Processes and Allergy *22018
 Pharmacology - Reproductive System; Implantation Studies *22028
 Neoplasms and Neoplastic Agents - Immunology *24003
 Neoplasms and Neoplastic Agents - Biochemistry *24006
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
 Immunology and Immunochemistry - General; Methods *34502
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals *00520
 BC Hominidae 86215
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Methods and Techniques
 IT Parts, Structures, & Systems of Organisms
 blood: blood and lymphatics; peripheral blood stem cells: blood and lymphatics, subsets; CD34-positive cells: blood and lymphatics, immune system; CD38-positive cells: blood and lymphatics, immune system
 IT Diseases
 breast cancer: neoplastic disease, reproductive system disease/female
 IT Chemicals & Biochemicals
 stem cell factor; G-CSF [filgrastim, granulocyte-colony stimulating factor]
 IT Methods & Equipment
 bone marrow transplantation: therapeutic method, transplantation method
 IT Miscellaneous Descriptors
 cell cycling; cell processing; neutrophil engraftment; peripheral blood stem cell mobilization; platelet engraftment; Meeting
 Abstract; Meeting Poster
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae): patient
 ORGN Organism Superterms
 Animals; Chordates; Humans; Mammals; Primates; Vertebrates
 RN 121181-53-1 (FILGRASTIM)

L124 ANSWER 11 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1998:66747 BIOSIS
 DN PREV199800066747
 TI Reconstitution of humoral, cellular and natural immunity after
 transplantation of autologous hematopoietic progenitor cells to support
 high-dose chemotherapy.
 AU Morgan, M. (1); Mawhinney, S.; Wang, J. K.; Shpall, E. J.; Curiel, T.
 CS (1) Univ. Colorado Health Sciences Cent., Med. Serv., Biometrics Bone
 Marrow Transplant Unit, Denver, CO USA
 SO Blood, (Nov. 15, 1997) Vol. 90, No. 10 SUPPL. 1 PART 1, pp.
 100A.
 Meeting Info.: 39th Annual Meeting of the American Society of
 Hematology San Diego, California, USA December 5-9, 1997 The American
 Society of Hematology
 . ISSN: 0006-4971.
 DT **Conference**
 LA English
 CC Neoplasms and Neoplastic Agents - Immunology *24003
 Anatomy and Histology, General and Comparative - Regeneration and
 Transplantation *11107
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
 *15004
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
 Reticuloendothelial System *15008
 Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Pharmacology - Clinical Pharmacology *22005
 Pharmacology - Blood and Hematopoietic Agents *22008
 Pharmacology - Endocrine System *22016
 Pharmacology - Reproductive System; Implantation Studies *22028
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology
 *34508
 General Biology - Symposia, Transactions and Proceedings of
 Conferences, Congresses, Review Annuals *00520
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - General *10060
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Biochemical Studies - Carbohydrates *10068
 Biochemical Studies - Minerals *10069
 Movement *12100
 Pathology, General and Miscellaneous - Therapy *12512
 Routes of Immunization, Infection and Therapy *22100
 BC Hominidae 86215
 IT Major Concepts
 Oncology (Human Medicine, Medical Sciences); Pharmacology
 IT Parts, Structures, & Systems of Organisms
 autologous hematopoietic progenitor cells: blood and lymphatics,
 cellular immunity reconstitution, transplantation, drug-induced
 mobilization, natural immunity reconstitution, humoral immunity
 reconstitution, high-dose chemotherapy support
 IT Diseases
 breast cancer: drug treatment, reproductive system disease/female,
 neoplastic disease, immunology
 IT Chemicals & Biochemicals
 carmustine: antineoplastic - drug, high-dose administration,
 combination therapy; cisplatin: antineoplastic - drug, combination
 therapy, high-dose administration; cyclophosphamide: antineoplastic -
 drug, combination therapy, high-dose administration; granulocyte
 colony-stimulating factor [Filgrastim]: hematologic - drug;
 stem cell factor [STEMGEN]: hematologic -
 drug
 IT Miscellaneous Descriptors
 Meeting Abstract; Meeting Poster
 ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae): female, patient
 ORGN Organism Superterms
 Animals; Chordates; Humans; Mammals; Primates; Vertebrates
 RN 50-18-0 (CYCLOPHOSPHAMIDE)
 15663-27-1 (CISPLATIN)
 154-93-8 (CARMUSTINE)
 121181-53-1 (FILGRASTIM)

L124 ANSWER 12 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:426598 BIOSIS
 DN PREV199799725801
 TI The effect of SCF, LIF, or Flt3L in combination with IL3 and IL6 on the
 retroviral gene transduction of hematopoietic stem cells.
 AU Tushinski, R.; De Vries, P.; Moon, J.; Polikof, D.; Boehnlein, E.;
 Tsukamoto, A.
 CS SyStemix Inc., Palo Alto, CA USA
 SO Experimental Hematology (Charlottesville), (1997) Vol. 25, No. 8, pp. 890.
 Meeting Info.: 26th Annual Meeting of the International Society for
 Experimental Hematology Cannes, France August 24-28, 1997
 ISSN: 0301-472X.
 DT Conference; Abstract
 LA English
 CC General Biology - Symposia, Transactions and Proceedings of
 Conferences, Congresses, Review Annuals 00520
 Cytology and Cytochemistry - Human *02508
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Nucleic Acids, Purines and Pyrimidines *10062
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Biochemical Studies - Carbohydrates *10068
 Biophysics - Molecular Properties and Macromolecules *10506
 Biophysics - Membrane Phenomena *10508
 Enzymes - Chemical and Physical *10806
 Enzymes - Physiological Studies *10808
 Movement *12100
 Pathology, General and Miscellaneous - Therapy *12512
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Metabolism - Nucleic Acids, Purines and Pyrimidines *13014
 Digestive System - Physiology and Biochemistry *14004
 Digestive System - Pathology *14006
 Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies
 *15002
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
 *15004
 Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and
 Reticuloendothelial Pathologies *15006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
 Reticuloendothelial System *15008
 Reproductive System - Physiology and Biochemistry *16504
 Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Endocrine System - Thymus *17016
 Neoplasms and Neoplastic Agents - Immunology *24003
 Neoplasms and Neoplastic Agents - Biochemistry *24006
 Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms
 *24010
 Developmental Biology - Embryology - General and Descriptive *25502
 Developmental Biology - Embryology - Morphogenesis, General *25508
 Genetics of Bacteria and Viruses *31500
 Microbiological Apparatus, Methods and Media *32000
 In Vitro Studies, Cellular and Subcellular *32600
 Virology - Animal Host Viruses *33506
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology
 *34508

Medical and Clinical Microbiology - Virology *36006

BC Retroviridae 02623

Hominidae *86215

IT Major Concepts

Biochemistry and Molecular Biophysics; **Blood** and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Development; Digestive System (Ingestion and Assimilation); Endocrine System (Chemical Coordination and Homeostasis); Enzymology (Biochemistry and Molecular Biophysics); Gastroenterology (Human Medicine, Medical Sciences); Genetics; Hematology (Human Medicine, Medical Sciences); Infection; Membranes (Cell Biology); Metabolism; Methods and Techniques; Microbiology; Oncology (Human Medicine, Medical Sciences); Pathology; Physiology; Reproductive System (Reproduction)

IT Chemicals & Biochemicals

NEOMYCIN PHOSPHOTRANSFERASE; THYMIDINE KINASE

IT Miscellaneous Descriptors

BLOOD AND LYMPHATIC DISEASE; BLOOD AND LYMPHATICS; BREAST CANCER; CD34-POSITIVE CELL; CELL CULTURE; CELL DIFFERENTIATION; CULTURE METHOD; ENDOCRINE SYSTEM; FETAL LIVER KINASE-2 RECEPTOR LIGAND; FLT3L; GENE THERAPY; GENE THERAPY METHOD; GENE TRANSFER METHOD; HEMATOPOIETIC STEM CELLS; HIV REV PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS REV PROTEIN; IL-3; IL-6; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASE; INTERLEUKIN-3; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LIF; MICROBIOLOGICAL METHOD; MOBILIZED PERIPHERAL BLOOD; MOLECULAR GENETICS; MULTIPLE MYELOMA; MURINE LEUKEMIA VIRUS LONG TERMINAL REPEAT; NEOMYCIN PHOSPHOTRANSFERASE GENE; NEOPLASTIC DISEASE; REPRODUCTIVE SYSTEM DISEASE/FEMALE; RETROVIRAL GENE TRANSDUCTION; SCF; **STEM CELL FACTOR**; THYMIDINE KINASE PROMOTER; VECTOR

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia;

Retroviridae: Viruses

ORGN Organism Name

human (Hominidae); retrovirus (Retroviridae)

ORGN Organism Superterms

animals; chordates; humans; mammals; microorganisms; primates; vertebrates; viruses

RN 62213-36-9 (NEOMYCIN PHOSPHOTRANSFERASE)

9002-06-6 (THYMIDINE KINASE)

L124 ANSWER 13 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1997:144506 BIOSIS

DN PREV199799443709

TI Site-specific requirements for interactions between c-Kit and its ligand during development and growth of TCR gamma-delta T cells.

AU Puddington, L. (1); Lewis, J.; Lefrancois, L. (1); Tigelaar, R.

CS (1) UCONN Health Cent., Farmington, CT USA

SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S242.

Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997

ISSN: 0091-6749.

DT Conference; Abstract

LA English

CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520

Cytology and Cytochemistry - Animal *02506

Biophysics - Molecular Properties and Macromolecules *10506

Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008

Integumentary System - Physiology and Biochemistry *18504

Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Muridae *86375

IT Major Concepts
Biochemistry and Molecular Biophysics; **Blood** and Lymphatics (Transport and Circulation); Cell Biology; Immune **System** (Chemical Coordination and Homeostasis); Integumentary System (**Chemical** Coordination and Homeostasis)

IT Miscellaneous Descriptors
ADULT; ALPHA BETA T CELL RECEPTOR; **BLOOD AND LYMPHATICS**; C-KIT
STEM CELL FACTOR RECEPTOR; DENDRITIC
EPIDERMAL T CELL; DIGESTIVE SYSTEM; ~~GAMMA~~ SIGMA T CELLS; IMMUNE SYSTEM;
INTEGUMENTARY SYSTEM; INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; NEWBORN;
THYMUS

ORGN Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
mouse (Muridae)

ORGN Organism Superterms
animals; chordates; mammals; nonhuman ~~mammals~~; nonhuman vertebrates;
rodents; vertebrates

L124 ANSWER 14 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1997:143939 BIOSIS

DN PREV199799443142

TI Induction of high affinity IgE receptor (Fc-**epsilon**-RI) on human mast cells by IL-4.

AU Toru, H. (1); Ra, C.; Nonoyama, S. (1); Suzuki, K.; Yata, J. (1); Nakahata, T.

CS (1) Tokyo Medical Dental Univ., Tokyo Japan

SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S103.
Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997
ISSN: 0091-6749.

DT **Conference; Abstract**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human *02508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biochemical Studies - Carbohydrates 10068
Biophysics - Molecular Properties and Macromolecules *10506
Biophysics - Membrane Phenomena *10508
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Allergy *35500

BC Hominidae *86215

IT Major Concepts
Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Biochemistry and Molecular Biophysics; **Blood** and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Membranes (Cell Biology)

IT Miscellaneous Descriptors
ALPHA-CHAIN MESSENGER RNA; BIOCHEMISTRY **AND** BIOPHYSICS; FC-EPSILON-RI; HIGH AFFINITY IMMUNOGLOBULIN-E RECEPTOR; **IMMUNE** SYSTEM; IMMUNOGLOBULIN-E-MEDIATED ALLERGIC REACTION; INDUCTION; INTERLEUKIN-4; INTERLEUKIN-6; MAST CELLS; **STEM CELL FACTOR**

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae)

ORGN Organism Superterms

animals; chordates; humans; mammals; primates; vertebrates

- L124 ANSWER 15 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:143906 BIOSIS
 DN PREV199799443109
 TI Murine embryonic yolk sac cells cultured with **stem cell factor** and interleukin-3 yield only unipotential mast cell colonies.
 AU Desimone, S. K.; Klisch, G.; Huff, T. F.
 CS Medical Coll. Virginia Campus/Virginia Commonwealth Univ., Richmond, VA USA
 SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S95.
 Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997
 ISSN: 0091-6749.
 DT Conference; Abstract
 LA English
 CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520
 Cytology and Cytochemistry - Animal *02506
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Reproductive System - Physiology and Biochemistry *16504
 Endocrine System - General *17002
 Developmental Biology - Embryology - General and Descriptive *25502
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Muridae *86375
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology; Development; Endocrine System (Chemical Coordination and Homeostasis); Immune System (Chemical Coordination and Homeostasis); Reproductive System (Reproduction)
 IT Miscellaneous Descriptors
 BLOOD AND LYMPHATICS; BONE MARROW; DEVELOPMENT; EMBRYO; EMBRYONIC STRUCTURE; EMBRYONIC YOLK SAC CELLS; IMMUNE SYSTEM; INTERLEUKIN-3; **STEM CELL FACTOR**; STRAIN-BALB/C; UNIPOTENTIAL MAST CELL COLONIES
 ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 mouse (Muridae)
 ORGN Organism Superterms
 animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates; rodents; vertebrates

- L124 ANSWER 16 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:143901 BIOSIS
 DN PREV199799443104
 TI Recombinant human (rh) GM-CSF, but not rhG-CSF, down-regulates the rhSCF-dependent differentiation of human fetal liver-derived mast cells.
 AU Du, Z.; Li, Y.; Xia, H.-Z.; Irani, A. A.; Schwartz, L. B.
 CS Virginia Commonwealth Univ., Richmond, VA USA
 SO Journal of Allergy and Clinical Immunology, (1997) Vol. 99, No. 1 PART 2, pp. S94.
 Meeting Info.: Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA February 21-26, 1997
 ISSN: 0091-6749.
 DT Conference; Abstract

LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Digestive System - Physiology and Biochemistry *14004
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Hominidae *86215
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Digestive System (Ingestion and Assimilation); Endocrine System (Chemical Coordination and Homeostasis)

IT Miscellaneous Descriptors
 BLOOD AND LYMPHATICS; DEPENDENT DIFFERENTIATION; FETUS; GROWTH FACTORS; IMMUNE SYSTEM; LIVER-DERIVED MAST CELLS; RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN STEM CELL FACTOR

ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 human (Hominidae)

ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 17 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:54804 BIOSIS
 DN PREV199799354007
 TI Engraftment of cultured human hematopoietic cells in sheep.
 AU Shimizu, Y. (1); Kobayashi, M.; Laver, J. H.; Almeida-Porada, G.; Zanjani, E. D.; Ogawa, M.
 CS (1) Dep. Med., Med. Univ. South Carolina, Charleston, SC USA
 SO Blood, (1996) Vol. 88, No. 10 SUPPL. 1 PART 1-2, pp. 456A.
 Meeting Info.: **Thirty-eighth Annual Meeting of the American Society of Hematology** Orlando, Florida, USA December 6-10, 1996
 ISSN: 0006-4971.

DT Conference; Abstract
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Animal *02506
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Biochemical Studies - Carbohydrates *10068
 Anatomy and Histology, General and Comparative - Regeneration and Transplantation *11107
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies *15002
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
 Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Reproductive System - Physiology and Biochemistry *16504
 Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology *18006

Developmental Biology - Embryology - Descriptive Teratology and Teratogenesis *25552
 In Vitro Studies, Cellular and Subcellular *32600
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Bovidae 85715
 Hominidae *86215

IT Major Concepts
 Biochemistry and Molecular Biophysics; **Blood** and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Development; Endocrine System (Chemical Coordination and Homeostasis); Hematology (Human Medicine, Medical Sciences); Metabolism; Physiology; Reproductive System (Reproduction); Skeletal System (Movement and Support)

IT Chemicals & Biochemicals
 ERYTHROPOIETIN

IT Miscellaneous Descriptors
 ADULT; ANALYTICAL METHOD; BLOOD AND LYMPHATICS; BONE MARROW; BONE MARROW TRANSPLANTATION; CD34-POSITIVE C-KIT-LOW CELLS; CD45-POSITIVE CELLS; CELL CULTURE; CELL EXPANSION; CELL PROCESSING; CELL SELECTION; ENGRAFTMENT; ERYTHROPOIETIN; FETUS; FLK2/FLT3 LIGAND; HEMATOPOIETIC CELLS; IL-3; IL-6; IN UTERO TRANSPLANTATION; INTERLEUKIN-3; INTERLEUKIN-6; **STEM CELL FACTOR**

ORGN Super Taxa
 Bovidae: Artiodactyla, Mammalia, Vertebrata, Chordata, Animalia;
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 human (Hominidae); sheep (Bovidae)

ORGN Organism Superterms
 animals; artiodactyls; chordates; humans; mammals; nonhuman mammals; nonhuman vertebrates; primates; vertebrates

RN 11096-26-7 (ERYTHROPOIETIN)

L124 ANSWER 18 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:54530 BIOSIS
 DN PREV199799353733
 TI Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHuSCF (SCF) and r-metHuG-CSF (Filgrastim) in heavily pretreated multiple myeloma (MM) patients.
 AU Tricot, G. (1); Jagannath, S.; Desikan, K. R.; Siegel, D.; Munshi, N.; Olson, E.; Wyres, M.; Parker, W.; Barlogie, B.
 CS (1) Univ. Arkansas Medical Sci., Little Rock, AR USA
 SO Blood, (1996) Vol. 88, No. 10 SUPPL. 1 PART 1-2, pp. 388A.
 Meeting Info.: **Thirty-eighth Annual Meeting of the American Society of Hematology** Orlando, Florida, USA December 6-10, 1996
 ISSN: 0006-4971.

DT **Conference; Abstract; Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human 02508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
 Pathology, General and Miscellaneous - Therapy 12512
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Pharmacology - Clinical Pharmacology *22005
 Pharmacology - Blood and Hematopoietic Agents *22008
 Pharmacology - Immunological Processes and Allergy *22018
 Toxicology - Pharmacological Toxicology *22504

Neoplasms and Neoplastic Agents - Immunology *24003
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
 Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms *24010
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Allergy *35500
 BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pathology; Pharmacology; Toxicology
 IT Chemicals & Biochemicals
 FILGRASTIM; DIPHENHYDRAMINE
 IT Miscellaneous Descriptors
 ANTI-HISTAMINE-DRUG; BLOOD AND LYMPHATIC DISEASE; BLOOD AND LYMPHATICS; DIPHENHYDRAMINE; FILGRASTIM; HEMATOLOGIC-DRUG; HEMATOLOGY; HYPERSENSITIVITY REACTION; IMMUNE SYSTEM DISEASE; MOBILIZATION; MULTIPLE MYELOMA; NEOPLASTIC DISEASE; ONCOLOGY; PATIENT; PERIPHERAL BLOOD PROGENITOR CELL; PHARMACOLOGY; R-METHUG-CSF; R-METHUSCF; RECOMBINANT HUMAN COLONY STIMULATING FACTOR; RECOMBINANT HUMAN
STEM CELL FACTOR
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 RN 121181-53-1 (FILGRASTIM)
 58-73-1 (DIPHENHYDRAMINE)
 L124 ANSWER 19 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1997:53724 BIOSIS
 DN PREV199799352927
 TI Enhancement of donor (human) hematopoietic stem cell (HSC) engraftment in sheep co-transplanted in utero with human IL-3 producing stroma.
 AU Almeida-Porada, G. D. (1); Nolta, J.; Tran, N.; Dao, M. A.; Zanjani, E. D.
 CS (1) VAMC, Univ. Nevada, Reno, NV USA
 SO Blood, (1996) Vol. 88, No. 10 SUPPL. 1 PART 1-2, pp. 186A.
 Meeting Info.: **Thirty-eighth Annual Meeting of the American Society of Hematology** Orlando, Florida, USA December 6-10, 1996
 ISSN: 0006-4971.
 DT **Conference; Abstract; Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Animal *02506
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Biochemical Studies - Carbohydrates *10068
 Anatomy and Histology, General and Comparative - Experimental Anatomy *11104
 Anatomy and Histology, General and Comparative - Surgery *11105
 Anatomy and Histology, General and Comparative - Regeneration and Transplantation *11107
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - General; Methods *15001
 Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies *15002
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004

Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Reproductive System - General; Methods *16501
 Reproductive System - Physiology and Biochemistry *16504
 Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods *18001
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology *18006
 Developmental Biology - Embryology - Experimental *25504
 Developmental Biology - Embryology - Descriptive Teratology and Teratogenesis *25552
 Immunology and Immunochemistry - General; Methods *34502
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Bovidae 85715
 Hominidae *86215

IT Major Concepts
 Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Development; Endocrine System (Chemical Coordination and Homeostasis); Hematology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis); Metabolism; Morphology; Physiology; Reproductive System (Reproduction); Skeletal System (Movement and Support); Surgery (Medical Sciences)

IT Miscellaneous Descriptors
 BLOOD AND LYMPHATICS; BONE MARROW CD34-POSITIVE CELLS; CYTOKINES; DONOR; DONOR HEMATOPOIETIC STEM CELL ENGRAFTMENT; FETUS; GM-CSF; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC MICROENVIRONMENT; HEMATOPOIETIC STEM CELL; HUMAN IL-3; HUMAN IL-3 PRODUCING STROMA; HUMAN IL-3 PRODUCING STROMA TRANSPLANTATION; HUMAN INTERLEUKIN-3; HUMAN/SHEEP XENOGRAFT; IL-6; IN-UTERO COTRANSPLANTATION; INTERLEUKIN-6; METHODOLOGY; PRODUCTION; RECIPIENT; SCF; **STEM CELL FACTOR**; STROMAL CELLS; SURGICAL METHOD

ORGN Super Taxa
 Bovidae: Artiodactyla, Mammalia, Vertebrata, Chordata, Animalia;
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 human (Hominidae); sheep (Bovidae)

ORGN Organism Superterms
 animals; artiodactyls; chordates; humans; mammals; nonhuman mammals; nonhuman vertebrates; primates; vertebrates

L124 ANSWER 20 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1996:550616 BIOSIS

DN PREV199699272972

TI Characterization of keratinocyte- and fibroblast-derived mitogens for human melanocytes: Their roles in stimulated cutaneous pigmentation.

AU Imokawa, Genji (1); Yada, Yukihiro; Morisaki, Naoko; Kimura, Mitsutoshi

CS (1) Inst. Fundamental Res., Kao Corporation, 2602 Akabane, Ichikai-Machi, Haga, Tochigi 321-34 Japan

SO Hori, Y. [Editor]; Hearing, V. J. [Editor]; Nakayama, J. [Editor].

International Congress Series, (1996) No. 1096, pp. 35-48.

International Congress Series; Melanogenesis and malignant melanoma: Biochemistry, cell biology, molecular biology, pathophysiology, diagnosis and treatment.

Publisher: Elsevier Science Publishers B.V. PO Box 211, Sara Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands.

Meeting Info.: **International Symposium on Melanogenesis and Malignant**

Melanoma Fukuoka, Japan December 4-6, 1995

ISSN: 0531-5131. ISBN: 0-444-82209-7.

DT Book; Conference

LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human 02508
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Metabolism - Nucleic Acids, Purines and Pyrimidines *13014
Endocrine System - General *17002
Integumentary System - Physiology and Biochemistry *18504
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**
BC Hominidae *86215
IT Major Concepts
Clinical Immunology (Human Medicine, Medical Sciences); Endocrine
System (Chemical Coordination and Homeostasis); Integumentary System
(Chemical Coordination and Homeostasis); Metabolism
IT Miscellaneous Descriptors
BOOK CHAPTER; DNA SYNTHESIS; ENDOTHELIN-1; EPIDERMAL MELANOSIS;
GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN-1 ALPHA;
MEETING PAPER; STEM CELL FACTOR
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
Hominidae (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 21 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1996:450913 BIOSIS
DN PREV199699173269
TI Amplification of the lymphoid compartments in serum-derived cultures of
human cord blood cells.
AU Sanchez, M. (1); Pascuccio, M.; Barca, A.; Migliaccio, A. R.; Migliaccio,
G.
CS (1) Ist. Superiore Sanita, Rome Italy
SO Experimental Hematology (Charlottesville), (1996) Vol. 24, No. 9, pp.
1099.
Meeting Info.: 25th Annual Meeting of the International Society for
Experimental Hematology New York, New York, USA August 23-27, 1996
ISSN: 0301-472X.
DT **Conference**
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**
Reproductive System - Physiology and Biochemistry *16504
Endocrine System - General *17002
Developmental Biology - Embryology - Morphogenesis, General *25508
Tissue Culture, Apparatus, Methods and Media *32500
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Clinical Immunology
(Human Medicine, Medical Sciences); Development; Endocrine System
(Chemical Coordination and Homeostasis); Methods and Techniques;
Reproductive System (Reproduction)
IT Miscellaneous Descriptors
BLOOD AND LYMPHATICS; CORD BLOOD CELLS; CYTOKINE; INTERLEUKIN-2;
INTERLEUKIN-4; INTERLEUKIN-7; LYMPHOID COMPARTMENT AMPLIFICATION;
**MEETING ABSTRACT; STEM CELL
FACTOR**
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name

human (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 22 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1996:450573 BIOSIS
DN PREV199699172929
TI Ontogeny-related predominance of multipotent lymphomyeloid stem cells in human fetal liver.
AU Zijlmans, J. M. J. M.; Duinkerken, N.; Lim, F. T. H.; Melenhorst, J. J.; Willemze, R.; Fibbe, W. E.
CS Lab. Exp. Hematol., Dep. Hematol., Univ. Med. Cent., Leiden Netherlands
SO Experimental Hematology (Charlottesville), (1996) Vol. 24, No. 9, pp. 1035.
Meeting Info.: 25th Annual Meeting of the International Society for Experimental Hematology New York, New York, USA August 23-27, 1996
ISSN: 0301-472X.
DT Conference
LA English
CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520
Cytology and Cytochemistry - Human *02508
Genetics and Cytogenetics - Human *03508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biochemical Studies - Carbohydrates 10068
Digestive System - Physiology and Biochemistry *14004
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Endocrine System - General *17002
Developmental Biology - Embryology - Morphogenesis, General *25508
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell Biology;
Clinical Immunology (Human Medicine, Medical Sciences); Development;
Digestive System (Ingestion and Assimilation); Endocrine System
(Chemical Coordination and Homeostasis); Genetics
IT Miscellaneous Descriptors
B LYMPHOCYTE; CELL DIFFERENTIATION; HEMATOPOIESIS; HLA; INTERLEUKIN-4;
INTERLEUKIN-7; MEETING ABSTRACT; POLYMERASE CHAIN
REACTION; STEM CELL FACTOR
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
Hominidae (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 23 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1996:300563 BIOSIS
DN PREV199699022919
TI Evidence that stem cell factor (SCF)
modulates neuroimmune interactions: Mast cell (MC) activation by substance
P is influenced by SCF via A G protein-dependent mechanism.
AU Furuta, G. T. (1); Williams, R. E.; Lavigne, J. A.; Galli, S. J.; Wershil, B. K.
CS (1) Combined Program Pediatric GI/Nutrition, Harvard Med. Sch., Boston, MA
USA
SO Gastroenterology, (1996) Vol. 110, No. 4 SUPPL., pp. A911.
Meeting Info.: 96th Annual Meeting of the American
Gastroenterological Association and the Digestive Disease Week San
Francisco, California, USA May 19-22, 1996
ISSN: 0016-5085.

DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Animal *02506
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
Digestive System - Pathology *14006
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Endocrine System - Neuroendocrinology *17020
 Nervous System - Physiology and Biochemistry *20504
 In Vitro Studies, Cellular and Subcellular *32600
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Muridae *86375
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology;
 Digestive System (Ingestion and Assimilation); Endocrine System
 (Chemical Coordination and Homeostasis); Immune System (Chemical
 Coordination and Homeostasis); Nervous System (Neural Coordination);
 Pathology
 IT Chemicals & Biochemicals
 SUBSTANCE P; NEUROKININ A; NEUROKININ B
 IT Miscellaneous Descriptors
 BONE MARROW CELL; **MEETING ABSTRACT**; NEUROKININ A;
 NEUROKININ B; SUBSTANCE P
 ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 mouse (Muridae)
 ORGN Organism Superterms
 animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates;
 rodents; vertebrates
 RN 33507-63-0 (SUBSTANCE P)
 86933-74-6 (NEUROKININ A)
 102577-23-1 (NEUROKININ B)
 L124 ANSWER 24 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1996:145013 BIOSIS
 DN PREV199698717148
 TI Immunolocalization of **stem cell factors** in
 inflamed human nasal tissues.
 AU Kim, Y. K.; Nakagawa, N.; Sulakvelidze, I.; Dolovich, J.; Denburg, J. A.
 CS Hamilton, ON Canada
 SO Journal of Allergy and Clinical Immunology, (1996) Vol. 97, No. 1 PART 3,
 pp. 282.
 Meeting Info.: **Fifty-second Annual Meeting of the American Academy of Allergy Asthma and Immunology** New Orleans, Louisiana, USA March
 15-20, 1996
 ISSN: 0091-6749.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human *02508
 Social Biology; Human Ecology *05500
 Ecology; Environmental Biology - Animal *07508
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Pathology, General and Miscellaneous - Comparative *12503
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008

Respiratory System - Physiology and Biochemistry *16004
 Respiratory System - Pathology *16006
 Endocrine System - General *17002
 Toxicology - General; Methods and Experimental *22501
 Developmental Biology - Embryology - Morphogenesis, General *25508
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 Allergy *35500
 BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences);
 Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Development; Ecology (Environmental Sciences);
 Endocrine System (Chemical Coordination and Homeostasis); Human Ecology (Anthropology); Pathology; Pulmonary Medicine (Human Medicine, Medical Sciences); Respiratory System (Respiration); Toxicology
 IT Miscellaneous Descriptors
 ALLERGIC INFLAMMATORY DISEASE; DIFFERENTIATION; EPITHELIAL CELL; IMMUNOLOGY; MAST CELL PROGENITOR; **MEETING ABSTRACT**;
 NASAL POLYP; PROLIFERATION; SEASONAL RHINITIS
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 L124 ANSWER 25 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1996:145012 BIOSIS
 DN PREV199698717147
 TI Regulation of production of **stem cell factor**
 (SCF) by fibroblasts: Role of serum factors.
 AU Finotto, S.; Horowitz, J.; McLaren, R.; Busse, P. J.; Metcalfe, D. D.
 CS Bethesda, MD USA
 SO Journal of Allergy and Clinical Immunology, (1996) Vol. 97, No. 1 PART 3, pp. 281.
 Meeting Info.: **Fifty-second Annual Meeting of the American Academy of Allergy Asthma and Immunology** New Orleans, Louisiana, USA March 15-20, 1996
 ISSN: 0091-6749.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Biochemical Studies - Nucleic Acids, Purines and Pyrimidines *10062
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Blood, Blood-Forming Organs and Body Fluids - Blood and Lymph Studies *15002
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Integumentary System - Physiology and Biochemistry *18504
 Developmental Biology - Embryology - Morphogenesis, General *25508
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 Allergy *35500
 BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences);
 Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Development; Endocrine System (Chemical Coordination and Homeostasis); Integumentary System (Chemical Coordination and

Homeostasis)
 IT Miscellaneous Descriptors
 ALLERGY; HEMATOPOIETIC GROWTH FACTOR; IMMUNOLOGY; ISOFORM; MAST CELL
 GROWTH FACTOR; **MEETING ABSTRACT**; MESSENGER RNA;
 SKIN
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 26 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1996:144931 BIOSIS
 DN PREV199698717066
 TI Histamine release from human skin mast cells by monocyte chemoattractant
 factor: 1. RANTES, macrophage inflammatory protein - 1-alpha, and
stem cell factor using microdialysis
 technique.
 AU Petersen, L. J.; Brasso, K.; Pryds, M.; Skov, P. S.
 CS Copenhagen Denmark
 SO Journal of Allergy and Clinical Immunology, (1996) Vol. 97, No. 1 PART 3,
 pp. 261.
 Meeting Info.: **Fifty-second Annual Meeting of the American Academy of**
Allergy Asthma and Immunology New Orleans, Louisiana, USA March
 15-20, 1996
 ISSN: 0091-6749.

DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of**
Conferences, Congresses, Review Annuals 00520
 Cytology and Cytochemistry - Animal *02506
 Cytology and Cytochemistry - Human *02508
 Clinical Biochemistry; General Methods and Applications *10006
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Metabolism - Proteins, Peptides and Amino Acids *13012
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and
 Biochemistry *18004
Integumentary System - Physiology and Biochemistry *18504
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
Allergy *35500

BC Hominidae 86215
 Muridae *86375
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood
 and Lymphatics (Transport and Circulation); Cell Biology; Clinical
 Chemistry (Allied Medical Sciences); Clinical Immunology (Human
 Medicine, Medical Sciences); Integumentary System (Chemical
 Coordination and Homeostasis); Metabolism; Skeletal System (Movement
 and Support)

IT Chemicals & Biochemicals
 HISTAMINE
 IT Miscellaneous Descriptors
 BASOPHILS; CHEMOKINES; **MEETING ABSTRACT**
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:
 Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 mouse (Muridae); rat (Muridae); Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; nonhuman mammals; nonhuman
 vertebrates; primates; rodents; vertebrates

RN 51-45-6 (HISTAMINE)

L124 ANSWER 27 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1996:48637 BIOSIS

DN PREV199698620772

TI Comparison of retroviral transduction conditions for gene marking of adult peripheral blood or marrow-derived CD34+ cells in a clinical trial.

AU Emmons, R. V. B. (1); Doren, S.; Hines, K.; Carter, C. S.; Cottler-Fox, M.; O'Shaughnessy, J. A.; Leitman, S. F.; Cowan, K.; Dunbar, C. E.

CS (1) Hematology Branch, NHLBI, Med. Branch, NCI, Bethesda, MD USA

SO Blood, (1995) Vol. 86, No. 10 SUPPL. 1, pp. 238A.

Meeting Info.: **37th Annual Meeting of the American Society of Hematology** Seattle, Washington, USA December 1-5, 1995
ISSN: 0006-4971.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**

Genetics and Cytogenetics - Human *03508

Biochemical Studies - Proteins, Peptides and Amino Acids 10064

Anatomy and Histology, General and Comparative - Regeneration and Transplantation *11107

Pathology, General and Miscellaneous - Therapy *12512

Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004

Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006

Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008

Reproductive System - Pathology *16506

Endocrine System - General *17002

Pharmacology - Blood and Hematopoietic Agents *22008

Pharmacology - Reproductive System; Implantation Studies *22028

Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008

Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms *24010

Genetics of Bacteria and Viruses *31500

Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Retroviridae 02623

Hominidae *86215

IT Major Concepts

Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Genetics; Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pathology; Pharmacology; Physiology; Reproductive System (Reproduction)

IT Miscellaneous Descriptors

AUTOLOGOUS TRANSPLANTATION; BREAST CANCER; HIGH-DOSE CHEMOTHERAPY;

INTERLEUKIN-3; INTERLEUKIN-6; **MEETING ABSTRACT;**

MEETING POSTER; MULTIPLE MYELOMA; STEM

CELL FACTOR

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia;

Retroviridae: Viruses

ORGN Organism Name

human (Hominidae); Retroviridae (Retroviridae)

ORGN Organism Superterms

animals; chordates; humans; mammals; microorganisms; primates; vertebrates; viruses

L124 ANSWER 28 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1995:518577 BIOSIS

DN PREV199598532877

TI In lethally irradiated mice interleukin-12 protects bone marrow but sensitizes intestinal tract to damage from ionizing radiation.

AU Neta, R.; Stiefel, S. M.; Ali, N.

CS Dep. Experimental Hematol., Armed Forces Radiobiol. Res. Inst., Bethesda,
MD 20889-5603 USA

SO Mackiewicz, A. [Editor]; Koj, A. [Editor]; Sehgal, P. B. [Editor]. Annals
of the New York Academy of Sciences, (1995) Vol. 762, pp. 274-281. Annals
of the New York Academy of Sciences; Interleukin-6-type cytokines.
Publisher: New York Academy of Sciences 2 East 63rd Street, New York, New
York 10021, USA.
Meeting Info.: **Conference** Poznan, Poland June 19-22, 1994
ISSN: 0077-8923. ISBN: 0-89766-932-0 (paper), 0-89766-931-2 (cloth).

DT Book; **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Animal 02506
Radiation - Radiation Effects and Protective Measures *06506
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biophysics - General Biophysical Techniques 10504
Digestive System - Pathology *14006
**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**
Endocrine System - General *17002
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**

BC Muridae *86375

IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Digestive System
(Ingestion and Assimilation); Endocrine System (Chemical Coordination
and Homeostasis); Immune System (Chemical Coordination and
Homeostasis); Radiation Biology

IT Miscellaneous Descriptors
BOOK CHAPTER; **MEETING PAPER**; **RADIOPROTECTION**; **STEM
CELL FACTOR**

ORGN Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
Muridae (Muridae)

ORGN Organism Superterms
animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals;
rodents; vertebrates

L124 ANSWER 29 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1995:423965 BIOSIS

DN PREV199598438265

TI A feasibility study of ex vivo expansion of CD34 positive peripheral blood
progenitor cells (PBPC) on a clinical scale.

AU Holyoake, T. L. (1); Alcorn, M. J. (1); Richmond, L. (1); Pearson, C. (1);
Farrell, E. (1); Kyle, B.; Dunlop, D. J. (1); Fitzsimons, E.; Pragnell, I.
B.; Franklin, I. M. (1)

CS (1) Glasgow Royal Infirmary, Glasgow UK

SO Experimental Hematology (Charlottesville), (1995) Vol. 23, No. 8, pp. 760.
Meeting Info.: **24th Annual Meeting of the International Society for
Experimental Hematology** Duesseldorf, Germany August 27-31, 1995
ISSN: 0301-472X.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Anatomy and Histology, General and Comparative - Regeneration and
Transplantation *11107
**Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
*15004**
**Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and
Reticuloendothelial Pathologies *15006**
**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**

Reproductive System - Pathology *16506
 Endocrine System - General *17002
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
 Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms *24010
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Hominidae *86215
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Physiology; Reproductive System (Reproduction)
 IT Chemicals & Biochemicals
 ERYTHROPOIETIN
 IT Miscellaneous Descriptors
 BREAST CANCER; ERYTHROPOIETIN; INTERLEUKINS; LYMPHOMA; **MEETING ABSTRACT; MEETING POSTER; MULTIPLE MYELOMA; MYELOSUPPRESSION; STEM CELL FACTOR; TRANSPLANTATION**
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 RN 11096-26-7 (ERYTHROPOIETIN)

 L124 ANSWER 30 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1995:421590 BIOSIS
 DN PREV199598435890
 TI Human keratinocytes release mast cell differentiation factors other than **stem cell factor**.
 AU Welker, Pia (1); Grabbe, Juergen; Czarnetzki, Beate M.
 CS (1) Freie Univ. Berlin, Rudolf Virchow Clin. Dermatol., Augustenburger-Platz 1, D-13344 Berlin Germany
 SO International Archives of Allergy and Immunology, (1995) Vol. 107, No. 1-3, pp. 139-141.
 Meeting Info.: **20th Symposium of the Collegium Internationale Allergologicum on Molecular and Clinical Implications for Allergy in the 21st Century** Nantucket, Massachusetts, USA September 25-29, 1994
 ISSN: 1018-2438.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human *02508
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Enzymes - Physiological Studies *10808
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies 15004
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Anatomy *18002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
 Integumentary System - Anatomy *18502
 Integumentary System - Physiology and Biochemistry *18504
 Developmental Biology - Embryology - Morphogenesis, General *25508

Tissue Culture, Apparatus, Methods and Media 32500
 Immunology and Immunochemistry - General; Methods *34502
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**

BC Hominidae *86215

IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology;
 Clinical Immunology (Human Medicine, Medical Sciences); Development;
 Enzymology (Biochemistry and Molecular Biophysics); Genetics; Immune
 System (Chemical Coordination and Homeostasis); Integumentary System
 (Chemical Coordination and Homeostasis); Metabolism; Pathology;
 Skeletal System (Movement and Support)

IT Chemicals & Biochemicals
 HISTAMINE; TRYPTASE

IT Miscellaneous Descriptors
 FIBROBLAST; HISTAMINE; HUMAN HACAT KERATINOCYTE CELL LINE; HUMAN HMC-1
 MAST CELL LINE; **MEETING ABSTRACT; MEETING**
 PAPER; TRYPTASE

ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 Hominidae (Hominidae)

ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

RN 51-45-6 (HISTAMINE)
 97501-93-4 (TRYPTASE)

L124 ANSWER 31 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1995:421562 BIOSIS

DN PREV199598435862

TI Regulation of mouse and human mast cell development, survival and function
 by **stem cell factor**, the ligand for the
 c-kit receptor.

AU Galli, Stephen J. (1); Tsai, Mindy; Wershil, Barry K.; Tam, See-Ying;
 Costa, John J.

CS (1) Dep. Pathol., Beth Isr. Hosp., 330 Brookline Ave., Boston, MA 02215
 USA

SO International Archives of Allergy and Immunology, (1995) Vol. 107, No.
 1-3, pp. 51-53.
 Meeting Info.: **20th Symposium of the Collegium Internationale**
Allergologicum on Molecular and Clinical Implications for Allergy in the
21st Century Nantucket, Massachusetts, USA September 25-29, 1994
 ISSN: 1018-2438.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of**
Conferences, Congresses, Review Annuals 00520
 Cytology and Cytochemistry - Animal *02506
 Cytology and Cytochemistry - Human *02508
 Genetics and Cytogenetics - Animal *03506
 Genetics and Cytogenetics - Human *03508
 Biochemical Methods - Proteins, Peptides and Amino Acids *10054
 Biochemical Methods - Carbohydrates *10058
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Replication, Transcription, Translation *10300
 Pathology, General and Miscellaneous - Inflammation and Inflammatory
 Disease *12508
 Pathology, General and Miscellaneous - Necrosis *12510
 Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Anatomy *18002

Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
Allergy *35500

BC Hominidae 86215
Muridae *86375

IT Major Concepts
Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Genetics; Metabolism; Methods and Techniques; Molecular Genetics (Biochemistry and Molecular Biophysics); Pathology; Skeletal System (Movement and Support)

IT Miscellaneous Descriptors
ALLERGY; ANAPHYLAXIS; APOPTOSIS; BCL-2; C-KIT; IMMUNOGLOBULIN E ANTIBODY; MAST CELL-DEFICIENT MOUSE; MASTOCYTOSIS; **MEETING ABSTRACT; MEETING PAPER; PATHOGENESIS; PROTO-ONCOGENES**

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
Hominidae (Hominidae); Muridae (Muridae)

ORGN Organism Superterms
animals; chordates; humans; mammals; nonhuman mammals; nonhuman vertebrates; primates; rodents; vertebrates

L124 ANSWER 32 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1995:380847 BIOSIS
DN PREV199598395147
TI The role of **stem cell factor** (C-kit ligand) and inflammatory cytokines in pulmonary mast cell activation.
AU Lukacs, N. W. (1); Kunkel, S. L. (1); Evanoff, H. (1); Strieter, R. M.; Key, M. L.; Kunkel, R. G. (1); Taub, D. D.
CS (1) Univ. Michigan Med. Sch., Dep. Pathol., NCI-FCRDC, Fredrick, MD USA
SO 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY.. (1995) pp. 40. The 9th International **Congress** of Immunology.
Publisher: 9th International **Congress** of Immunology San Francisco, California, USA.
Meeting Info.: **Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies** San Francisco, California, USA July 23-29, 1995

DT **Conference**
LA English
CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Animal *02506
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biochemical Studies - Carbohydrates 10068
Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Respiratory System - Physiology and Biochemistry *16004
Respiratory System - Pathology *16006
Endocrine System - General *17002
Developmental Biology - Embryology - Morphogenesis, General *25508
In Vitro Studies, Cellular and Subcellular *32600
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Allergy *35500

BC Muridae *86375

IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell Biology; Development; Endocrine System (Chemical Coordination and Homeostasis); Immune System (Chemical Coordination and Homeostasis); Pathology; Respiratory System (Respiration)

IT Miscellaneous Descriptors

ALLERGIC AIRWAY RESPONSE; INTERFERON-ALPHA; INTERLEUKIN-10;
INTERLEUKIN-3; INTERLEUKIN-4; MAST CELL PROLIFERATION; **MEETING**

ABSTRACT

ORGN Super Taxa

Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

mouse (Muridae)

ORGN Organism Superterms

animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates;
rodents; vertebrates

L124 ANSWER 33 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1995:197839 BIOSIS

DN PREV199598212139

TI Identification and immunotyping of committed non-granulated mast cell precursors in the peripheral blood of a patient with aggressive systemic mastocytosis.

AU Castells, M. (1); Friend, D.; Bunnell, C.; Austen, K. F.

CS (1) Brigham and Women's Hosp., Boston, MA 02115 USA

SO FASEB Journal, (1995) Vol. 9, No. 4, pp. A1047.

Meeting Info.: Experimental Biology 95, Part II Atlanta, Georgia, USA

April 9-13, 1995

ISSN: 0892-6638.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**

Cytology and Cytochemistry - Human *02508

Biochemical Studies - Proteins, Peptides and Amino Acids 10064

Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and

Reticuloendothelial Pathologies *15006

Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and

Reticuloendothelial System *15008

Endocrine System - General *17002

Immunology and Immunochemistry - General; Methods *34502

Immunology and Immunochemistry - Immunopathology, Tissue Immunology

***34508**

Allergy *35500

BC Hominidae *86215

IT Major Concepts

Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Hematology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis)

IT Miscellaneous Descriptors

BONE MARROW; DIFFERENTIATION; MATURATION; **MEETING**

ABSTRACT; STEM CELL FACTOR

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

human (Hominidae)

ORGN Organism Superterms

animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 34 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1995:196426 BIOSIS

DN PREV199598210726

TI Role of c-kit ligand in allergic airway eosinophilia.

AU Lukacs, N. W. (1); Strieter, R. M.; Lincoln, P.; Kunkel, S. L.

CS (1) Univ. Mich. Med. Sch., Dep. Pathol., Div. Pulmonary Critical Care Med., Ann Arbor, MI USA

SO FASEB Journal, (1995) Vol. 9, No. 4, pp. A803.

Meeting Info.: Experimental Biology 95, Part II Atlanta, Georgia, USA

April 9-13, 1995

ISSN: 0892-6638.

DT **Conference**
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human 02508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Pathology, General and Miscellaneous - Inflammation and Inflammatory
Disease *12508
**Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
*15004**
**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**
Respiratory System - Pathology *16006
Endocrine System - General *17002
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**
Allergy *35500
BC Hominidae *86215
IT Major Concepts
Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood
and Lymphatics (Transport and Circulation); Clinical Immunology (Human
Medicine, Medical Sciences); Endocrine System (Chemical Coordination
and Homeostasis); Pathology; Pulmonary Medicine (Human Medicine,
Medical Sciences)
IT Miscellaneous Descriptors
INFLAMMATION; MEETING ABSTRACT; PULMONARY DISEASE;
STEM CELL FACTOR
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 35 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1995:194729 BIOSIS
DN PREV199598209029
TI Pulmonary mast cell-derived chemokines.
AU Kunkel, R. G. (1); Strieter, R. M.; Kunkel, S. L. (1); Evanoff, H. L. (1);
Lukacs, N. W. (1)
CS (1) Univ. Mich. Med. Sch., Dep. Pathol., Ann Arbor, MI USA
SO FASEB Journal, (1995) Vol. 9, No. 3, pp. A511.
Meeting Info.: Experimental Biology 95, Part I Atlanta, Georgia, USA April
9-13, 1995
ISSN: 0892-6638.
DT **Conference**
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human *02508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Pathology, General and Miscellaneous - Inflammation and Inflammatory
Disease *12508
**Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
*15004**
Respiratory System - Physiology and Biochemistry *16004
Endocrine System - General *17002
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**
Allergy *35500
BC Muridae *86375
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell Biology;
Endocrine System (Chemical Coordination and Homeostasis); Immune System
(Chemical Coordination and Homeostasis); Pathology; Respiratory System

(Respiration)

IT Miscellaneous Descriptors
ALLERGEN SPECIFIC DEGRANULATION; INFLAMMATION; INTERLEUKIN-3;
**MEETING ABSTRACT; STEM CELL
FACTOR**

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:
Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae); Muridae (Muridae)

ORGN Organism Superterms
animals; chordates; humans; mammals; nonhuman mammals; nonhuman
vertebrates; primates; rodents; vertebrates

L124 ANSWER 36 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1995:190180 BIOSIS
DN PREV199598204480
TI Interactions between c-kit and **stem cell
factor** are required for intestinal immune system homeostasis.
AU Puddington, Lynn; Olson, Sara; Lefrancois, Leo
CS Univ. Conn. Health Center, Farmington, CT 06030 USA
SO Journal of Cellular Biochemistry Supplement, (1995) Vol. 0, No. 19A, pp.
250.
Meeting Info.: **Keystone Symposium on Mucosal Immunity: New Strategies
for Protection Against Viral and Bacterial Pathogens** Keystone,
Colorado, USA January 16-23, 1995
ISSN: 0733-1959.

DT **Conference**
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human *02508
Genetics and Cytogenetics - Animal *03506
Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Replication, Transcription, Translation *10300
Pathology, General and Miscellaneous - Inflammation and Inflammatory
Disease *12508
Metabolism - Proteins, Peptides and Amino Acids *13012
Digestive System - Pathology *14006
**Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
*15004**
**Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008**
**Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508**

BC Muridae *86375

IT Major Concepts
Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport
and Circulation); Cell Biology; Digestive System (Ingestion and
Assimilation); Genetics; Immune System (Chemical Coordination and
Homeostasis); Metabolism; Molecular Genetics (Biochemistry and
Molecular Biophysics); Pathology

IT Miscellaneous Descriptors
CD4-POSITIVE; CD8-POSITIVE; DEVELOPMENT; INTRAEPITHELIAL LYMPHOCYTES;
MEETING ABSTRACT; MEETING POSTER;
MUCOSAL IMMUNE RESPONSE

ORGN Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
mice (Muridae)

ORGN Organism Superterms
animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates;
rodents; vertebrates

L124 ANSWER 37 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1995:143356 BIOSIS

DN PREV199598157656
 TI Human nasal polyp fibroblasts produce **stem cell factor** (SCF).
 AU Nakagawa, N.; Howie, K.; Switzer, J.; Marshall, J.; Denburg, J. A.
 CS Hamilton, ON Canada
 SO Journal of Allergy and Clinical Immunology, (1995) Vol. 95, No. 1 PART 2, pp. 292.
 Meeting Info.: **Fifty-first Annual Meeting of the American Academy of Allergy and Immunology** New York, New York, USA February 24-March 1, 1995
 ISSN: 0091-6749.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human *02508
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System 15008
 Respiratory System - Pathology *16006
 Endocrine System - General *17002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
 Tissue Culture, Apparatus, Methods and Media 32500
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 Allergy *35500
 BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Genetics; Metabolism; Pathology; Pulmonary Medicine (Human Medicine, Medical Sciences); Skeletal System (Movement and Support)
 IT Miscellaneous Descriptors
 ALLERGIC AIRWAY DISEASE; C-KIT GENE EXPRESSION; INFLAMMATION; MAST CELL ACTIVATION; **MEETING ABSTRACT**
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 L124 ANSWER 38 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1995:47052 BIOSIS
 DN PREV199598061352
 TI Effect of c-kit ligand on human intestinal **mast** cells.
 AU Schwengberg, S. (1); Bischoff, S. C. (1); Wordelmann, K. (1); Raab, H. R.; Dralle, H.; Meyer, H. J.; Manns, M. P. (1)
 CS (1) Dep. Gastroenterol., Hannover Med. Sch., Hannover Germany
 SO Immunobiology, (1994) Vol. 191, No. 2-3, pp. 190.
 Meeting Info.: **XXVth Meeting of the Society of Immunology** Konstanz, Germany September 21-24, 1994
 ISSN: 0171-2985.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Anatomy and Histology, General and Comparative - Regeneration and

Transplantation *11107
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
Digestive System - Physiology and Biochemistry *14004
 Endocrine System - General *17002
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Allergy *35500
 BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Cell Biology; Clinical Immunology (Human Medicine, Medical Sciences); Digestive System (Ingestion and Assimilation); Endocrine System (Chemical Coordination and Homeostasis); Pathology; Physiology
 IT Miscellaneous Descriptors
 ALLERGIC REACTION; INFLAMMATION; **MEETING ABSTRACT;**
 REGENERATION; **STEM CELL FACTOR**
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 39 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1994:328471 BIOSIS
 DN PREV199497341471
 TI Topical tretinoin increases dermal mast cells and induces **stem cell factor** in hairless mice.
 AU Kligman, Lorraine H.; Murphy, George F.
 CS Dep. Dermatol., Univ. Pennsylvania, Philadelphia, PA USA
 SO Journal of Investigative Dermatology, (1994) Vol. 102, No. 4, pp. 612.
 Meeting Info.: **Annual Meeting of the Society for Investigative Dermatology** Baltimore, Maryland, USA April 27-30, 1994
 ISSN: 0022-202X.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Animal *02506
 Biochemical Studies - Vitamins 10063
 Biochemical Studies - Lipids 10066
 Pathology, General and Miscellaneous - Therapy *12512
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
 Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Integumentary System - General; Methods *18501
 Integumentary System - Pathology *18506
 Pharmacology - Clinical Pharmacology 22005
 Pharmacology - Integumentary System, Dental and Oral Biology *22020
 Routes of Immunization, Infection and Therapy *22100
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Muridae *86375
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology; Immune System (Chemical Coordination and Homeostasis); Integumentary System (Chemical Coordination and Homeostasis); **Methods and Techniques;**
 Pathology; Pharmacology
 IT Chemicals & Biochemicals
 TRETINOIN
 IT Miscellaneous Descriptors
 DERMATOLOGICAL-DRUG; **MEETING ABSTRACT;**

MEETING POSTER; PHARMACODYNAMICS; TRETINOIN

ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Muridae (Muridae)
 ORGN Organism Superterms
 animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals;
 rodents; vertebrates
 RN 302-79-4 (TRETINOIN)

L124 ANSWER 40 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1994:150493 BIOSIS
 DN PREV199497163493
 TI Recombinant human **stem cell factor** (rhSCF)
 induces cutaneous mast cell activation and hyperplasia, and
 hyperpigmentation in humans in vivo.
 AU Costa, J. J.; Demetri, G. D.; Harrist, T. J.; Dvorak, A. M.; Hayes, D. F.;
 Merica, E. A.; Menchaca, D. M.; Gringeri, A. J.; Galli, S. J.
 CS Boston, MA USA
 SO Journal of Allergy and Clinical Immunology, (1994) Vol. 93, No. 1 PART 2,
 pp. 225.
 Meeting Info.: **Fiftieth Annual Meeting of the American Academy of**
 Allergy and Immunology Anaheim, California, USA March 4-9, 1994
 ISSN: 0091-6749.
 DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of**
 Conferences, Congresses, Review Annuals 00520
 Cytology and Cytochemistry - Human *02508
 Biochemical Studies - Proteins, Peptides and Amino Acids *10064
 Pathology, General and Miscellaneous - Inflammation and Inflammatory
 Disease *12508
 Endocrine System - General *17002
 Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods
 *18001
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology
 ***34508**
 Allergy *35500
 BC Diptera 75314
 Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences);
 Biochemistry and Molecular Biophysics; Cell Biology; Clinical
 Immunology (Human Medicine, Medical Sciences); Endocrine System
 (Cheical Coordination and Homeostasis); Pathology; Skeletal System
 (Movement and Support)
 IT Miscellaneous Descriptors
 ALLERGY; MEETING ABSTRACT
 ORGN Super Taxa
 Diptera: Insecta, Arthropoda, Invertebrata, Animalia; Hominidae:
 Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae); Diptera (Diptera)
 ORGN Organism Superterms
 animals; arthropods; chordates; humans; insects; invertebrates;
 mammals; primates; vertebrates

L124 ANSWER 41 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1994:93764 BIOSIS
 DN PREV199497106764
 TI A novel mutation affecting the second immunoglobulin-like domain of the
 human kit receptor.
 AU Fleischman, R. A.
 CS Markey Cancer Cent. and VA Hosp., Univ. Kentucky Med. Cent., Lexington, KY
 USA
 SO Blood, (1993) Vol. 82, No. 10 SUPPL. 1, pp. 231A.

Meeting Info.: **Thirty-fifth Annual Meeting of the American Society of Hematology** St. Louis, Missouri, USA December 3-7, 1993
ISSN: 0006-4971.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
Genetics and Cytogenetics - Human *03508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biophysics - Molecular Properties and Macromolecules *10506
Biophysics - Membrane Phenomena *10508
Enzymes - Physiological Studies *10808
Metabolism - Proteins, Peptides and Amino Acids *13012
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Endocrine System - General *17002
Integumentary System - Pathology *18506
Developmental Biology - Embryology - Morphogenesis, General *25508
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Hominidae *86215

IT Major Concepts
Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Dermatology (Human Medicine, Medical Sciences); Development; Endocrine System (Chemical Coordination and Homeostasis); Enzymology (Biochemistry and Molecular Biophysics); Genetics; Membranes (Cell Biology); Metabolism

IT Chemicals & Biochemicals
TYROSINE KINASE

IT Miscellaneous Descriptors
ADHESION; HEMATOPOIETIC GROWTH FACTOR; LIGAND BINDING; **MEETING ABSTRACT; MEETING POSTER; PIEBALDISM;**
RECEPTOR DIMERIZATION; **STEM CELL FACTOR**
BINDING; TYROSINE KINASE

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae)

ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

RN 80449-02-1 (TYROSINE KINASE)

L124 ANSWER 42 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1993:334146 BIOSIS

DN PREV199345028871

TI Effects of chronic treatment with the c-kit ligand, **stem cell factor**, on IgE-dependent anaphylaxis in mice:
Genetically mast cell-deficient Sl/Sl-d mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses.

AU Ando, A. (1); Martin, T. R.; Galli, S. J.

CS (1) Dep. Pathol., Beth Israel Hosp., Harvard Med. Sch., Boston, MA 02215
USA

SO Journal of Immunology, (1993) Vol. 150, No. 8 PART 2, pp. 178A.

Meeting Info.: **Joint Meeting of the American Association of Immunologists and the Clinical Immunology Society** Denver, Colorado, USA May 21-25, 1993
ISSN: 0022-1767.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Animal *02506

Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Pharmacology - Immunological Processes and Allergy *22018
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Allergy *35500
 BC Muridae *86375
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Cell Biology;
 Genetics; Immune System (Chemical Coordination and Homeostasis);
 Pharmacology
 IT Miscellaneous Descriptors
 ABSTRACT; IMMUNOGLOBULIN E; IMMUNOLOGIC-DRUG
 ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Muridae (Muridae)
 ORGN Organism Superterms
 animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals;
 rodents; vertebrates

 L124 ANSWER 43 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1993:201090 BIOSIS
 DN PREV199344097340
 TI Modulation of human lung mast cell function by the c-kit receptor ligand.
 AU De Paulis, Amato; Ciccarelli, Anna; Cirillo, Raffaele; De Crescenzo,
 Gennaro; Columbo, Michele; Marone, Gianni
 CS Cattedra Immunol. Clin. Allergol., II Fac. Med. Chirurgia, Univ. Napoli
 Federico II, Via S. Pansini 5, I-80131 Naples Italy
 SO International Archives of Allergy and Immunology, (1992) Vol. 99, No. 2-4,
 pp. 326-329.
 Meeting Info.: 19th CIA (Collegium Internationale Allergologicum)
 Symposium on Chemical Mediators and Cellular Interactions in Clinical Immunology Capri, Italy May 3-7, 1992
 ISSN: 1018-2438.
 DT Article
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human 02508
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Lipids 10066
 Biophysics - Membrane Phenomena 10508
 Enzymes - Physiological Studies *10808
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Respiratory System - Physiology and Biochemistry *16004
 Endocrine System - General *17002
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Hominidae *86215
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Enzymology (Biochemistry and Molecular Biophysics); Genetics; Respiratory System (Respiration)
 IT Chemicals & Biochemicals
 TYROSINE KINASE; HISTAMINE; PROSTAGLANDIN D2; LEUKOTRIENE C4
 IT Miscellaneous Descriptors
 HISTAMINE; LEUKOTRIENE C4; PROSTAGLANDIN D2; PROTO-ONCOGENE;
 STEM CELL FACTOR; TYROSINE KINASE
 ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 RN 80449-02-1 (TYROSINE KINASE)
 51-45-6 (HISTAMINE)
 41598-07-6 (PROSTAGLANDIN D2)
 72025-60-6 (LEUKOTRIENE C4)

L124 ANSWER 44 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1993:201089 BIOSIS
 DN PREV199344097339
 TI Effect of recombinant human c-kit receptor ligand on mediator release from human skin mast cells.
 AU Columbo, Michele (1); Horowitz, Edward M.; Botana, Luis M.; Macglashan., Donald W., Jr.; Bochner, Bruce S.; Gillis, Steven; Zsebo, Krisztina M.; Galli, Stephen J.; Lichtensen, Lawrence M.
 CS (1) Div. Immunol. Clin., Ist. Med. Interna Cardiol. Chirurgia Cardiovasc., II Fac. Med. Chirurgia, Univ. Napoli Federico II, Via S. Pansini 5, I-80131 Naples Italy
 SO International Archives of Allergy and Immunology, (1992) Vol. 99, No. 2-4, pp. 323-325.
 Meeting Info.: 19th CIA (Collegium Internationale Allergologicum) Symposium on Chemical Mediators and Cellular Interactions in Clinical Immunology Capri, Italy May 3-7, 1992
 ISSN: 1018-2438.
 DT Article
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Human 02508
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Lipids 10066
 Biochemical Studies - Minerals 10069
 Metabolism - Minerals *13010
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
Integumentary System - Physiology and Biochemistry *18504
 In Vitro Studies, Cellular and Subcellular 32600
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 BC Hominidae *86215
 IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Genetics; Integumentary System (Chemical Coordination and Homeostasis); Metabolism
 IT Chemicals & Biochemicals
 CALCIUM; HISTAMINE
 IT Miscellaneous Descriptors
 CALCIUM; HISTAMINE; IMMUNOGLOBULIN E; PROSTAGLANDIN D- 2; **STEM CELL FACTOR**
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Hominidae (Hominidae)
 ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
 RN 7440-70-2 (CALCIUM)
 51-45-6 (HISTAMINE)

L124 ANSWER 45 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1993:179863 BIOSIS

DN PREV199344087463
 TI Expression of IL-4 mRNA in human dermal mast cells in response to Fc receptor crosslinkage in the presence of SCF.
 AU Okayama, Y. (1); Quint, D.; Hunt, T. C. (1); El-Lati, S. (1); Heusser, C. H.; Bullock, G.; Mueller, R.; Bradding, P. (1); Howarth, P. (1); et al.
 CS (1) Immunopharmacol. Group, University Southampton UK
 SO Journal of Allergy and Clinical Immunology, (1993) Vol. 91, No. 1 PART 2, pp. 256.
 Meeting Info.: **Forty-ninth Annual Meeting of the American Academy of Allergy and Immunology** Chicago, Illinois, USA March 12-17, 1993
 ISSN: 0091-6749.

DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Genetics and Cytogenetics - Human *03508
 Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Replication, Transcription, Translation *10300
 Pathology, General and Miscellaneous - Inflammation and Inflammatory Disease *12508
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Endocrine System - General *17002
 Integumentary System - Pathology *18506
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
 Allergy *35500

BC Hominidae *86215
 IT Major Concepts
 Allergy (Clinical Immunology, Human Medicine, Medical Sciences); Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Dermatology (Human Medicine, Medical Sciences); Endocrine System (Chemical Coordination and Homeostasis); Genetics; Molecular Genetics (Biochemistry and Molecular Biophysics); Pathology

IT Miscellaneous Descriptors
ABSTRACT; ALLERGY; INFLAMMATION; INTERLEUKIN-4 MESSENGER RNA; PATHOGENESIS; STEM CELL FACTOR

ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 Hominidae (Hominidae)

ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

L124 ANSWER 46 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
 AN 1993:87198 BIOSIS
 DN PREV199344041448
 TI Antigenic heterogeneity and tumor progression in cutaneous malignant melanoma (CMM).
 AU Natali, P. G.; Nicotra, M. R.; Cavaliere, F.; Bigotti, A.
 CS Regina Elena Cancer Inst., Rome Italy
 SO Anticancer Research, (1992) Vol. 12, No. 6A, pp. 1846.
 Meeting Info.: **Fourth International Conference of Anticancer Research** Rethymnon, Crete, Greece October 21-25, 1992
 ISSN: 0250-7005.

DT **Conference**
 LA English
 CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
 Cytology and Cytochemistry - Animal *02506
 Genetics and Cytogenetics - Animal *03506
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biophysics - Molecular Properties and Macromolecules *10506

Biophysics - Membrane Phenomena *10508
Integumentary System - Physiology and Biochemistry *18504
Integumentary System - Pathology *18506
Neoplasms and Neoplastic Agents - Diagnostic Methods *24001
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects *24004
Immunology and Immunochemistry - General; Methods *34502
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Muridae *86375
IT Major Concepts
 Biochemistry and Molecular Biophysics; Cell Biology; Genetics; Immune System (Chemical Coordination and Homeostasis); Integumentary System (Chemical Coordination and Homeostasis); Membranes (Cell Biology); Tumor Biology
IT Chemicals & Biochemicals
 INTEGRIN
IT Miscellaneous Descriptors
 ABSTRACT; C-KIT RECEPTOR-STEM CELL
 FACTOR COMPLEX; CYTOKINE PRODUCTION; IMMUNOPATHOLOGY; INTEGRIN PHENOTYPE; INTERCELLULAR ADHESION MOLECULE-1; LAMININ; TENASCIN

ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
 mouse (Muridae)
ORGN Organism Superterms
 animals; chordates; mammals; nonhuman mammals; nonhuman vertebrates; rodents; vertebrates

RN 153-87-7Q (INTEGRIN)
60791-49-3Q (INTEGRIN)

L124 ANSWER 47 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1992:378921 BIOSIS
DN BR43:45871
TI **STEM CELL FACTOR** MAINTAINS THE VIABILITY AND FUNCTION OF CULTURED RAT PERITONEAL MAST CELLS.
AU WU S V; WEI J Y; HONG L S; WANG Y H; GO V L W
CS DEP. MED., BRI AND CURE/DDC, UCLA, LOS ANGELES, CALIF.
SO DIGESTIVE DISEASE WEEK AND THE 93RD ANNUAL **MEETING** OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION, SAN FRANCISCO, CALIFORNIA, USA, MAY 9-15, 1992. GASTROENTEROLOGY. (1992) 102 (4 PART 2), A766.
CODEN: GASTAB. ISSN: 0016-5085.

DT **Conference**
FS BR; OLD
LA English
CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Animal *02506
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines *10062
Digestive System - Anatomy *14002
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508

BC Muridae 86375
IT Miscellaneous Descriptors
 ABSTRACT DNA SYNTHESIS

L124 ANSWER 48 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1992:378703 BIOSIS
DN BR43:45653
TI BONE MARROW-DERIVED CULTURED MAST CELLS BMCMC GROWN IN **STEM CELL FACTOR** MATURE AND ACQUIRE RESPONSIVENESS TO SUBSTANCE P SP WHICH INDUCES THE CELLS TO RELEASE HISTAMINE AND TUMOR NECROSIS FACTOR-ALPHA TNF-ALPHA.
AU WERSHIL B K; LAVIGNE J A; ZSEBO K M; GALLI S J
CS DEP. PATHOL., BETH ISR. HOSP., BOSTON, MASS., USA.
SO DIGESTIVE DISEASE WEEK AND THE 93RD ANNUAL **MEETING** OF THE

AMERICAN GASTROENTEROLOGICAL ASSOCIATION, SAN FRANCISCO, CALIFORNIA, USA,
MAY 9-15, 1992. GASTROENTEROLOGY. (1992) 102 (4 PART 2), A712.
CODEN: GASTAB. ISSN: 0016-5085.

DT **Conference**
FS BR; OLD
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Animal *02506
Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Digestive System - Pathology *14006
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies
***15004**
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
Bones, Joints, Fasciae, Connective and Adipose Tissue - Anatomy *18002
Nervous System - Physiology and Biochemistry *20504
Immunology and Immunochemistry - General; Methods *34502
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
BC Muridae 86375
IT Miscellaneous Descriptors
ABSTRACT MOUSE CYTOKINE
RN 51-45-6 (HISTAMINE)
33507-63-0 (SUBSTANCE P)

L124 ANSWER 49 OF 49 BIOSIS COPYRIGHT 2000 BIOSIS
AN 1992:203218 BIOSIS
DN BR42:96293
TI RECOMBINANT HUMAN **STEM CELL FACTOR** RHSCF IS
AN ACTIVATOR-MODULATOR OF MEDIATOR RELEASE FROM HUMAN SKIN MAST CELLS.
AU COLUMBO M; HOROWITZ E M; BOTANA L M; MACGLASHAN D W JR; ZSEBO K M; GALL S
J; LICHTENSTEIN L M
CS JOHNS HOPKINS MED. SCH., BALTIMORE, MD.
SO FORTY-EIGHTH ANNUAL **MEETING** OF THE AMERICAN ACADEMY OF ALLERGY
AND IMMUNOLOGY, ORLANDO, FLORIDA, USA, MARCH 6-11, 1992. J ALLERGY CLIN
IMMUNOL. (1992) 89 (1 PART 2), 243.
CODEN: JACIBY. ISSN: 0091-6749.

DT **Conference**
FS BR; OLD
LA English
CC **General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals 00520**
Cytology and Cytochemistry - Human 02508
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Biochemical Studies - Lipids 10066
Biochemical Studies - Minerals 10069
Metabolism - Minerals 13010
Metabolism - Proteins, Peptides and Amino Acids 13012
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
Reticuloendothelial System *15008
Endocrine System - General *17002
Integumentary System - Physiology and Biochemistry *18504
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
***34508**
BC Hominidae 86215
IT Miscellaneous Descriptors
ABSTRACT IMMUNOGLOBULIN E SUBSTANCE P PROSTAGLANDIN D-2
CALCIUM
RN 7440-70-2 (CALCIUM)
33507-63-0 (SUBSTANCE P)
41598-07-6 (PROSTAGLANDIN D-2)

=> fil wpids

FILE 'WPIDS' ENTERED AT 10:43:24 ON 28 JUN 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE LAST UPDATED: 24 JUN 2000 <20000624/UP>
>>>UPDATE WEEKS:
MOST RECENT DERWENT WEEK 200030 <200030/DW>
DERWENT WEEK FOR CHEMICAL CODING: 200030
DERWENT WEEK FOR POLYMER INDEXING: 200030
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS -
SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT ALL 'NEW CONTENT' CHANGES TO
WPIDS, INCLUDING THE DERWENT CHEMISTRY RESOURCE (DCR),
PLEASE VISIT <http://www.derwent.com/newcontent.html> <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/covcodes.html> <<<

=> d his 1127-

(FILE 'BIOSIS' ENTERED AT 10:32:15 ON 28 JUN 2000)

FILE 'WPIDS' ENTERED AT 10:33:48 ON 28 JUN 2000
L127 685 S STEM CELL FACTOR
L128 23 S STEM CELL FACTOR/TI
L129 5 S L128 AND (PREVENT? OR ANTIBOD?)/TI
L130 46 S L127 AND (SIGNAL? OR TRANSDUC?)
L131 0 S L127 AND ACK2
L132 1 S L130 AND CLINICAL/TI
L133 6 S L129,L132

FILE 'WPIDS' ENTERED AT 10:43:24 ON 28 JUN 2000

=> d all abeq tech tot

L133 ANSWER 1 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1999-508554 [42] WPIDS
CR 2000-293134 [25]
DNC C1999-148555
TI Controlling the proliferation and differentiation of stem cells or
progenitor cells, used in **clinical** applications.
DC B04 D16
IN FIBACH, E; FRIEDMAN, M M; PELED, T; TREVES, A
PA (GAMI-N) GAMIDA CELL LTD; (HADA-N) HADASIT MEDICAL RES SERVICES & DEV
CYC 84
PI WO 9940783 A1 19990819 (199942)* EN 60p A01N001-02
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD
GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZW
AU 9926624 A 19990830 (200003) A01N001-02
ADT WO 9940783 A1 WO 1999-US2664 19990208; AU 9926624 A AU 1999-26624 19990208
FDT AU 9926624 A Based on WO 9940783
PRAI US 1998-130367 19980807; US 1998-24195 19980217
IC ICM A01N001-02
ICS A61K035-12; C12N015-85; C12N015-86; C12P019-34
AB WO 9940783 A UPAB: 20000524
NOVELTY - Expanding a population of cells, while at the same time
inhibiting differentiation of the cells by providing the cells with
conditions for cell proliferation and, at the same time, for reducing a

capacity of the cells in utilizing transition metals, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) hemopoietic cells transplantation comprising:
 - (a) obtaining hemopoietic cells to be transplanted from a donor;
 - (b) providing the cells ex vivo with conditions for cell proliferation and, at the same time, for reducing a capacity of the cells in utilizing transition metals to expand a population of the cells, while at the same time, inhibiting differentiation of the cells; and
 - (c) transplanting the cells to a patient;
- (2) **transducing** stem cells with an exogene comprising:
 - (a) obtaining stem cells to be **transduced**;
 - (b) as in (1b), and
 - (c) **transducing** the cells with the exogene;
- (3) adoptive immuno-therapy comprising:
 - (a) obtaining progenitor hematopoietic cells from a patient, and
 - (b) as in (1b) and (1c);
- (4) mobilization of bone marrow stem cells into the peripheral blood of a donor for harvesting the cells comprising:
 - (a) administering to the donor an agent for reducing a capacity of the cells in utilizing transition metals, to expand a population of stem cells, while at the same time, inhibiting differentiation of the stem cells; and
 - (b) harvesting the cells by leukapheresis;
- (5) decelerating maturation/differentiation of erythroid precursor cells for the treatment of beta -hemoglobinopathic patients comprising administering to the patient an agent as in (4a), such that upon natural removal of the agent from the body, the stem cells undergo accelerated maturation resulting in elevated production of fetal hemoglobin;
- (6) a therapeutical ex vivo cultured cell preparation comprising ex vivo cells propagated in presence of an agent as in (4a);
- (7) preservation of stem cells comprising handling the stem cell in at least one of the steps selected from harvesting, isolation and storage, in a presence of a transition metal chelator, and
- (8) stem cells collection bags, separation and washing buffers supplemented with an effective amount or concentration of a transition metal chelator, which inhibits cell differentiation.

USE - The expansion of stem cells and other defined lympho-hemopoietic cell subpopulations by ex-vivo culturing is especially useful in clinical applications.

ADVANTAGE - In order to achieve maximal ex vivo expansion of stem cells the following conditions should be fulfilled:

- (i) differentiation should be reversibly inhibited or delayed, and
- (ii) self-renewal should be maximally prolonged.

The new methods satisfy these requirements.

Dwg.0/17

FS CPI

FA AB; DCN

MC CPI: B04-F02; B04-H02C; B04-H02G; B04-H04A; B05-A03A; B07-D11; B10-B01B; B14-H01; D05-H08; D05-H14B2

TECH UPTX: 19991014

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Methods: The cells are in vivo, and the conditions for cell proliferation are naturally provided, whereas reducing the capacity of the cells in utilizing transition metals is effected by administering a transition metal chelator. Reducing the capacity of the cells in utilizing transition metals is further effected by administering zinc. Alternatively, the cells are ex vivo. Then providing the cells with the conditions for cell proliferation, include providing the cells with nutrients and with cytokines. The **transduction** in (2) is effected by a vector including the exogene. Preferred Cytokines: The cytokines are early acting cytokines selected from **stem cell factor**, FLT3 ligand, interleukin-6, thrombopoietin and interleukin-3. Alternatively, the cytokines are late acting cytokines selected from granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor and erythropoietin.

Preferred Cells: The cells are selected from hematopoietic cells, neural cells and oligodendrocyte cells, skin cells, hepatic cells, muscle cells, bone cells, mesenchymal cells, pancreatic cells, chondrocytes and stroma cells. The cells are derived from a source selected from bone marrow, peripheral blood and neonatal umbilical cord blood. The cells are enriched for hematopoietic CD34+ cells. The cells are selected from non-differentiated stem cells and committed progenitor cells. The donor and the patient are a single individual.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Chelator: The transition metal chelator is selected from polyamine chelating agents, ethylenediamine, diethylenetriamine, triethylenetetramine, triethylenediamine, tetraethylenepentamine (TEPA), aminoethylethanolamine, aminoethylpiperazine, pentaethylenhexamine, triethylenetetramine-hydrochloride, tetraethylenepentamine-hydrochloride, pentaethylenhexamine-hydrochloride, tetraethylpentamine, captopril, penicilamine and transition metal binding peptides.

L133 ANSWER 2 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
 AN 1999-084645 [08] WPIDS
 DNN N1999-061085 DNC C1999-025651
 TI New monoclonal **antibody** specific for bovine derived **stem cell factor** - useful for producing hybridoma and method of bovine derived **stem cell factor** detection.
 DC B04 D16 S03
 PA (NORQ) NORINSUISANSHO KACHIKU EISEI; (NORI-N) ZH NORIN SUISAN SENTAN GIJUTSU SANGYO
 CYC 1
 PI JP 10313860 A 19981202 (199908)* JA 12p C12N015-02
 ADT JP 10313860 A JP 1997-131437 19970521
 PRAI JP 1997-131437 19970521
 IC ICM C12N015-02
 ICS C07K016-24; C12P021-08; G01N033-53; G01N033-577
 ICI C12P021-08, C12R001:91
 AB JP 10313860 A UPAB: 19990302
 New monoclonal antibody specifically reacts to bovine-derived stem cell factor (SCF). Also claimed is a hybridoma producing the above monoclonal antibody.
 USE - The antibody is useful in a method for determining bovine-derived SCF (claimed).
 Dwg.0/8
 FS CPI EPI
 FA AB
 MC CPI: B04-F05; B04-G21; D05-H08; D05-H11A
 EPI: S03-E14H4

L133 ANSWER 3 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
 AN 1997-367060 [34] WPIDS
 DNC C1997-117736
 TI Monoclonal **antibody** to human **stem cell factor** - comprises specifically binding to human **stem cell factor**, useful in diagnosis of blood diseases..
 DC B04 D16
 PA (NCHK) NICHIREI KK
 CYC 1
 PI JP 09154578 A 19970617 (199734)* 5p C12N015-02
 ADT JP 09154578 A JP 1995-335685 19951201
 PRAI JP 1995-335685 19951201
 IC ICM C12N015-02
 ICS C07K016-18; C12N005-10; C12P021-08
 ICI C12N005-10, C12R001:91; C12P021-08, C12R001:
 AB JP 09154578 A UPAB: 19970820
 A monoclonal antibody specifically binding to human stem cell factor is new.
 Also claimed are: a hybridoma capable of producing the monoclonal

antibody; and a process for producing the monoclonal antibody by culturing the hybridoma.

The monoclonal antibody can prevent human stem cell factor from binding to a product of a human c-kit gene. The subclass of the monoclonal antibody is IgG.

USE - Human stem cell factor (SCF) is ligand of c-kit receptor expressed on haematopoietic stem cells and plays an important role in haematopoiesis, and it is of importance for diagnosis of various diseases including blood diseases. The monoclonal antibody of the invention binds specifically to SCF to diagnose such diseases. The monoclonal antibody can further be used as a therapeutic agent for such diseases.

ADVANTAGE - SCF is present in blood in 2 forms i.e. soluble type active SCF (free SCF) and membrane-bound inactive SCF (c-kit bound SCF). Because the monoclonal antibody binds to free SCF but not to c-kit-bound SCF, the antibody can be used to measure only the active SCF or to monitor artificially administered soluble type SCF, as opposed to a conventional measurement method where SCF is detected without distinguishing the 2 forms.

Dwg.0/2

FS CPI

FA AB

MC CPI: B04-F05; B04-G02; B04-G21; B12-K04A2; B14-F03; D05-H11A1; D05-H15

L133 ANSWER 4 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1997-066617 [07] WPIDS

DNN N1997-054751 DNC C1997-021981

TI Monoclonal **antibody** to human **stem cell factor** receptor - for diagnostic and therapeutic use.

DC B04 D16 S03

IN BUEHRING, H

PA (UYTU-N) UNIV TUEBINGEN EBERHARD-KARLS

CYC 12

PI DE 19600589 C1 19970116 (199707)* 9p C07K016-22

EP 787743 A2 19970806 (199736) DE 10p C07K016-28

R: AT BE CH DE ES FR GB IT LI NL SE

EP 787743 A3 19970820 (199745) C07K016-22

US 5808002 A 19980915 (199844) C07K016-28

ADT DE 19600589 C1 DE 1996-19600589 19960110; EP 787743 A2 EP 1996-118320

19961115; EP 787743 A3 EP 1996-118320 19961115; US 5808002 A US

1997-778524 19970103

PRAI DE 1996-19600589 19960110

REP No-SR.Pub; 2.Jnl.Ref; WO 9217505; WO 9221766

IC ICM C07K016-22; C07K016-28

ICS A61K039-395; C12N005-16; C12N005-18; C12N005-20; C12P021-08;

G01N033-53; G01N033-577

AB DE 19600589 C UPAB: 19970212

New monoclonal antibody that binds specifically to human stem cell factor (SCF) receptor is produced by hybridoma cell line A3C6E2 (DSM ACC 2247).

Also claimed are hybridoma cells that produce the antibody.

USE - The antibody is used in compsns. to treat tumours. The antibody can also be used to detect and isolate haematopoietic stem cells, e.g. for gene therapy treatment by retroviral-mediated gene transfer into the haematopoietic cells. The antibody can also be used to inhibit haematopoiesis. The antibodies can be used to inhibit the binding of SCF. The antibody can be used to modify the sensitivity of patients to cell-cycle-specific chemotherapeutic agents (all claimed).

Dwg.0/3

FS CPI EPI

FA AB

MC CPI: B04-F01; B04-F05; B04-G21; B04-K01; B11-C07A7; B12-K04A1; B14-H01A;

D05-H11A1; D05-H15

EPI: S03-E14H4

L133 ANSWER 5 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1993-207031 [26] WPIDS

DNC C1993-091695

TI Stem cell factor binding proteins e.g. Kit-X
 - useful for treating and **preventing** SCF-associated diseases
 e.g. neoplasias, anaemia(s), myeloid leukaemia and glioblastoma.

DC B04 D16
IN GIVOL, D; YARDEN, Y
PA (YEDA) YEDA RES & DEV CO LTD
CYC 8

PI EP 548867 A2 19930630 (199326)* EN 24p C12N015-12
 R: CH DE ES FR GB IT LI NL
EP 548867 A3 19940413 (199522) C12N015-12

ADT EP 548867 A2 EP 1992-121681 19921221; EP 548867 A3 EP 1992-121681 19921221
PRAI IL 1991-100469 19911223; IL 1992-103434 19921015

REP No-SR.Pub; 3.Jnl.Ref; WO 9010013; WO 9217505

IC ICM C12N015-12
ICS A61K037-02; C07K013-00; C12N005-10; C12P021-08

AB EP 548867 A UPAB: 19931116
 The protein is of (a) a soluble SCF-receptor comprising the extra cellular domain of an SCF-receptor and (b) analogues of (a) obtd. by deletion, addn. or replacement of aminoacid residue(s) without affecting the binding properties to SCF.
 Pref. the protein may be a soluble SCF-receptor designated Kit-X.
 Pref. a conjugate comprises the protein bound to another bioactive molecule of cytoactive drugs, cytotoxins and antibodies.
 USE - The protein is to SCF and acts as an antagonist for SCF-mediated bioactivities in the treatment and prevention of diseases e.g. hyperproliferative or neoplastic states of myeloid neuronal or germ cells, macrocytic anaemia, neutropenia, myeloid leukaemia, mastocytoma, glioblastoma and myelodysplasia. The protein may also be used for the detection, isolation and purificn. of SCF. Antibodies to the protein may be used for purifying the protien in assays for determining bioactivities of the protein and for detection of SCF-receptor.
 Dwg.0/18

FS CPI
FA AB
MC CPI: B04-B02B1; B04-B04A1; B04-B04A3; B04-B04A6; B04-B04C6; B12-G01; B12-G05; B12-G07; B12-K04A; D05-C12; D05-H08; D05-H09; D05-H12

L133 ANSWER 6 OF 6 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1992-366198 [44] WPIDS
DNC C1992-162617

TI Monoclonal antibodies against stem cell factor receptors - for treating leukaemia(s) and solid tumours and for purifying haematopoietic cells.

DC B04 D16
IN BROUDY, V C; LIN, N
PA (UNIW) UNIV WASHINGTON; (AMGE-N) AMGEN INC
CYC 18

PI WO 9217505 A1 19921015 (199244)* EN 59p C07K015-28
 RW: AT BE CH DE DK ES FR GB GR IT LU MC NL SE
 W: CA JP
EP 578774 A1 19940119 (199403) EN C07K015-28
 R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
JP 06506833 W 19940804 (199435) 18p C12P021-08
US 5489516 A 19960206 (199612) 17p G01N033-53
EP 578774 A4 19951115 (199626) C07K015-28
EP 578774 B1 19980729 (199834) EN C07K016-18
 R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
DE 69226431 E 19980903 (199841) C07K016-18
ES 2118820 T3 19981001 (199848) C07K016-18
US 5906938 A 19990525 (199928) C12N015-85
US 5919911 A 19990706 (199933) A61K039-395
US 5922847 A 19990713 (199934) A61K035-14

ADT WO 9217505 A1 WO 1992-US2674 19920403; EP 578774 A1 EP 1992-910836 19920403, WO 1992-US2674 19920403; JP 06506833 W JP 1992-510017 19920403, WO 1992-US2674 19920403; US 5489516 A Cont of US 1991-681245 19910405, US 1993-11078 19930129; EP 578774 A4 EP 1992-910836 ; EP 578774 B1 EP

1992-910836 19920403, WO 1992-US2674 19920403; DE 69226431 E DE
 1992-626431 19920403, EP 1992-910836 19920403, WO 1992-US2674 19920403; ES
 2118820 T3 EP 1992-910836 19920403; US 5906938 A Cont of US 1991-681245
 19910405, Cont of US 1993-11078 19930129, US 1995-449139 19950524; US
 5919911 A Cont of US 1991-681245 19910405, Cont of US 1993-11078 19930129,
 US 1995-462638 19950605; US 5922847 A Cont of US 1991-681245 19910405, Div
 ex US 1993-11078 19930129, US 1994-255193 19940607

FDT EP 578774 A1 Based on WO 9217505; JP 06506833 W Based on WO 9217505; EP
 578774 B1 Based on WO 9217505; DE 69226431 E Based on EP 578774, Based on
 WO 9217505; ES 2118820 T3 Based on EP 578774; US 5906938 A Cont of US
 5489516; US 5919911 A Cont of US 5489516; US 5922847 A Div ex US 5489516

PRAI US 1991-681245 19910405; US 1993-11078 19930129; US 1995-449139
 19950524; US 1995-462638 19950605; US 1994-255193 19940607

REP 10Jnl.Ref; No-Citns.

IC ICM A61K035-14; A61K039-395; C07K015-28; C07K016-18; C12N015-85;
 C12P021-08; G01N033-53
 ICS A01N001-02; A61K039-44; C07K001-22; C07K016-28; C07K016-30;
 C12N005-18; C12N005-20; C12N015-02

AB WO 9217505 A UPAB: 19931116
 A monoclonal antibody (MAb) having an ability to bind to a stem cell
 factor (SCF) receptor is claimed. Also claimed is a hybridoma capable of
 producing the MAb.
 USE/ADVANTAGE - The MAb can be used for purifying haematopoietic
 cells. The purified cells can be used in bone marrow transplantation or
 gene therapy after retrovirally-mediated gene transfer into the purified
 cells. The MAb can also be used for sepg. normal cells from neoplastic
 cells based on differential numbers of SCF receptors. The MAb can also be
 conjugated.
 Dwg.0/7

FS CPI
 FA AB

MC CPI: B04-B04A3; B04-B04C5; B12-D02B; B12-G05; B12-G07; B12-K04A1; D05-H11

ABEQ US 5489516 A UPAB: 19960322
 A monoclonal antibody produced by hybridoma cell line ATCC No. HB 10716.
 receptoris used against stem cell factor receptors for treating leukaemia
 and solid tumours and for purifying haematopoietic cells.
 Dwg.0/7